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     Apoptotic stimuli induce conformational changes of Bax and trigger its translocation 
from cytosol to mitochondria. Upon assembling into the mitochondrial outer membrane, 
Bax initiates a death program through a series of events, culminating in the release of 
apoptogenic factors such as Cytochrome c. Although it is known that Bax is one of the key 
factors for integrating multiple death signals, the mechanism by which Bax functions in 
mitochondria remains controversial. MOAP-1, initially named MAP-1 (Modulator of 
Apoptosis-1), has previously been cloned as a Bax-associating protein from an yeast two-
hybrid screen using Bax as bait. It is known that MOAP-1 is a low-abundance  protein and 
is pro-apoptotic when over-expressed, but its functional relationship with Bax in 
contributing to apoptosis signaling as well as its molecular regulation during apoptosis 
remain unclear.  
     In this study, MOAP-1 was first demonstrated to be a mitochondria-enriched protein 
that associates with Bax only upon apoptotic induction. Small interfering RNAs (siRNA) 
that diminish MOAP-1 levels in mammalian cell lines confer selective inhibition of Bax-
mediated apoptosis. Mammalian cells with stable expression of MOAP-1 siRNA are 
resistant to multiple apoptotic stimuli in triggering apoptotic death as well as in inducing 
conformation change and translocation of Bax. Remarkably, recombinant Bax- or tBid-
mediated release of Cytochrome c from isolated mitochondria is significantly 
compromised in the MOAP-1 knockdown cells. These data together suggest that MOAP-1 
is a critical effector for Bax function in mitochondria.  
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      During characterization of the role of MOAP-1 in apoptosis signaling in mammalian 
cells, it was discovered that MOAP-1 protein can be rapidly up-regulated by multiple 
apoptotic stimuli. Further investigation reveals that MOAP-1 is a short-lived protein (t1/2= 
25 min) that is constitutively degraded by the ubiquitin-proteasome system. Proteasome 
inhibitors are capable of dramatically extending the half-life of MOAP-1 and promote the 
accumulation of poly-ubiquitinated forms of MOAP-1 in a variety of mammalian cell 
lines. Interestingly, induction of MOAP-1 by apoptotic stimuli ensues through inhibition 
of its poly-ubiquitination process. Deletion analysis suggests that the center region (a.a. 
141-190) of MOAP-1 is required and sufficient for coupling MOAP-1 and other unrelated 
proteins such as GST for ubiquitin-mediated degradation. Mammalian cells have low 
basal levels of MOAP-1 and elevation of MOAP-1 levels sensitizes cells to apoptotic 
stimuli and promotes recombinant Bax-mediated Cytochrome c release from isolated 
mitochondria. Mitochondria depleted of short-lived proteins by cycloheximide become 
resistant to recombinant Bax-mediated Cytochrome c release. Remarkably, incubation of 
these mitochondria with in vitro-translated MOAP-1 effectively restores the Cytochrome c 
releasing effect of recombinant Bax. These data not only lend further support to the idea 
that MOAP-1 plays an effector role for Bax function in mitochondria as suggested from 
MOAP-1 RNAi knockdown study, but also raise an intriguing possibility that MOAP-1 
could be the key short-lived mitochondrial protein that is required for mediating Bax 
function in mitochondria. 
     Identification of MOAP-1 as a mitochondrial effector for Bax and a substrate for the 
ubiquitin-proteasome system would thus afford the opportunity for conceptualizing novel 
therapeutic strategies aimed at altering functional activity of Bax in mitochondria.  
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1.1.1 Definition and morphology of apoptosis 
         Apoptosis, the dominant form of programmed cell death, refers to the shedding of 
leaves from trees in Greek. The distinct morphological changes of cells undergoing 
apoptosis are characterized by shrinkage of the cell, hypercondensation of chromatin, 
cleavage of chromosomes into nucleosomes, violent blebbing of the plasma membrane 
without rupture and packaging of cellular contents into membrane-enclosed vesicles called 
‘apoptotic bodies’ (Figure 1.1 and Table 1.1) (Kerr et al., 1972; Hacker, 2000). In vitro, 
apoptotic cells ultimately swell and become permeable to PI staining, resulting in the so-
called “secondary necrosis” phase (Mills et al., 1999; Hacker, 2000; Desagher & 
Martinou, 2000), whereas, in vivo, they are recognized and removed by either phagocytes 
or adjacent cells, thereby avoiding inappropriate inflammation. DNA degradation into 
oligonucleosomal fragments by engonuleases is one of the classical biochemical hallmarks 
of apoptosis (Wyllie, 1980; Janicke et al., 1998; Hacker, 2000; Desagher & Martinou, 
2000). Genetic and biochemical studies in Caenorhabditis elegans, Drosophila 
melanogaster and mammals have led to the identification of the main players of the cell 
death machinery and have shown that this process has been conserved throughout 
evolution (Vaux & Strasser, 1996; Strasser et al., 2000). The collapse of the cell is brought 
about by the action of aspartate-specific cysteine proteases termed caspases (Thornberry & 
Lazebnik, 1998; Porter & Janicke, 1999). Caspases are normally present in healthy cells as 





Figure 1.1 Morphology changes during apoptosis.  (A) Healthy control cells; (B) Chromatin condensation 
as a whole;  (C) Chromatin condensation in the nucleus;  (D) Fragmentation of Chromatin in the cytosol; (E) 
Formation of apoptotic body;  (F) Secondary necrosis. Cells were stained with HO33342 and PI. 
 
Table 1.1    Differential features and significance of necrosis and apoptosis. 
Necrosis Apoptosis 
Morphological features  
· Loss of membrane integrity · Membrane blebbing, but no loss of integrity 
· Flocculation of chromatin · Aggregation of chromatin at the nuclear membrane 
· Swelling of the cell and lysis · Cellular condensation (cell shrinkage) 
· No vesicle formation, complete lysis · Formation of membrane bound vesicles (apoptotic bodies) 
·Disintegation (swelling of organelles) · No disintegration of organelles; organells remain intact 
Biochemical features  
· Loss of regulation of ion homeostasis · Tightly regulated process involving activation and enzymatic steps 
· No energy requirement (passive 
process, also occurs at 4 0C) 
· Energy(ATP)-dependent (active process, does not occur at 4 0C) 
· Random digestion of DNA (Smear of 
DNA after agarose gel electrophoresis) 
· Non-random mono-and oligonucleosomal length fragmentation of 
DNA (Ladder pattern after agarose gel electrophoresis) 
· Postlytic DNA fragmentation (= late 
event of death) 
· Prelytic DNA fragmentation (= early event of cell death) 
Caspase activation No caspase activation 
Physiological significance  
· Death of cell groups · Death of single, individual cells 
· Evoked by non-physiological 
disturbances 
· Induced by physiological stimuli 
· Phagocytosis by macrophages · Phagocytosis by adjacent cells or macrophages 
· Significant inflammatory response · No inflammatory response 
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through proteolysis via autocatalytic processing (initiator caspases such as Caspase 8 and 
9) or by already active caspases (effector caspases such as Caspase 3 and 7) (Adams & 
Cory, 2002; Ho & Zacksenhaus, 2004). 
 
1.1.2 Extrinsic and Intrinsic pathways  of apoptosis 
      Two types of signaling pathway have been identified to mediate apoptosis (Figure 
1.2). The initiation and amplification of caspase cascades are involved in both pathways 
(Kroemer et al., 2007). The “extrinsic” pathway begins with the interaction between 
various cell death receptors and their corresponding ligands or agonist, resulting in the 
formation of membrane bound and muticomponent death inducing signaling complex 
(DISC). DISC further recruits and induces auto-proteolytic activation of initiator caspases, 
such as caspase 8 or caspase 10 (Adams & Cory, 2002; Ho & Zacksenhaus, 2004). These 
activated initiator caspases trigger cell death by directly or indirectly activating 
downstream executioner caspases, such as caspase 3 and caspase 7. The “intrinsic” 
pathway is stimulated by noxious factors, such as DNA damage, unbalanced proliferative 
stimuli, and nutrient or energy depletion. The execution phase of this pathway is initiated 
by the release of Cytochrome c and other apoptogenic factors from mitochondrial 
intermembrane space (Li et al., 2004). Cytochrome c binds to the adaptor molecule 
apoptotic protease activating factor (Apaf-1) in the presence of ATP or dATP and form a 
large complex named as apoptosome. The apoptosome then recruits caspase 9 and trigger 
its activation by auto-cleavage (Jiang & Wang, 2004). Activated caspase can, in turn, 
directly activate downstream executioner caspases and trigger apoptosis.   
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       As mentioned above, the initiation of early capsase activation is different between the 
“extrinsic” and “intrinsic” pathways. Although in certain cell types, the “extrinsic” or cell 
death receptor mediated pathway does not require mitochondria involvement to activate 
executioner capsases, the extrinsic and intrinsic death pathways converge on mitochondria 
in most cell types (Green & Kroemer, 2004). Therefore, for most of mammalian cells, as 
discussed below in detail, mitochondria play a central role in controlling apoptosis events 
by integrating upstream apoptosis-inducing (proapototic) signals and regulating the release 
of apoptogenic factors. Bid, a Bcl-2 member, serves as one of linkers between “extrinsic” 
and “intrinsic” apoptosis pathways (Figure 1.2).  
 
 
Figure  1.2 Extrinsic versus intrinsic caspase activation cascades (Adapted from Kroemer et al., 2007). 
Left: extrinsic pathway. The ligand-induced activation of death receptors induces the assembly of the death-
inducing signaling complex (DISC) on the cytoplasmic side of the plasma membrane. This promotes the 
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activation of caspase-8 (and possibly of caspase-10), which in turn is able to cleave effector caspase-3, -6, 
and -7. Caspase-8 can also proteolytically activate Bid, which promotes mitochondrial membrane 
permeabilization (MMP) and represents the main link between the extrinsic and intrinsic apoptotic 
pathways. The extrinsic pathway includes also the dependency receptors, which deliver a death signal in the 
absence of their ligands, through yet unidentified mediators. Right: intrinsic pathway. Several intracellular 
signals, including DNA damage and endoplasmic reticulum (ER) stress, converge on mitochondria to induce 
MMP, which causes the release of proapoptotic factors from the intermembrane space (IMS). Among these, 
Cytochrome c (Cyt c) induces the apoptosis protease-activating factor 1 (APAF-1) and ATP/dATP to 
assemble the apoptosome, a molecular platform which promotes the proteolytic maturation of caspase-9. 
Active caspase-9, in turn, cleaves and activates the effector caspases, which finally lead to the apoptotic 
phenotype. DNA damage may signal also through the activation of caspase-2, which acts upstream 
mitochondria to favor MMP. See section IIA for further details. 
 
 
1.1.3 Apoptosis and human diseases 
 
           Apoptosis, the dominant form of programmed cell death, plays a critical role in 
controlling the number of cells in development and throughout the life of multicellular 
organisms by removing unwanted, damaged and infected cells at the appropriate time. 
Alterations of this normal process can result in the disruption of the delicate balance 
between cell proliferation and cell death and can lead to a variety of diseases (Thompson, 
1995; Fischer & Schulze-Osthoff, 2005). Increased apoptosis has been associated with 
acute ischemic diseases associated with reperfusion injury, such as myocardial infarction, 
stroke and renal hypoxia. Inappropriate apoptosis also contributes to several neurologic 
disorders. In Alzheimer’s, Parkinson’s and Huntington’s disease, specific neurons 
prematurely commit suicide, which can lead to irreversible memory loss, uncontrolled 
muscular movements and depression (Nijhawan et al, 2000; Vila & Przedborski, 2003). 
Involvement of increased apoptosis in arteriosclerosis, infertility, heart failure, AIDS, 
diabetes and hepatitis have also been reported (Thompson, 1995; Fischer & Schulze-
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Osthoff, 2005). Decreased apoptosis is known to be involved in cancer and autoimmune 
disorders. In many forms of cancer, key pro-apoptotic proteins are mutated or anti-
apoptotic proteins such as Bcl-2/Bcl-xL are frequently up-regulated, leading to the 
accumulation of cells and the inability to respond to harmful mutations, DNA damage, or 
chemotherapeutic agents (Reed, 1999; Meng et al., 2006; Adams & Cory, 2007). Since 
effective chemotherapy depends on the induction of apoptosis, cancers with serious 
defects in the apoptosis signaling pathways are particularly difficult to treat. Identification 
of small-molecule Bcl-2 antagonist holds one of new promises for selectively inducing 
PCD in cancer cells (Chan & Yu, 2004; Letai, 2006). Indeed, the efficacy of the chemical 
inhibitor of pro-survival members of the Bcl-2 family, ABT-737, as an anti-tumor agent 
has recently been demonstrated in the mouse model (Oltersdorf et al., 2005).   Apoptosis 
is also important for eliminating autoreactive T cells after an immune response. When this 
normal process is disrupted through mutations of the proteins that trigger apoptosis (e.g. 
Fas ligand or the Fas receptor), an autoimmune lymphoproliferative syndrome (ALPS) can 
result, with complications such as hypersplenism, autoimmune hemolytic anemia, 
thrombocytopenia, and neutropenia (Pope, 2002; Prasad & Prabhackar, 2003). 
 
 
1.2 MITOCHONDRIA AS THE CENTRAL ORGANELLES FOR REGULATING 
APOPTOSIS SIGNALING 
1.2.1  Mitochondria  
      Mitochondria are regarded as the “the power plant” of the cell as it is found that most 
cellular ATP is produced in these organelles through oxidation phosphorylation. 
Introduction 
 -7-
Mitochondria possess two distinct forms of membrane structure (Figure 1.3A). The inner 
membrane (IM), which surrounds the mitochondrial matrix and is usually tightly folded in 
cristae, holds the molecular complexes for the electron transport. The mitochondrial 
potential (∆Ψm) is principally achieved by the hydrogen ion gradient (∆pH) generated by 
the electron transport through the complex I, complex II, complex III and complex IV 
across the inner membrane. This H+ gradient is necessary for the F0F1 to synthesize ATP. 
In order to maintain this crucial gradient, transport across the inner membrane is tightly 
regulated by many different, specific transporters for the metabolites that need to cross the 
inner membrane, including the tricarboxylate carrier, the phosphate carrier as well as the 
dicarboxylate carrier. The inner membrane also encompasses protein import channels 
(TIMs) and the adenine nucleotide translocator (ANT) which exchanges ADP and ATP 
between the mitochondrial matrix and the intermembrane space (IMS) between the outer 
membrane and the inner membrane. The outer membrane separates the mitochondria from 
cytosol and it is thought to play an important role in the free exchange of substrate and 
ATP/ADP between mitochondria and the cytosol. Voltage-dependent anion channel 
(VDAC) is the most common protein integrating in the outer membrane and it is critical 
for controlling the permeability of the outer membrane. Another outer membrane 
integrating protein, the translocase of outer membrane (TOM) is involved in importing the 
nuclear DNA encoding mitochondrial proteins into mitochondria. Unlike VDAC and 
TOM which tightly are integrated into the outer membrane, Hexokinase, which 
phophorylates glucose in the cytosol, just loosely binds to the mitochondrial outer 




Figure 1.3   Mitochondrial architecture. (A) Mitochondria are organelles composed of two distinct 
membranes (Adapted from micro.magnet.fsu.edu). (B)  A schematic representation of the respiratory 
complexes, the F0F1-ATP synthase, the translocase of inner membrane/translocase of outer membrane 
(TIM/TOM) proteins, and the PTP complex in the mitochondrial inner membrane (IM) and outer membrane 
(OM). The localization and functions (if known) of the different proteins is depicted. The ∆Ψm is 
principally achieved by an H+ ion gradient generated by electron transport (∆pH). This H+ gradient is used 
by the F0F1 synthase to synthesize ATP. PTP is proposed to be composed or influenced by clustered 
components of the inner and outer mitochondrial membrane including hexokinase, creatine kinase (CK), 
voltage-dependent anion channel (VDAC), adenine nucleotide translocation (ANT), the peripheral 
benzodiazepine receptor (PBR), and the mitochondrial matrix cyclophilin D (CycD). Different agents that 





1.2.2 Discovery of the involvement of mitochondria in apoptosis 
      Kerr et al. (1972) proposed in their seminal paper on apoptosis that apoptosis is a 
nuclear event and that mitochondria are not likely to be involved even as a part in the 
apoptotic process. The authors claimed that “the apoptotic body shows closely aggregated 
but apparently intact mitochondria of epithelial cell types”. Only “when apoptotic bodies 
undergo a process within phagosomes, the matrix of mitochondria becomes electron-
lucent and displays focal flocculent densities”. This assumption was further supported by 





mitochondrial DNA and are therefore deficient in respiration, nevertheless still can 
undergo normal apoptosis (Jacobson et al., 1993). However, indirect evidence seemed to 
point to a possible involvement of mitochondria in apoptosis. Some of the earliest study 
on Bcl-2 protein appeared to indicate that Bcl-2 protein is localized in mitochondria and it 
blocks apoptosis through affecting mitochondria potential, the production of oxygen 
radicals as well as Ca2+ cycling in mitochondria (Hockenbery et al., 1990; Hennet et al., 
1993; Richter, 1993; Hockenbery et a.l, 1993). The first evidence directly connecting 
mitochondria with apoptosis was provided by Newmeyer et al. (1994) using a cell-free 
model system. In this paper, the authors found that a dense organelle fraction enriched 
with mitochondria from Xenopus extract was able to induce chromatin condensation, the 
shrinkage and fragment of the nuclei, all of which are hallmarks of apoptosis.  
 
1.2.3 Release of apoptogenic factors from mitochondria 
      A breakthrough in understanding the importance of mitochondria in the regulation of 
apoptosis signaling pathway and the molecular mechanism of apoptotic cell death was the 
discovery of Cytochrome c release from mitochondria in contributing to the initiation of 
caspase cascades by Wang and colleagues (Liu et al., 1996; Li et al., 1997). Cytochrome c 
was described for the first time in 1930. It is known to play a pivotal role in the oxidative 
phosphorylation as an electron shuttle between Complex III (Cytochrome c reductase) and 
Complex IV (Cytochrome c oxidase). For more than 60 years, this was the only known 
function of Cytochrome c even though the translocation of Cytochrome c from 
mitochondria to the cytosol has already been observed in the mid-twentieth century. As 
illustrated in Figure 1.4, Cytochrome c was released from mitochondria during apoptosis 
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in mammalian cells to induce the assembly of the apoptosome. The apoptosome is a 
complex consisting of Cytochrome c, Apaf-1 and dATP. The apoptosome serves as a 
platform for procaspase-9 assembly and auto-activation (Liu et al., 1996; Li et al., 1997). 
In certain systems, such as fibroblasts upon c-myc expression (Juin et al, 1999) or neurons 
upon growth factor withdrawal (Neame et al, 1998), it has been reported that neutralizing 
Cytochrome c in the cytosol by injecting antibodies is enough to prevent the cells from 
apoptosis. However, due to the obligate function of Cytochrome c for electron transport, 
which correspond to the embryonic lethality of knockout animals (Li et al., 2000), its 
requirement for apoptosis and caspase activation in animals has been difficult to establish. 
Remarkably, “knockin” mice expressing a mutant Cytochrome c (K72A), which retains 
normal electron transfer function but fails to activate Apaf-1 were successfully generated 
(Hao et al, 2005). Most mice harboring both alleles of this mutant displayed embryonic or 
perinatal lethality caused by the defects in the central nervous system. The few surviving 
animals exhibited a severe impairment in lymphocyte homeostasis, Moreover, embryonic 
fibroblasts from KO mice are resistant to apoptosis induction by multiple stimuli (Hao et 
al, 2005). This study lends further support to the idea that Cytochrome c-mediated 
apoptosis pathway plays an important role in mammals.  
       In addition to Cytochrome c, a few other proteins are subsequently found to be 
released during apoptosis from mitochondria in mammals (Figure 1.5). These proteins 
include:  
      AIF: AIF (Apoptosis inducing factor) is a 57KD flavoprotein oxidoreductase and 
resides in the mitochondrial intermembrane space. Upon apoptosis stimulation, AIF was 
found to translocate to the nucleus and cause chromatin condensation and large-scale 
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DNA fragmentation in a caspase-independent manner (Susin et al, 1999; Miramar et al., 
2001). Compared to Cytochrome c release, the release of AIF appears to be a relatively 
late event after commitment of apoptosis (Ekert et al., 2005). AIF itself does not have any 
DNase activity. The mechanism by which AIF causes DNA fragmentation and chromatin 
condensation remains largely unclear. Deficiency of AIF has shown significant effects on 
animal development (Joza et al., 2001). However, since it has been found recently that  
AIF is also involved in the respiratory complex I formation and plays an important role in 
normal mitochondria physiology (Vahsen et al., 2004), further investigation is required to 
address whether the profound phenotypes of AIF knockout animals is due to its pro-
apoptotic activity or its oxidoreductase function. Interestingly, knockout of AIF in human 
tumor cells has led to the surprising finding that AIF suppresses chemical stress-induced 
apoptosis in certain cellular contexts instead of serving as a pro-apoptotic molecule 
(Urbano et al., 2005).  
        Smac/DIABLO: Smac/DIABLO (second mitocondria-derived activator of caspases/ 
direct IAP-binding protein with low pI) is a small mitochondria protein residing in the 
intermembrane space, and it is released from mitochondria with similar kinetics as 
Cytochrome c upon apoptotic stimulation (Du et al., 2000; Verhagen et al, 2000).  IAPs 
(inhibitor of apoptosis protein) are a family of proteins which possess one or multiple BIR 
(Baculovirus IAP repeat) domains, which are known to inhibit active caspase through 
physical interaction (Liu et al., 2000; Wu et al., 2000). Smac has an IAP-binding domain 
at its extreme N-terminus and is able to bind to the surface groove of the BIR domain of 
several IAP family proteins (Liu et al., 2000; Wu et al., 2000). This would effectively 
prevent IAPs from binding and inactivating caspase and thereby restoring caspase activity.        
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         Omi/HtrA2: The involvement of Omi/HtrA2 (High temperature requirement protein 
A2) was first identified through its ability to bind and block IAPs after releasing into the 
cytosol from mitochondria during apoptosis (Suzuki et al., 2001). However, this protein is 
also known to be a serine protease with high homology to a bacterial heat shock 
endoprotease, HtrA (Faccio et al., 2000; Savopoulos et al., 2000). The regulation of 
Omi/HtrA2 in caspase-independent apoptotic pathways might rely on its serine protease 
activity (Suzuki et al, 2001; Verhagen et al., 2002; van Loo et al, 2002). Recent data from 
a knockout study appears to suggest that Omi/HtrA2 does not simply act as a apoptotic 
regulator, it might play an important role in the maintenance of normal mitochondrial 
function (Jones et al., 2003; Martins et al., 2004).  
 
Figure 1.4 Cytochrome c–mediated caspase activation (Adapted from Wang, 2001 with some 









Cytochrome c associates with the cytosolic protein Apaf-1 that normally exists as an inactive monomer. (C) 
The association of Cytochrome c triggers a conformational change of Apaf-1, allowing it to bind dATP or 
ATP. (D) dATP or ATP, Cytochrome c and Apaf-1 form a complex (Apoptosome). (E) Apoptosome recruits 
procaspase-9 and promotes its auto-activation. (F)Activated Caspase-9 further cleaves and activates the 
downstream caspases, such as caspase-3, to initiate apoptosis cascades. 
       
      Endonuclease G: Edonulease G is a non-specific mitochondrial nuclease (Li et al., 
2001; Parrish et al., 2001). During apoptosis, endonuclease G is released from 
mitochondria and translocates to the nucleus to cause the fragmentation of chromatin 
DNA in the absence of caspase activity (Kim et al., 2005).  
 
                       
Figure 1.5  Release of apoptogenic factors from mitochondria and their involvement in capspase-
dependent and independent apoptosis pathway (Adapted from Donovan & Cotter, 2004). Several 
proteins are found to be released from the mitochondrial intermembrane space during apoptosis. Released 
Cytochrome c associates with Apaf-1 to promote the activation of Caspase 9, which can further cleave and 
activate downstream effector Caspase such as Caspase 3 Cleavage of ICAD by Caspase 3 triggers activation 
of the CAD endonuclease, which mediates oligonucleosomal DNA fragmentation (Stage II). The caspase co-
activator Smac/Diablo is released along with Cytochrome c to counter the inhibitory activity of IAPs on 
activated Caspase. Omi has also been reported to bind XAIP and disrupting the inhibition of Caspase 
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activity by XAIP. But, Omi is also able to induce caspase-independent apoptosis though its serine pretease 
activity. AIF, once released from mitochondria to cytosol, will further translocate to the nucleus and induces 
peripheral chomation condensation and large-scale DNA fragmentation (Stage I) by unknown mechanism. 
Upon apoptotic insults, endonuclease G is also released to cytosol where it translocates to the nucleus and 
induces oligonuleosomal DNA fragmentation (Stage II).    
 
 
1.3  BCL-2 FAMILY PROTEINS: LIFE-AND-DEATH SWITCH IN MITOCHONDRIA 
1.3.1 Discovery of Bcl-2 as an oncogene  
      Bcl-2 gene was first discovered as a proto-oncogene found at the break-points of 
t(14;18) chromosomal translocations in follicular non-Hodgkin’s B-cell lymphoma 
marked by slow growth and accumulation of mature B lymphocytes (Pegoraro et al., 
1984; Tsujimoto et al., 1985a; Tsujimoto et al., 1985b; Tsujimoto & Croce, 1986). The 
consequential effect of this translocation is over-production of wide-type Bcl-2 RNA and 
protein (Seto et al., 1988) (Figure 1.6). Initial transfection experiments demonstrated that, 
unlike other oncogenic gene products such as myc and Ras, Bcl-2 does not display any 
transforming activity, suggesting that Bcl-2 represents a new type of oncogenes that 
possess a novel oncogenic mechanism. In a seminal paper published by Vaux and 
colleagues, Bcl-2 was shown to play a role in cell survival by a study on the IL-3-
deprivation-induced death of a lymphoid cell line (Vaux et al., 1988). It was subsequently 
reported that Bcl-2 also inhibits cell death induced by a variety of apoptotic stimuli such 
as glucocorticoid treatment of thymocytes and lymphoid leukemia cells, γ-irradiation of 
thymocytes, and NGF-deprivation from fetal sympathetic neurons (Reed, 1994). 
Conversely, antisense-mediated suppression of Bcl-2 expression was demonstrated to 
induce or accelerate cell death (Kitada et al., 1993). The anti-death role was subsequently 
demonstrated in vivo by the generation of mice lacking the Bcl-2 gene, which showed a 
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variety of abnormalities, most of which could be explained by excessive cell death (Veis 
et al., 1993; Nakayama et al., 1994; Kamada et al., 1995). Thus, the role of Bcl-2 as an 
intracellular apoptosis-suppresser was finely established and the concept of proto-
oncogene which can contribute to neoplasia through its function on regulating cell life 
span rather than proliferation was emerging.  
         Genetic analysis in C. elegans showed that ced-9 gene protects cells from 
programmed cell death (Hengartner et al., 1992). Strikingly, ced-9 displays significant 
sequence homology to Bcl-2, implying that Bcl-2 governs an evolutionarily conserved 
step in the programmed cell death machinery. The rescue of ced-9 deficient worms by 
human Bcl-2 lent further support to this hypothesis (Vaux et al., 1992). While these early 
studies of Bcl-2 and its C. elegans homolog ced-9 created great interest in understanding 
how the Bcl-2 protein performs its pro-apoptotic functions in cells, but accumulating 
evidence suggests that the underlying mechanism by which Bcl-2 regulates apoptosis 
pathway is far more complicate in mammals as discussed below.  
                                           
Figure 1.6  Chromosomal translocation of the Bcl-2 gene.  The t(14;18) chromosomal translocation 
removes the Bcl-2 gene from its normal regulatory sequences on chromosome 18 and juxtaposes it to the 5’ 
immunoglobulin heavy chain gene (IgG) located on chromosome 14. This translocation results in over-





1.3.2 The Bcl-2 family  
1.3.2.1 Bcl-2 homology (BH) domains 
      In 1993, several Bcl-2 related proteins, including Bax, Bcl-xL and A1 were identified 
by distinct cloning strategies. Subsequent sequence alignment analysis led to the 
identification of two conserved regions of amino-acid sequence similarity among these 
proteins, resulting in the coining by Korsmeyer in 1994 of the term “Bcl-2 Homology 
(BH) domain” (Yin et al., 1994).  These two BH domains, termed BH1 and BH2, of Bcl-2 
appeared to be required for its pro-survival activity and its heterodimerization with pro- 
 
Figure 1.7 Sequence alignment of Bcl-2 family proteins (Adapted from Petros et al., 2004). Bcl-2 
homology (BH) domain 1-4 are indicated with rectangular boxes. Helices 1-8 for Bcl-xL are shown above 
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the sequence along with helix 9 of Bax and Bcl-w. In addition, the putative transmembrane domain is also 
indicated. For the aligned sequence, black boxes highlight strictly conserved residues, while green boxes 
indicate conserve substitutions. 
 
apoptotic molecule Bax (Yin et al., 1994). A degenerate PCR approach was subsequently 
used to search for the genes which contain DNA sequence homology to BH1 and BH2 
domains of Bcl-2. A novel pro-apoptotic gene, Bak, was quickly identified (Chittenden et 
al., 1995a; Kiefer et al., 1995). Interestingly, a subsequent study suggested that a 
conserved domain in Bak which is completely distinct from previously defined BH1 and 
BH2 domains among the Bcl-2 family proteins (Yin et al., 1994) mediates cell death and 
protein binding functions of Bak (Chittenden et al., 1995b). This conserved domain was 
further defined as a novel Bcl-2 homology domain 3 (BH3) (Boyd et al., 1995; Zha et al., 
1996). This finding led to the subsequent identification of a large number of new members 
of the Bcl-2 family. Now, it is known that most of the proteins, if not all, in the Bcl-2 
family contain a BH3 domain, which is functionally important for death-promoting 
activity (Kelekar & Thompson, 1998; Cory & Adams, 2002). The BH4 domain, originally 
termed A-box (Sato et al., 1994; Yin et al., 1994; Zha et al., 1996) was found only in the 
anti-apoptotic members of the Bcl-2 family. Its function still remains controversial. The 
BH4 domain was first shown to be necessary for Bcl-2 to associate with and sequester 
Ced-4 (the C. elegans Apaf-1 homologue) in mitochondria and thereby prevent apoptosis 
(Huang et al., 1998). Hence, it was postulated that the pro-survival members of the Bcl-2 
family should also bind to and sequester the mammalian ced-4 homologue Apaf-1 in 
mitochondria through the BH4 domain. However, it was subsequently shown that Apaf-1 
does not interact with any Bcl-2 family members (Moriishi et al., 1999; Hausmann et al., 
2000).  Thus, whether the major function of the BH4 domain in mammalian cells is to 
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mediate the interaction of the pro-survival members of the Bcl-2 family with Apaf-1 still 
requires further investigation. Alternative functions for the BH4 domain have also been 
reported. For example, this domain appeared to be critical for the interaction between the 
multidomain pro-survival and pro-apoptotic members (Hirotani et al., 1999). It has also 
been found that the BH4 domain plays an important role to regulate the close of VDAC-
mediated channel (Shimizu et al, 1999). More interestingly, intraperitoneal delivery of 
BH4 peptides  has been shown to exert cytoprotective effects in vitro as well as in vivo 
(Sugioka et al., 2003; Klein et al., 2004; Ono et al., 2005; Hotchkiss et al., 2006). 
Nevertheless, the BH4 domain is generally believed to possess pro-survival activity while 
the underlying mechanism for that remains to be determined.  
 
1.3.2.2 Three classes of the Bcl-2 family 
      In the last decade, at least 20 members of the Bcl-2 family proteins have been 
identified. The overall amino acid sequence homology among the Bcl-2 family proteins is 
relatively low and the sequence homology is confined to four specific regions as 
mentioned above. All members possess at least one of the four conserved BH domains. 
Based on conservation of Bcl-2 homology domains (BH1-BH4), the Bcl-2 family is 
divided into three classes of proteins. 
      Multidomain pro-survival: In addition to Bcl-2, the anti-apoptotic subfamily 
includes Bcl-xL, Mcl-1, A1/Bfl-1, Bclw, Boo/Diva/Bcl-B, and Nr-13. These proteins all 
(except for Boo) share four BH regions. In addition to the four BH domains, they all 
harbor a transmembrane domain in their c-terminus and reside in the cytoplasmic faces of 
intracellular membranes of certain organelles, such as the outer mitochondrial membrane, 
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endoplasmic reticulum, and possibly the nuclear envelope (Marsden & Strasser, 2003; 
Cory & Adams, 2002; Scorrano & Korsmeyer, 2003). Structural analysis of Bcl-xL 
reveals that the BH1, BH2 and BH3 domains form a hydrophobic cleft serving as a 
receptor for binding to the BH3 domain which represents the “death ligand” of pro-
apoptotic members.  
      Multidomain pro-apoptotic: Mutltidomain pro-apoptotic molecules include Bax, 
Bak and Bok, and they all display sequence conservation in the BH1-3 domains. Unlike 
BH3-only proteins, Bax and Bak can homodimerize, in addition to heterodimerizing with 
multidomain pro-survival members. Analogous to the BH3-only proteins, over-expression 
of distinct fragments of Bax or Bak which encompass little more than the BH3 domain 
have been shown to be sufficient for binding to Bcl-2 or Bcl-xL and inducing apoptosis in 
mammalian cells (Chittenden et al., 1995; Simonen et al., 1997). In addition, substituting 
the BH3 domain of Bcl-2 for that of Bax has been reported to convert Bcl-2 from a 
protector to a killer protein (Hunter & Parslow, 1996). These data together suggest that the 
BH3-domain is important for the death-promoting function of the Bax/Bak sub-family. 
Bok was initially reported to be a testis-specific gene, however, its expression in other 
tissues has been observed. For instance, it has been shown to play an important role in 
DNA damage-induced apoptosis in the neuron-like cell line SY5Y (Yakovlev et al., 
2004).  The mechanism by which Bok promotes apoptosis, however, remains unclear and 
requires further investigation. 
      BH3-only protein: This class of proteins shares no homology with Bcl-2 other than 
the BH3 domain. BH3-only proteins are unable to form homo-dimers, but have the ability 
to heterodimerize with both pro-survival and pro-apoptotic Bcl-2 members by binding to 
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their hydrophobic pocket through the BH3 domain. Most members of the BH3-only 
subfamily of pro-apoptotic molecules act by relaying distinct death signals to the  
 
 
Figure 1.8 Classification of the Bcl-2 family based on conservation of BH domains (Adapted from 
Scorrano & Korsmeyer, 2003).  Three subfamilies are indicated. BH1 to BH4 are the 4 conserved sequence 
motifs. All pro-survival member contains 4 conserved BH domains. Certain members of BH3-only 
subfamily lack of tansmembrane (TM) domain.  
Introduction 
 -21-
Table 1.2  Identification of Bcl-2 family members 
Name Subfamily Approach for 
identication 
Reference 
Bcl-2 Muti-domain pro-survival  Genetical analysis of follicular 
lymphoma  
 
Tsujimoto et al., 1984; 
Bakhshi et al., 1985; 
Cleary and Sklar, 1985;  
Vaux et al., 1988 
A1/bfl-1 Muti-domain pro-survival Genetical analysis of stomach 
cancer 
Choi et al., 1995; 
Lin et al., 1996; 
Bcl-w Muti-domain pro-survival PCR-based strategy Gibson et al., 1996 
 
Bcl-xL Muti-domain pro-survival DNA hybridization using Bcl-
2 probe 
Boise et al., 1993; 
Boo/Diva/Bcl-B Muti-domain pro-survival EST database search for Cdna 
sequences homologous to NR-
13 
 
Song et al., 1999; 
Inohara et al., 1998; 
Mcl-1 Muti-domain pro-survival Genetical analysis of genes 
invoved in ML-1 human 
myeloid leukemia cell 
differentiation 
Kozopas et al., 1993; 
 
NR-13 Muti-domain pro-survival Screening for the target gene 
of p60v-src 
Gillet et al., 1995; 
Bax  Muti-domain pro-apoptotic pull down screen for  Bcl-2 
interacting protein 
Oltvai et al., 1993; 
 
Bak Muti-domain pro-apoptotic Degenerate PCR using 
primers corresponding to the 
BH1 and BH2 domains of 
Bcl-2 
Chittenden et al, 1995; 
Kiefer et al., 1995; 
Bok/Mtd Muti-domain pro-apoptotic Yeast tow hybrid screen using 
Mcl-1 as bait; 
 
EST database search  for Cdna 
sequences homologous to Bcl-
2 and Bcl-xL 
 
Hsu et al., 1997; 
 
 
Inohara et al, 1998; 
Bad BH3-only protein Yeast two-hybrid screening 
and lambda expression 
cloning for Bcl-2 interacting 
protein 
Yang et al, 1995; 
 
Bid  BH3-only protein Screen for Bcl-2 interacting 
protein 
Wang et al., 1996; 
Bik/Nbk/Blk BH3-only protein  
 
EST database search for 
sequences encoding BH3 
domain 
Boyd et al., 1995; 
 
 
Hegde et al., 1998; 
 
Bim/Bod BH3-only protein Expression library screening 
for Bcl-2 interacting protein 
O’Connor et al., 1998; 
 
Bmf BH3-only protein Yeast two-hybrid screening 
using Mcl-1 as bait 
Puthalakath et al., 2001 
Hrk/DP5 BH3-only protein Differential display screening 
for genes involved in NGF 
withdrawal-induced death in 
neuron culture; 
 
Yeast tow hybrid screen using 
Mcl-1 as bait; 





Inohara et al., 1997; 
 
Noxa BH3-only protein Differential display screening 
for p53 targeting gene 
Oda et al., 2000; 
Puma/Bbc3 BH3-only protein Micro-array screening for p53 
targeting gene; 
 
Yeast two hybrid screening 
using Bcl-2 as bait; 
Nakano et al., 2001; 
Yu et al., 2001; 
 





mitochondria through binding to members of the multi-domain pro-survival subfamily 
(e.g. Bcl-2 and Bcl-xL) (Cory & Adams, 2002; Cartron et al., 2004; Danial & Korsmeyer, 
2004), while the BH3-only molecule, tBid, Bim and Puma, may also have an additional 
role in promoting activation of members of the multidomain pro-apoptotic subfamily such 
as Bax and Bak (Letai et al., 2002; Kuwanna et al., 2005; Certo et al., 2006; Oh et al., 
2006; Walensky et al., 2006; Kim et al., 2006). 
 
 
1.3.2.3 Models for the functional interplay among Bcl-2 family proteins in apoptosis 
signaling 
(1) C.elegans sequestration model 
      The molecular characterization of the Caenorhabditis elegans (C. elegans) cell death 
genes has been informative in revealing some of the biochemical mechanisms underlying 
apoptosis in all animals. Four C. elegans genes, egl-1, ced-9, ced-4, and ced-3 are required 
for somatic programmed cell death to occur. The pro-death gene egl-1 and the anti-death  
gene ced-9 have structural and functional similarities to the BH3-only proteins and 
multidomain pro-survival Bcl-2 family molecules, respectively. The killer gene ced-3 
encodes a cysteine aspartic protease (caspase), which is the archetype of a family of 
conserved proteins known as effectors of apoptosis in mammals. The identification of an 
apoptotic protease activating factor (Apaf-1), a human homologue of C. elegans ced-4, 
provides important clues as to how ced-4 and its potential relatives might work (Zou et al., 
1997). It has been well established that ced-4 is sequestered by ced-9, the mammalian Bcl-
2 homology, in mitochondria. During apoptosis, the BH3-only protein homologue egl-1 




ced-3 to promote the activation of its caspase activity (Figure 1.9). Based on this model 
and the assumption that the genetic network for apoptosis signaling should be highly 
conserved during evolution as human Bcl-2 was able to rescue the ced-9 deficient worms 
(Vaux et al., 1992; Hengartner & Horvitz, 1994), it was speculated that the Bcl-2 family 
members might act in a similar way to regulate apoptosis signaling in mammalian cells. 
Indeed, Bcl-2, Bcl-xL and Boo have been shown to interact with Apaf-1 (Hu et al., 1998; 
Pan et al., 1998; Song et al., 1999). However, it was subsequently demonstrated that 
Apfa-1 displays a cytoplasmic localization distinct from Bcl-2 and Bcl-xL (Hausmann et 
al., 2000). Furthermore, the physical interaction between Apaf-1 and the pro-survival 
members of the Bcl-2 family was not observed by other research groups when analyzing 
various Bcl-2 family members in their endogenous and overexpressed forms using cell 
lysates from normal and apoptotic cells (Moriishi et al., 1999; Hausmann et al., 2000). 
Some of other studies suggest that Bcl-xL might be able to associate with Apaf-1 in 
certain circumstance, however, Bxl-XL is found to be inefficient in inhibiting the Apaf-1-
dependent activation of caspases in vitro (Newmeyer et al., 2000; Chipuk et al., 2001). 
Therefore, it still remains controversial whether the mammalian ced-4 homologue Apaf-1 
is a target and mediator of the death-protective activities of Bcl-2 and Bcl-xL. In addition 
to Apaf-1, it is proposed that other unidentified ced-4 like molecules might exist in 
mammals and the Bcl-2 family proteins could regulate apoptosis signaling through 
affecting the function of those yet to be identified ced-4 like molecules in mammalian 




                                 
Figure 1.9   Two proposed models for Bcl-2 survival activity (Adapted from Cory & Adams, 2002). (A) 
Caenorhabditis elegans: sequestration of a caspase activator. The Bcl2 homologue CED-9 binds the adaptor 
protein CED-4 and prevents it from activating the CED-3 caspase until the BH3-only protein EGL-1 binds 
to CED-9 and displaces CED-4. (B) Mammals: protection of mitochondrial integrity. Bcl2 and its anti-
apoptotic homologues guard mitochondrial membrane integrity until neutralized by a BH3-only protein. Bax 
and Bak then form homo-oligomers within the mitochondrial membrane, resulting in the release of the 
apoptogenic factors such as Cytochrome c, Omi and Diablo to initiate apoptosis cascades. 
 
 
(2) Bax/Bak activation model 
       While the interaction between Bcl-2 like molecules and Apaf-1 remains controversial, 
the interaction of BH3-only molecules with multidomain pro-survival members has been 
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demonstrated by complementary techniques. Similar to egl-1 (BH3-only homologue) 
binding to ced-9 (Bcl-2 homologue) to activate the apoptosis pathway in worms, the 
physical interaction between BH3-only and multidomain pro-survival Bcl-2 family 
proteins play an important role in the initiation of apoptosis signaling in mammals. In 
contrast to C. elegans genome where only one gene encoding a BH3-only molecule (egl-
1) has been identified, the multiplicity and complex regulation of BH3-only proteins in 
mammals has emerged and remains a focus for intensive investigation. In healthy cells, 
the pro-apoptotic activity of BH3-only proteins is kept in check by transcriptional and 
post-translational mechanisms to prevent inappropriate cell death (Chan & Yu, 2004). 
They mediate death induced not only by physiological stimuli such as cytokine 
deprivation or detachment from the cell matrix (a type of cell death termed anoikis) but 
also by the signals induced by activated oncogenes, DNA damage, chemotherapy drugs 
and γ-irradiation (Bouillet & Strasser, 2002; Willis & Adams, 2005; Ham et al., 2005; 
Strasser, 2005; Labi et al., 2006; Fletcher, et al., 2006). To allow exquisite control over 
apoptosis, diverse cellular signaling pathways engage the apoptotic program by activating 
distinct BH3-only proteins (Figure 1.10). For example, loss of Bim renders lymphocytes 
refractory to paclitaxel (Taxol), ionomycin and cytokine deprivation (Bouillet et al., 
1999). Puma was initially identified as a p53 target gene, but it appears to be involved in 
the regulation of p53 dependent and independent apoptosis signaling (Villunger et al., 
2003; Jeffers et al, 2003). Activation of death receptors triggers caspase-8 mediated 
cleavage of Bid (Li et al., 1998; Luo et al., 1998). Bad-deficient mammary epithelial cells 
show some resistance to withdrawal of epidermal growth factor (Ranger et al., 2003). Bmf 
seems to be required for anoikis, a form of apoptosis engaged by epithelial cells when they 
detach from the extracellular matrix (Puthalakath et al., 2001). Bim and Bik play an 
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important role in the sensitization of cells by proteasome inhibitor Bortezomib to TRAIL-
induced apoptosis (Nikrad et al., 2005). 
 
 
Figure 1.10    Diverse cellular signaling pathways activate the apoptotic program through recruiting 
distinct BH3-only proteins to engage downstream multidomain Bcl-2 family members (Adapted from 
Willis & Adams, 2005). 
 
 
     
 
Figure 1.11 Differential binding profiles of BH3-only proteins to the anti-apoptotic Bcl-2 family 
members and their apoptotic potency. (a) The BH3 peptides from the BH3-only proteins Bim, Bid and 
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Puma displays high binding affinity to all anti-apoptotic Bcl-2 family members. However, the BH3 peptides 
from Bad and Noxa selectively bind to Bcl-2/Bcl-xL/Bcl-w and Mcl-1/A1, respectively. (b) Bim, Puma and 
tBid are more potent killer, compared to the BH3-only proteins which selectively bind to subset of anti-
apoptotic Bcl-2 family members. Noxa in conjunction with a Bad BH3 peptide significantly increase its 
potency in inducing apoptosis (Chen et al., 2005).    
 
 
      Recently, a systematic study of the binding affinities of BH3 peptides from the eight 
mammalian BH3-only proteins (Bim, Puma, tBid, Bik, Hrk, Bad, Bmf and Noxa) to the 
five pro-survival relatives (Bcl-2, Bcl-xL, Bcl-w, A1 and Mcl-1) has provided further 
insight into the interplay among Bcl-2 family members through physical interaction (Chen 
et al., 2005). Bim, Puma and tBid are able to bind to all five pro-survival members. 
However, Bad and Bmf bind only to Bcl-2, Bcl-w and Bcl-xL, whereas Noxa binds only 
to Mcl-1 and A1 (Chen et al., 2005) (Figure 1.11).  
      It has been demonstrated that multidomain pro-apoptotic members such as Bax and 
Bak are able to homodimerize and hetrodimerize with multidomain pro-survival members 
and certain BH3-only molecules (Marani et al., 2002; Carton et al., 2004; Walensky et al., 
2006; Oh et al., 2006; Kim et al., 2006). However, it is impossible to get any clues from 
the studies on apoptosis in C. elegans about the role for multidomain pro-apoptotic 
members in the interplay of the Bcl-2 family proteins as no homologue of multidomain 
pro-apoptotic members of the Bcl-2 family has been identified in C. elegans. It have been 
found that apoptosis induced by the over-expression of BH3-only molecules is largely 
dependent on the presence of pro-apoptotic proteins Bax and Bak (Cheng et al., 2001; 
Zong et al., 2001). Furthermore, BH3-only molecules fail to induce Cytochrome c release 
from mitochondria isolated from both Bax and Bak deficient cells (Kim et al., 2006). 
These together suggest that Bax and Bak function downstream of the BH3-only proteins.   
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Figure 1.12   Models for the functional interplay among the Bcl-2 family proteins in mammalian cells 
(Adapted from Strasser, 2005). Three postulated models are shown. (a) BH3-only proteins might inactivate 
Bcl-2-like pro-survival proteins, which keep cells alive by inactivating the multidomain pro-apoptotic 
members Bax/Bak; (b) Death stimuli might jointly activate pro-apoptotic BH3-only proteins and BAK/BAK 
proteins, which both block the pro-survival function of Bcl-2-like proteins; (c) BH3-only proteins might 
activate Bax/Bak proteins directly, or pro-survival Bcl-2-like proteins might function by binding and 
inactivating BH3-only proteins and/or Bax/Bak. 
 
Based on these observations, two alternative models (“direct activation” vs “indirect 
activation”) for the functional interplay among the Bcl-2 family proteins have been 
proposed in the last few years. In these two models, BH3-only and multi-domain pro-
survival proteins serve as a positive and negative regulator respectively, whereas Bax and 
Bak act as the executioners for promoting the initiation of apoptosis. However, for the 
“direct activation” model (Figure 1.12c), certain BH3-only proteins, termed activators 
(Bim, Bid and Puma), can bind to Bax and Bak directly and promote their activation. In 
this model, the remaining BH3-only proteins, termed sensitizers (or de-repressor), bind 
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only the anti-apoptotic Bcl-2 family proteins and mainly act by displacing activator BH3-
only protein from anti-apoptotic Bcl-2 family members, allowing them to directly activate 
Bax/Bak (Letai et al., 2002; Kuwana, et al,. 2005; Marani et al, MCB, 2002; Carton et al., 
2004; Walensky et al., 2006). For the “indirect activation model (Figure 1.12a), all the 
BH3-only proteins only directly bind to their anti-apoptotic relatives and act by preventing 
them from countering Bax/Bak activation (Willis et al., 2007).  
 
 1.3.2.4 Knockout studies among the Bcl-2 family genes 
      Gene targeting knockout through homologous recombination has been extensively 
used for the studies of the function of the Bcl-2 family. Most of the identified members of 
the Bcl-2 family have been subjected to knockout analyses in mouse models. Among the 
members of the Bcl-2 family, only deletion of Bcl-x or Mcl-1 causes embryonic lethality, 
suggesting these two pro-survival multidomain molecules play an essential and non-
redundant role in the embryo development, and none of the other pro-survival members 
such as Bcl-2, Bcl-w or A1 can compensates the function of these two molecules during 
embryo development. A recent study (Chen et al., 2005) demonstrating that different 
BH3-only molecules selectively interact with particular pro-survival members appears to 
be consistent with the diverse phenotypes of different pro-survival members. Knockout 
analysis of a combination of genes encoding pro-survival and pro-apoptotic members 
provides powerful insights on the importance of the balance between the pro-survival and 
pro-apoptosis member of the Bcl-2 family for life or death. For example, even one Bim 
allele mutant is sufficient to rescue certain phenotypes in the Bcl-2 deficient mice 




Table 1.3    Knockout phenotypes of different Bcl-2 family members 
 
Bcl-2 members Phenotypes References 
Bcl-2 Reduced body weight and life span; Lymphopenia; Multicystic 
kidney, renal hypoplasia and rental failure;  Loss of hair 
pigmentation due to accelerated  loss of melanocytes; Decreased 
number of oocytes and primordial follicles; Distorted small 
intestine with accelerated exfoliation of epithelial cells; 
Degradation of motoneurons, sympathetic and sensory neurons 
during early postnatal development; Enhanced susceptibility of 
cerebellar granule neurons to undergo apoptosis in vitro; Reduced 
axon growth rate in embryonic sensory neurons cultured in vitro. 
 
Nakayama et al, 1994;  
Veis et al, 1993;  
Ratts et al., 1995; 
Kamada et al., 1995; 
Michaelidis et al., 1996; 
Sorenson et al., 1996; 
Tanabe et al, 1997;  
Hilton et al., 1997. 
Bcl-2/Bax DKO 
 
Apotosis and thymic hypoplasia characteristic of Bcl-2 deficient 
mice are largely absent in mice also deficient in Bax. 
 





Loss of even one Bim allele restored normal kidney development, 
growth and health of Bcl-2 mutant mice. 




Die during embrogenesis (E13) with massive increase in 
developing postmitotic cells of dorsal root ganlia, brain stem and 
the embryonic cord;  Enhanced death of serum-depleted 
telencephalic cells in vitro. 
 
Motoyama et al., 1995; 







Bcl-x was deleted in the hemapopietic system; Profound 
enlargement of the spleen; Developing splenomegaly and severe 
thrombocytopenia due to hyperpoliferation of megakaryocytes and 
erythroid cells; Decline in the number of circulating platelets. 
 
Wagner et al., 2000. 
 
 
Bcl-x/ Bax DKO 
(Bxl-x conditional) 
 
Remaining Bcl-x conditional KO phenotypes, suggesting that 
enthroid hyperplasia and hemolytic anemia is independent of Bax. 
 




Both males and females showed severe reproductive defects due to 
lose of germ cells;  




Loss of Bcl-x function in the hypomorph was corrected by the 
deletion of both copies of the Bax gene.   
Rucker et al., 2000. 
Bcl-w 
 
Viable, healthy, normal in appearance; Males are infertile due to 
progressive testicular degeneration and blockage in late 
spermiogenesis. 
 
Ross et al., 1998; 
Russell et al., 2001. 
 
 
Bcl-w /Bax DKO 
 
 
 Bax suppressed the loss of Sertoli cells in Bcl-w mutants; 
 





Bak has no effect on the loss of sertoli cells in Bcl-w mutants Ross et al., 2001. 
Mcl-1 
(Conventional)  
Embryonic lethality; Peri-implantation. 
 
Rinkenberger et al., 2000. 
Mcl-1 
(Conditional) 
Profound reduction in B and T lymphocytes; loss of early bone 
marrow progenitor populations, including HSCs 
Opferman et al., 2003; 
Opferman et al., 2005. 
 
A1 Spontaneous apoptosis of peripheral blood neutrophils; 
Diminution of acute inflammatory response. 
Hamasaki et al., 1998; 







Table 1.3      Knockout phenotypes of different Bcl-2 family members (Continued) 






Viable; Increased number of thymocytes and B cells; Sympathetic 
neurons are resistant to cell death induced by trophic factors 
deprivation;  Males are infertile with accumulation of atypical 
premeiotic germ cells in testis; Artretic follieles with excess 
granulose cells in ovary; Abolish doxorubicin-induced occyte 
apoptosis;  
Knudson et al., 1995. 
Deckwerth et al., 
1996;  
Perez et al., 1997. 
Bak Viable, healthy, no detectable abnormal phenotypes. Lindsten et al., 2000. 
 
Bax/Bak Die perinatally due to multiple developmental defects; MEF cells 
are resistant to various apoptotic stimuli, including over-
expression of BH3-only proteins; Defect in thymic selection and 
lymphoid homeostasis. 
Lindsten et al., 2000; 
Wei et al., 2001; 
Zong et al., 2001; 
Cheng et al., 2001; 
Rathmell et al., 2002. 
Bid Hepatocytes are resistant to Fas-induced apoptosis; Development 
of a myeloproliferative disorder;  
Yin et al., 1999. 
 
 
Bim Increased numbers of lymphoid and myeloid cells; inhibition of 
loss of autoreactive thymocytes promoted by superantigen as well 
as by peptide; thymocytes are refractory to apoptosis induced by 
TCR-CD3 stimulation; Inhibition of BCR-induced apoptosis and 
deletion ot autocreactive B cells; Osteoclasts was increased in 
skeletal tissues due to defect of apoptosis; Osteoclasts cultured in 
vitro showed a marked prolongation of survival in the absence of 
M-CSF; 
Bouillet et al., 1999; 
Bouillet et al., 2002; 
Akiyama et al., 2003; 
Enders et al., 2003. 
Bid/Bim  
DKO 
Alive, healthy, normal appearance, expected Mendelian 
frequency. DKO MEF showed no significant defect to apoptotic 
stimuli    




Defects in hematopoiesis and in thymocyte apoptosis Hutcheson et al., 
2005. 
Puma Alive, healthy, normal appearance, normal body and organ 
weights; Decreased p53 dependent and independent apoptosis in 
fibroblasts and lymphocytes;   
Villunger et al., 
2003; Jeffers et al, 
2003. 
Noxa Normal development and physiology; Fibroblasts were resistant to 
DNA damage-induced apoptosis. 
Villunger et al., 
2003. 
Bad Alive, healthy; Lymphoid cells did not exhibit significant resistant 
to a broad range of apoptotic stimuli; Old mice developed diffuse 
large B cell lymphoma. 
Ranger et al., 2003. 
Bim/Bad DKO Apoptosis of Bcr/Abl+ leukemic cells induced by imatinib was 
blocked. 
Kuroda et al., 2006; 
Hrk Certain neuronal population displayed resistance to nerve-growth-
factor deprivation-induced apoptosis;  
Imaizumi et al., 
2004. 
Bik Alive, no abnormalities were found. Coultas et al., 2004; 
Bik/Bim DKO 
 
Hematopoietic compartments showed similar phenotypes to Bim-
/-; Males are infertile due to defect of spermatogenesis;  
Coultas et al., 2005. 








of Bcl-2 deficient mice are largely absent in mice also deficient in Bax (Knudson & 
Korsmeryer, 1997). The regulation of survival and death in vivo through the balance of 
Bcl-x and Bax has also been reported (Rucker et al., 2000). Bax, Bak and Bok are the 
identified members in the multi-domain pro-apoptotic class of the Bcl-2 family. Although 
Bok deficient study has not been reported, it is unlikely to play a redundant role of Bax or 
Bak in most of cell types as the absence of both Bax and Bak exhibited a profound defects 
in diverse apoptosis pathways (Lindsten et al., 2000; Wei et al., 2001; Zong et al., 2001; 
Cheng et al., 2001; Rathmell et al., 2002). Gene disruption of the BH3-only proteins in 
mice has further supported the idea that individual BH3-only protein might be responsible 
for initiating apoptosis in response to select stimuli and only within certain cell types. 
Moreover, the protective effect conferred by the deficiency of a single BH3-only protein is 
usually not as marked as that conveyed by Bcl-xL and Mcl-1, or loss of both Bax and Bak. 
This may be explained by functional redundancy or compensation among members of 
BH3 only proteins. Indeed, it has recently been shown that concomitant loss of certain 
members of BH3 only proteins display much more profound and even novel phenotypes in 
comparison to the deletion of a single BH3-only protein. For instance, Loss of Bim plus 
Bad, but not either of them, abrogates imatinib-induced apoptosis of Bcr/Abl+ leukemic 
cells (Kuroda et al., 2006). While testes develop normally in mice lacking either Bik or 
Bim, adult Bik-/-Bim-/- mice were infertile with reduced testicular cellularity and absence 
of spermatozoa (Coultas et al., 2005). Hence, combined knockout of two or more BH3-
only proteins might provide a powerful approach for shedding light on understanding the 





1.3.3 Regulation of mitochondrial outer membrane permeability by the Bcl-2 family  
1.3.3.1 Regulation of MPT  
      The mitochondrial membrane permeability transition (MPT) is a Ca2+-dependent 
increase in the permeability of the inner mitochondrial membrane, resulting in the loss of 
Δψ, mitochondrial swelling, and rupture of the outer mitochondrial membrane (Sharpe & 
Youle, 2004; Tsujimoto et al., 2006). MPT is thought to occur after the opening of a 
putative channel complex. While the exact composition of the mitochondria permeability 
transition (MPT) pore complex is not completely addressed, this complex is thought to at 
least consist of proteins from the cytosol (hexokinase), the outer membrane (voltage-
dependent anion channel, VDAC), the inner membrane (the adenine nucleotide 
translocator, ANT), and the matrix (Cyclophilin D) (Figure 1.3). A role of ANT in the 
MPT is supported by inhibition or activation of the MPT by bonkrekic acid and 
atractyloside, respectively, which are specific ligands for ANT. However, the gene 
knockout study suggests that ANT might not play a crucial role, if any, in the MPT as the 
liver mitochondria from both ANT1 and ANT2 deficient mice are able to undergo MPT 
(Kokoszka et al., 2004). Cyclophilin D is a mitochondrial member of the cyclophilin 
family, which shows peptidyl prolyl-cis, trans-isomerase (PPIase) activity and has an 
important role in protein folding. The involvement of Cyclophilin D in controlling the 
MPT came from the observation that cyclosporine (CsA), a specific inhibitor of the 
cyclophilin family, blocks MPT. Cyclophilin D resides in the mitochondrial matrix in 
healthy cells, but it binds to the inner membrane protein ANT and thereby triggering a 
conformational change of an inner membrane channel, leading to an increase of inner 
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membrane permeability. In addition to the CsA-sensitive and Ca2+-dependent, some 
evidence appeared to suggest that a CsA insensitive and Ca2+-independent MPT may also 
exist, although the underlying mechanism and relationship to the CsA-sensitive MPT is 
completely unknown (Tsujimoto et al., 2006).  
      Some forms of apoptosis can be inhibited by CsA or bonkrekic acid, suggesting a role 
of MPT in this process of cell death. Moreover, certain Bcl-2 family proteins, including 
both multidomain pro-survival proteins such as Bcl-2 and Bcl-xL and multidomain pro-
apoptotic molecules such as Bax and Bak, has been shown to interact with VDAC and 
ANT (Marzo et al., 1998; Shimizu et al., 1999). It was proposed that multidomain Bcl-2 
family proteins regulate the apoptotic program through controlling the opening of the 
MPTP. The opening of the MPTP may eventually lead to mitochondrial swelling, rupture 
of the outer membrane and subsequent release of Cytochrome c. However, some argue 
that this hypothesis is unlikely to be true because swelling and rupturing of the outer 
membrane would disrupt ATP production, which is required for apoptosis (Halestrap, 
2005). Indeed, recent work in characterizing the phenotypes of Cyclophilin D knock-out 
animals uncovered crucial evidence to cast doubt on the idea that MPTP is essential for 
apoptosis (Baines et al., 2005; Nakagawa et al., 2005; Halestrap, 2005). Various cells 
isolated from Cyclophilin D-deficient mice, such as thymocytes, MEFs and hepatocytes, 
were found to undergo apoptosis normally in response to various stimuli, including 
etoposide, stautosporine and TNFα, while these cells were severely defective in MPTP 
opening stimulated by necrotic stimuli (Baines et al., 2005; Nakagawa et al., 2005). 
Importantly, mitochondria isolated from cells of Cyclophilin D-deficient animals 
exhibited no defect in responding to the direct stimulatory effect of recombinant Bax or 
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tBid proteins in releasing Cytochrome c (Baines et al., 2005; Nakagawa et al., 2005). The 
data from Cyclophilin D deficient mice indicate that Cyp D-dependent MPT does not 
appear to play an essential role in the regulation of apoptosis, however, the pro-apoptotic 
members of the Bcl-2 family may still be able to control the MPT during necrosis, 
possibly through the interaction with VDAC (Figure 1.13).  
 
 
Figure 1.13  Release of mitochondrial apoptogenic factors by formation of apoptotic protein-
onducting pores during apoptosis or MPTP during necrosis. Pore formation that leads to release of 
proteins from the mitochondrial intermembrane space or physical rupture due to the MPT are both repressed 
by pro-survival members of the Bcl-2 family (Adapted from Tsujimoto et al., 2006). 
 
 
1.3.3.2 Regulation of a putative VDAC-dependent protein-releasing pore  
      While the classical MPT, which is characterized by mitochondria swelling and outer 
membrane rupture, might not be directly involved in the regulation of apoptosis as 
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mentioned above, VDAC, which is known to serve as a channel in the outer membrane for 
the exchange of all metabolites between mitochondria and the cytosol, could contribute to  
                  
Figure 1.14  VDAC as a convergence point for a variety of death-signals (Adapted from Tsujimoto, 
2002).  Bax/Bak mediated mitochondrial outer membrane permeabilization is dependent on VDAC. The 
Ca2+ dependent death signaling also requires VDAC-mediated mitochondrial permeability transition to 
disrupt the mitochondrial outer membrane. The pro-survival Bcl-2-like molecules prevents  the increase in 
mitochondrial outer membrane permeability either through heterodimerization with pro-apoptotic Bcl-2 




the release of apoptogenic factors in an MPT-independent manner. Shimizu et al. (1999) 
showed that Bax associated with VDAC and induced Cytochrome c release from 
mitochondria isolated from wild-type yeast. Bax-mediated Cytochrome c release was 
significantly compromised in mitochondria isolated from a VDAC1-deficient yeast strain. 
In an additional study from the same group, Bax and VDAC reconstituted in liposomes 
were shown to form a new channel activity with a conductance 4–10 times larger than the 
individual proteins (Shimizu et al. 2000). Thus, Cytochrome c was able to be released 
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from the chimeric channel whereas it could not pass through channels formed by the 
individual proteins. The role of VDAC in mammalian cells was further investigated by 
using anti-VDAC1 specific antibodies which are able to inhibit VDAC activity. Bax-
induced Cytochrome c release and Δψ loss in intact cells or in isolated mitochondria were 
blocked by these antibodies (Shimizu et al. 2001). More recently, the evidence from the 
VDAC1 RNAi knockdown study also suggests that VDAC is an important regulator for 
apoptosis triggered by multiple stimuli (Abu-Hamad et al., 2006). Indeed, it has been 
proposed that VDAC serves as a convergence point in mitochondria for a variety of death 
signals (Tsujimoto, 2002). Independent evidence supporting the implication of VDAC in 
apoptosis regulation is furnished by the observation that Hexokinase I and II may bind to a 
not yet defined VDAC isofrom, as a result, hindering its interaction with Bax and 
attenuating Bax-mediated apoptosis (Pastorino et al,., 2002; Majewski et al., 2004). 
      However, the model suggesting that VDAC is the convergence point for the regulation 
of mitochondria-dependent apoptosis is in contradiction to a number of reports.  A study 
by Priault et al. (1999) showed that Bax-induced Cytochrome c release in yeast deficient 
of VDAC was as efficient as in wild-type yeast. Gross et al. (2000) also concluded that 
VDAC was not required for Bax killing activity in yeast. Furthermore, Saito et al. (2000) 
have shown that Bax oligomers were able to form Cytochrome c-conducting channels in 
liposomes in the absence of VDAC. More recently, it has been reported that VDAC1 -/- 
ES cells displayed a similar sensitivity to STS- and Etop-induced apoptosis as wide type 
cells (Cheng et al., 2003). Moreover, VDAC2 acts as a negative regulator to prevent the 
activation of pro-apoptotic protein Bak through direct interaction. Thus, ES cells with 
deficiency of VDAC2 are even more sensitive to apoptotic stimuli (Cheng et al., 2003). 
Introduction 
 -38-
All together, it is a matter of intense debate whether the overall role of VDAC in 
regulating the permeability of the mitochondrial outer membrane remains controversial.    
 
1.3.3.3 Channel formation 
        Structural studies have been performed on several mammalian Bcl-2 family 
members encompassing both anti- (Bcl-xL, Bcl-2 and Bcl-w) and pro-apoptotic (Bax, Bid)  
members. Despite an overall divergence in amino acid sequence and function (pro-
apoptotic versus anti-apoptotic), structural analyses revealed that anti- and pro-apoptotic 
members of the Bcl-2 family all show a remarkably similar fold (Petros et al., 2004). The 
three-dimensional structures of Bcl-2 family members consist of two central, 
predominantly hydrophobic α-helices (α5 and α6) surrounded by six or seven amphipathic 
a-helices. The structures of the Bcl-2 proteins show a striking similarity to the overall fold 
of the pore-forming domains of bacterial toxins and colicins, a key feature of which is the 
ability to form ion channels in the biological membrane (Muchmore et al, 1996). This 
observation led to the hypothesis that Bcl-2 family proteins may be able to form channels 
directly, which in turn cause the membrane to become permeable to ions and/or proteins.  
        Indeed, it has been shown that both the pro- and anti-apoptotic members are able to 
form channels in artificial membranes. It is notable, however, that the anti-apoptotic 
members of the Bcl-2 family proteins and t-Bid only have channel activity in artificial 
membrane at pH below 5.5 (Dejean et al., 2006). This has raised question as to whether 
both the pro-survival and BH3-only proteins can function as channel-forming molecules 
under physiological conditions. Interestingly, it has been reported that under certain 
conditions, Bcl-2 was able to block the channel formation by Bax protein (Antonsson et 
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al., 1997). On the contrary, Bax has pore-forming activity at neutral pH while the channel 
activity is further increased at lower pH. Monomers of Bax were originally shown to form  
 
channels that are quite large (from a few pS to 1.5 nS) (Schlesinger et al., 1997; 
Antonsson et al., 1997). However, even at this large peak conductance, it corresponds 
only to a pore that is undoubtedly too narrow to allow release of even very small proteins 
such as Cytochrome c. Subsequently, it has been found that the oligomerization of Bax 
before its insertion into planar bilayers allows for the formation of non-selective, voltage 
independent channels that show a gradual increase in conductance from 0.09 to 5.4 nS 
(Roucou et al., 2002). The estimated diameter of the 5.4 nS conductance Bax is 5.5 nm, 
which is theoretically consistent with the passage of ~3 nm Cytochrome c. This discovery 
was recently confirmed in a study in which the channel-forming activity of oligomeric 
Bax was monitored by patch clamp techniques (Dejean et al., 2005). It is believed that the 
Bax oligomerization process is essential step for the channel-formation of Bax in artificial 
membranes or in mitochondria in intact cells. However, it is still in active debate whether 
Bax oligomeration occurs earlier than its insertion into mitochondrial outer membrane 
through the α5 and α6 helices during apoptosis (Garcia-Saez et al., 2004; Annis et al., 
2005). It is noteworthy that, although it has been shown that Bax protein alone can form 
channels in artificial membrane systems, the channels formed by Bax in mitochondria 
might not compose exclusively of Bax protein, other molecules in mitochondria might 







Figure 1.15  The structures of the Bcl-2 proteins show a striking similarity to the pore-forming 
domains of bacterial colicins (Adapted from Schlesinger & Saito, 2006). The models were colored as 
follows: green-hydrophobic core helices; red-helix containing BH3; gold-“insertion-blocking helix 
associated with the hydrophobic core.  
 
Figure1.16    Comparison of pore-forming models for Bax (Adapted from Annis et al., 2005). (A) In 
untreated cells, Bax is a cytoplasmic monomer. Model I:  (B) Bax binds to membranes peripherally or by 
insertion of helix 9. (C) Membrane-bound monomers oligomerize to generate a structure capable of forming 
a pore in the membrane. (D) A concerted conformational change inserts helices 5–6 and 9 (unless helix 9 is 
already embedded) and reorganizes lipids to form a large hole in the membrane.  Model II: (B’) Bax inserts 
helices 5–6 and 9 into the bilayer as a monomer. (C’) Monomers undergo a conformational change at the 
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amino-terminus initiating oligomerization. (D) Ongoing oligomerization reorganizes the bilayer to form a 




1.4 THE MULTIDOMAIN PRO-APOPTOTIC PROTEIN BAX AND BAK 
1.4.1  Bax plays dominant role over Bak 
      Murine embryonic fibroblasts (MEFs) isolated from mice with either Bax or Bak 
deleted displayed no significant defect in apoptosis (Danial & Korsmeyer, 2004; Lindsten 
et al., 2000). However, MEFs with double Bax and Bak knockouts showed dramatic 
resistance to diverse apoptotic stimuli (Lindsten et al., 2000; Wei et al., 2001), including 
apoptosis initiated by the over-expression of BH3-only molecules (Zong et al., 2001; 
Cheng et al., 2001). These observations suggest that Bax and Bak are central, but 
redundant, effectors of the Bcl-2 family proteins responsible for the execution of 
mitochondria-dependent apoptosis. Analyses of apoptosis signaling events in neurons 
obtained from knock-out animals,  however, argued that Bax, but not Bak, is exclusively 
required for apoptosis signaling in a neuronal context (Putcha et al., 2002). Furthermore, 
emerging evidence from studies performed on human cell lines and tumors suggests that 
Bax exerts a dominant function over Bak and that the functional dominance exhibited by 
Bax over Bak does not seem to be attributed simply to low level of expression of Bak 
protein in the human cell lines or tumors examined (Deckwerth et al., 1996; Zhang et al., 
2000; LeBlanc et al., 2002; Cartron et al., 2003; Arnoult et al., 2004).  
      Interestingly, the human Bax gene contains a special tract of eight deoxyguanosines 
(G8 tract) and it was found to be frequently inactivated due to frameshift mutations in 
tumors of the microsatellite mutator phenotype, which comprises 15% of human colon, 
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gastric, and endometrial cancers (Rampino et al., 1997; Ionov et al., 2000). Moreover, the 
importance of Bax in tumor progression has been documented in numerous studies of 
human tumors as well as in animal models (Rampino et al., 1997; Ionov et al., 2000; 
Cartron et al., 2003; LeBlanc et al., 2002). 
 
1.4.2  Regulation of Bax function 
       Bak is a resident protein in mitochondria and its pro-apoptotic activity appears to be 
restrained by associating with VDAC2 (Cheng et al., 2003) or Mcl-1 (Cuconati et al., 
2003; Leu et al.,2004). In contrast to Bak, Bax is predominantly localized in cytosol or 
loosely attached to mitochondrial membranes in an inactive form in healthy cells (Wolter 
et al., 1997). Identification of a Bax-conformation-dependent antibody in 1997 provides a 
powerful tool for studying Bax activation during apoptosis (Hsu & Youle, 1997). 
Moreover, recent data from an NMR study suggest that in the latent form of Bax, the c-
terminus (α9 helix) occupies the hydrophobic pocket formed by its BH1-3 domains 
(Suzuki et al., 2000). Apoptotic stimuli cause Bax to undergo conformation changes that 
involve the unfolding of N- and C-terminus (Goping et al., 1998; Nechushtan et al., 1999). 
These structural changes may be required for facilitating the translocation of Bax from the 
cytosol to mitochondria where Bax oligomerizes into a high molecular weight complex 
that integrates into the mitochondria membrane, leading to permeabilization of the 
mitochondrial outer membranes ( Eskes et al.,2000; Antonsson et al., 2001; Kuwana et al., 
2002). Interestingly, other studies offer evidence to argue that conformation changes and 
translocation of Bax from the cytosol to mitochondria alone are insufficient for engaging 
its molecular function in mitochondria, suggesting that additional steps may be necessary 
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for Bax to execute its pro-apoptotic function in mitochondria (Makin et al., 2001; Roucou 
et al., 2002). 
          Recently, several proteins have been reported to associate with inactive form of Bax 
in resting cells and maintain Bax in its inactive form and localization in the cytosol. 
Humanin (HN), a neuroprotective small secreted peptide against Alzheimer's disease-
related insults, has been found to suppress apoptosis through associating with Bax in the 
cytosol and preventing its translocation to mitochondria in certain circumstances (Guo et 
al., 2003). However, other than with Bax, Humanin is able to interact with Bcl-2 family 
protein BimEL and Bid, two well characterized activators of Bax (Zhai et al., 2005; 
Luciano et al., 2005), to suppress Bax activation by those two molecules, which implies 
that Humanin may not interfere Bax function through direct interaction. KU70 has been 
shown to form a complex with Bax in healthy cells. Interestingly, a small peptide from the 
c-terminus of KU70 is cell –permeable and able to bind to the N-terminus of Bax to 
suppress Bax activation and translocation in vivo during apoptosis (Sawada et al., 2003a; 
Sawada et al., 2003b). Moreover, it has been further revealed that the acetylaion of the c-
terminus of KU70 controls its association with Bax, and whereby it regulates Bax-
mediated apoptosis (Cohen et al., 2004; Cohen et al., 2004; Subramanian et al., 2005). 
However, KU70 was initially identified as a nuclear protein which forms a complex with 
KU80 to play important role in DNA double-strand break repair. Although overexpression 
of KU80 does not suppress Bax-mediated apoptosis (Sawada et al., 2003a; Sawada et al., 
2003b), the phenotypes of KU70–/– mice and of KU80–/– mice are similar (Gu et al., 
1997). This suggests that, even though a cytosolic fraction of KU70 associates with Bax, it 
might not be relevant under physiological conditions (Lucken-Ardjomande & Martinou, 
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2005). The 14-3-3 family Proteins might also serve as another retention factor for Bax in 
cytosol (Samuel et al., JBC, 2001), however, the 14-3-3 family are adaptors that modulate 
the localization and activities of a wide array of targets and are known to have other anti-
apoptotic activities – for example, through the sequestration of the BH3-only protein Bad 
– and to inhibit cell cycle progression following DNA damage (Zha et al., 1996). 
Therefore, whether the direct interaction of 14-3-3 family proteins with Bax in cytosol is 
critical for them to inhibit apoptosis still requires further thorough studies.  ARC is the 
only Bax-interacting protein whose downregulation results in exposure of the N-terminus 
of Bax and increased cell death (Nam et al., 2004). However, the insertion of Bax into the 
mitochondria and its oligomerization status has not been assessed in this study, and cell 
death was only monitored by trypan blue exclusion in these experiments.  
      In contrast to those studies suggesting that certain molecules are involved in keeping 
Bax in an inactive form and sequestering Bax in the cytosol, gel filtration and cross 
linking analysis have indicated that in vitro-translated Bax or Bax protein from healthy 
cells exist in a inactive conformation and does not form any homooligomers or complexes 
with other molecules (Antosson et al, 2000; Cartron et al., 2004; Walensky et al., 2006). 
Therefore, while it is now wildly accepted that the conformation change is a critical step 
for the movement of Bax from cytosol to mitochondria during apoptosis, it remains 
controversial whether certain cytosolic molecules are necessary for maintaining the proper 
conformation of Bax in the resting cells.   
         In addition to the proteins that might serve as retention factors to keep Bax in 
inactive form, other proteins have been identified to activate Bax, probably through direct 
physical interaction. Bif-1 was initially identified as an interacting partner of Bax in an 
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yeast two-hybrid screen (Cuddeback, 2001), however, recent data from Bif-1 knockout 
animals suggest Bif-1 is involved in both Bax- and Bak-mediated apoptosis (Takahashi et 
al., 2005). Both Bid and Puma are fished out as a bind partner for Bax from a bacteria two 
hybrid screen (Cartron et al., 2004), and their interaction with Bax was further confirmed 
in vivo by co-immunoprecipitation analyses (Carton et al., 2004). In addition, Bid was 
shown to be able to directly activate in vitro-translated Bax proteins through physical 
interaction (Carton et al., 2004). More recently, the direct binding interaction between Bax 
and a hydrocarbon-stapled Bid BH3 domain, but not a stapled Bad BH3 peptide, has been 
detected and quantified (Walensky et al., 2006). In consistence with the previous study 
(Carton et al., 2004), the stapled Bid BH3 helix was found to be able to trigger the 
functional activation of Bax in vitro through direct binding (Walensky et al., 2006). In 
another study, a splicing isoform of the BH3-only molecule Bim has been shown to 
activate Bax through direct binding (Marani et al,  2002).  More recently, the apoptosis-
associated speck-like protein (ASC) has also been found to interact with Bax (Ohtsuka et 
al., 2004). Over-expression of this protein leads to cell death, and its down-regulation 
inhibits apoptosis following DNA damage. However, ASC contains a caspase recruitment 
domain and can also lead to caspase activation and apoptosis independent of Bax and Bak 
(Ohtsuka et al., 2004). P53 is a tumor suppressor and transcription factor, however, it is 
proposed that p53 can play an important role in Bax activation through physical 
interaction (Chipuk et al., 2004). Some other distinct ways have also been reported to 
activate Bax during apoptosis. For example, the cleavage of Bax by calpain or other 
proteases results in the generation of p18 truncated protein which is constitutively active 
due to the lack of the N-terminal conformation regulation domain (Wood et al., Exp Cell 
Res, 2000; Cao et al., Blood, 2003; Cartron et al., JBC, 2004). Phosphorylation of Bax by 
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AKT, GSK-beta and JNK/P38 may also play an important role in Bax conformation 
changes and activation during apoptosis (Gardai et al., 2004; Linseman et al., 2004; Kim 
et al., 2006). 
 
 
Figure 1.17     Model for the mechanism of activation of Bax.  In resting cells, Bax is loosely attached to 
mitochondria or sequestered in the cytosol, probably through interactions with retention factors (14-3-3; 
humanin; Ku70; ARC; Hsp70). The C-terminal tail of Bax is unleashed from its hydrophobic pocket upon 
apoptotic stimulation. This conformation change leads to the translocation of Bax to mitochondria and 
whereby form oligomerization.  Apoptogenic factors are then released from the mitochondrial inter 
membrane space. Several proteins have been suggested to participate in the activation of Bax, most likely 
through direct interaction (Adapted from Lucken-Arjomande & Martinou, 2005). 
 
       While it has been demonstrated recently that an in vitro system consisting of tBid, 
Bax and a defined lipid environment was sufficient to reconstitute some properties of 
proapoptotic mitochondrial membrane permeabilization (MMP) (Kuwana et al., 2002), 
this artificial system, however, does not recapitulate all the properties of MMP (Kuwana et 
al., 2002; Zamzami and Kroemer, 2003). The property of Bax oligomerization in the 
reconstituted system and the physiology of apoptosis have been found to be different. In 
whole cells, upon apoptotic stimulation, Bax forms an oligomeric complex with estimated 
molecular mass exceeding 200 kDa. This higher-order complex is also formed when t-Bid 
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and Bax are added to intact mitochondria and OMVs. However, in cardiolipin-containing 
liposomes devoid of mitochondrial proteins, only smaller Bax oligomers (~100 kDa) are 
formed. Furthermore, crosslinking experiments suggest that the oligomers contain Bax-
reactive bands that do not correspond to multimers of Bax molecules, indicating the 
presence of other yet unidentified proteins. Whether such a protein or protein complex 
facilitates the t-Bid/Bax-triggered permeabilization reaction has not been determined in 
detail. Indeed, additional unidentified mitochondrial outer membrane factor appears to be 
required for executing Bax function in mitochondria as recombinant active Bax protein 
failed to induce Cytochrome c release from isolated mitochondria pretreated with 
proteinase K (Roucou et al., 2002). Recently, the hypothesis that additional factors are 
required for Bax function in mitochondria has been further supported by the evidence that 
mitochondria isolated from myc deficient cells are much more resistant to the Cytochrome 
c releasing effect of recombinant Bax (Annis et al.,  2005).                              
               
                    
 
 
1.5 REGULATION OF MITOCHONDRIA-DEPENDENT APOPTOIS BY THE 
UBIQUITIN-PROTEASOME SYSTEM  
1.5.1 The ubiquitin-proteasome system 
      Protein degradation was a neglected area until the discovery of the complex cascade of 
the ubiquitin-proteasome system (UPS) in 1978. It is now clear that the degradation of 
cellular proteins by this system is a highly complex, temporally controlled and tightly 
regulated process that plays major roles in many pivotal physiological processes including 
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cell cycle progression, signal transduction, transcription regulation, stress responses, 
oncogenesis and apoptosis. 
      Degradation of a protein via the UPS involves at least two discrete and successive 
steps. The protein substrate is first tagged by covalent attachment of multiple ubiquitin 
molecules to generate the polyubiquitin chain that serves as a recognition marker to the 
downstream 26S proteasome complex. The tagged protein is then degraded by the 26S 
proteasome complex.  
      (1) Polyubiquitination by E3 ligase:  Conjugation of ubiquitin, a highly 
evolutionarily conserved 76 amino acid residue polypeptide, to the protein substrate 
proceeds via a three-step cascade mechanism (Figure 1.18). Initially, the ubiquitin-
activating enzyme (E1) activates ubiquitin in an ATP-dependent reaction to generate a 
thiol ester intermediate, E1-S~ubiquitin. E2 enzymes known as ubiquitin-carrier proteins 
or ubiquitin-conjugating enzymes (UBCs) then transfer the activated ubiquitin from E1 via 
an additional high energy thiol ester intermediate, E2-S~ubiquitin, to the substrate which 
is specifically bound to a member of the ubiquitin-protein ligase family (E3 ligases). E3 
ligases are a large and diverse group of proteins, characterized by one of the several 
defining domains. These include a HECT (Homologous to the E6-AP C-Terminus), RING 
(Really Interesting New Gene) or U-box (a modified RING motif without the full 
complement of Zn2+-binding ligands) domain (Ardley & Robinson, 2005). For the HECT 
domain E3s, the ubiquitin is transferred once again from the E2 enzyme to an active site 
cysteine residue on the E3 to generate a third thiol ester intermediate, E3-S~ubiquitin, 
prior to its transfer to the ligase-bound substrate. However, RING finger-containing E3s 
catalyze the direct transfer of the activated ubiquitin moiety to the E3-bound substrate 
(Hicke et al., 2005). Although many RING-containing E3s, such as MDM2 (murine 
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double minute clone 2 oncoprotein) and c-Cbl, can apparently act alone, others are found 
as components of much larger multi-protein complexes, such as the anaphase-promoting 
complex (Ardley & Robinson, 2005). E3 ligase is the enzyme that recognizes specific 
target proteins and catalyzes the last step in the conjugation process, namely the covalent 
attachment of ubiquitin to the substrate. Thus, the human genome contains large numbers 
(~1000) of different E3s to endow the ubiquitin-proteasome system with high specificity 
(Hicke et al., 2005). It was thought that E3 ligase conjugates ubiquitin to its target protein 
through the isopetide bond formed between the carboxyl-terminal Gly (G76) of ubiquitin 
and the ε-NH2 group of lysine residue in substrate proteins and that lysine in substrates 
was necessary for their ubiquitination and degradation via proteasome. However, it has 
recently been demonstrated that ubiquitin is able to be conjugated to the N-terminal amino 
group of the substrate (Bloom et al., 2003; Coulombe et al., 2004; Kuo et al. 2004; 
Ciechanover, 2005) or even internal Cysteine residues (Cadwell & Coscoy, Science, 
2005). By successively adding activated ubiquitin moieties to internal lysine residues on 
the previously conjugated ubiquitin molecule (mostly to Lys48), a polyubiquitin chain is 
synthesized. This is subsequently recognized by the downstream 26S proteasome 
complex. Certain substrates are conjugated by a single ubiquitin moiety in a three-step 
mechanism similar to the attachment of ubiquitin that occurs during polyubiquitination. 
Monoubiquitinated substrates, however, are not degraded as the single ubiquitin moiety is 
not recognized by the 26S proteasome complex. Rather, the single ubiquitin moiety serves 
as a routing post-tanslational modification signal for regulating the function of the proteins 




                                      
Figure 1.18    The ubiquitin-proteasome system (Adapted from ocw.mit.edu with some modification). 
Under the sequential action of E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme or UBC) 
and E3 (ubiquitin protein ligase), ubiquitin is conjugated to cellular proteins. Ubiquitin can be directly 
transferred to the E3-bound substrates if the E3 belongs to RING finger family of ligases.  In case of HECT-
containing E3 ligase, the activated ubiquitin is transferred first to the E3 before it is transferred to the E3-
bound substrate.  
 
 
      (2) Degradation via proteasome:   Degradation of polyubiquitinated substrates is 
carried out by a large, ~2 mega Dalton protease complex, referred to as the 26S 
proteasome. Proteasome is a large, multicatalytic cyclindrial complex, located in both 
nucleus and cytoplasm. It consists of two components with distinct functions: one 20S 








proteins and two 19s regulatory subunits that recognize polyubiquitinated substrate 
proteins for degradation. Interestingly, partially due to the high replication rates of tumor 
cells, which implies rapid protein synthesis and degradation, but might also because of the 
genetic changes that accompany transformation, transformed cells are more sensitive to 
proteasome inhibition than normal cells. Accordingly, proteasome has emerged as an 
attractive target for cancer therapy and proteasome inhibitors represent a new class of 
promising anticancer agents (Adams, 2004). In the last two decades, many proteasome 
inhibitors, including MG132, LLnL, Epoxomycin and Lactacystin, have been identified. 
Now, certain proteasome inhibitors are being tested in Phase I and Phase II trials against 
multiple myeloma, prostate and breast cancer (Melino, 2005). Bortezomib, one of these 
inhibitors in clinical trials, demonstrated significant response rates in advanced multiple 
myeloma in a large, multiple center clinical trial and on this basis was the first ptoreasome 
inhibitor to be approved by FDA in 2004 for clinical use (Adams, 2004).  
 
 
1.5.2 Regulation of the Bcl-2 family proteins by UPS 
      Recently, increasing evidence suggests that the ubiquitin-proteasome system plays a 
pivotal role in the regulation of apoptosis signaling pathway. Many key regulators of 
apoptosis, such as p53, IAPs, and Smac, have been identified as substrates of the 
proteasome (Orlowski, 1999; Pickart, 2001; Jesenberger & Jentsch, 2002; Martin 2002; 
Lee and Peter, 2003; Yang & Yu, 2003; Zhang et al., 2004).  Besides being regulated via 
transcription, phosphorylation, conformation change, and proteolytic cleavage (Chan & 
Yu, 2004), it is becoming evident that the ratio between anti-apoptotic and pro-apoptotic 
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Bcl-2 members is crucial to determine the sensitivity of a cell responding to apoptotic 
stimuli. The ubiquitin-proteasome system is critical for delicately controlling the balance 
between pro-apoptotic and pro-survival Bcl-2 members. For instance, proteasomal 
degradation of pro-survival Bcl-2 family members has been shown to be critical for the 
initiation of the apoptosis machinery. The dephosphorylation and subsequent ubiquitin and 
proteasome dependent degradation of Bcl-2 is a key regulatory event in the execution of 
TNF- induced apoptosis in endothelial cells (Dimmeler et al, 1999; Breitschopf et al, 
2000). Mcl-1 is a short-lived protein and is constitutively degraded by the ubiquitin-
proteasome pathway in healthy and apoptotic cells. However, due to the inhibition of 
synthesis of de novo Mcl-1 protein by unknown mechanisms, Mcl-1 is eliminated when 
the cells are exposed to DNA damage stimuli. Moreover, the disappearance of Mcl-1 is 
believed to be necessary for facilitating other mitochondrial apoptotic events including 
Bax translocation, Cytochrome c release, and caspase activation (Nijhawan et al, 2003). 
By using a biochemical fractionation approach, a 482 kDa HECT-domain-containing 
protein has been identified as an E3 ligase for Mcl-1 (Zhong et al., 2005). More recently, 
another pro-survival Bcl-2 member A1/Bfl-1 is found to be highly unstable and its unique 
c-terminus controls its rapid proteasomal degradation (Kucharczak et al, 2005; Herold et 
al, 2006). Levels of BH3-only protein Bim are normally very low in resting cells as a 
consequence of the rapid ubiquitin-dependent degradation. Serum withdrawal, however, 
dramatically increases the levels of Bim protein mainly due to the inhibition of its 
ubiquitination and proteasomal degradation (Akiyama et al, 2003). Similar to Bim, the 
BH3-only molecule, Bik/NBK,  is a short-lived protein in healthy cells and its levels can 
be significantly up-regulated by proteasome inhibitors, but the physiological signals that 
can regulate the stability of Bik/NBK have yet to be identified (Marshansky et al, 2001; 
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Zhu et al, 2005; Nikrad, 2005; Hur et al., 2006).  In contrast to Bim and Bik/NBK, the 
BH3-only molecule Bid is stable and only the proapoptotic active form of Bid (tBid) is 
rapidly degraded by the ubiquitin-proteasome system (Breitschopf et al, 2000). 
Interestingly, Puma-beta, one of the mRNA splicing isoforms of Puma gene was found to 
be regulated via proetasome (Nakano & Vousden, 2001). Some studies seem to suggest 
that the death-promoting mutlidomain Bcl-2 members Bak and Bax can also be regulated 
by the proteasome system. The oncoprotein human papillomavirus E6 protein was found 
to inhibit apoptosis in differentiating keratinocytes through directly interacting with, 
ubiquitinating and subsequently targeting Bak for the degradation by the proteasome 
system (Thomas et al, 1998). Although it was reported that Bax was a substrate of the 
ubiquitin-proteasome system (Li et al., 2000), accumulating evidence reveal that Bax is a 
stable protein with a very long half life and proteasome inhibitors have no effect on the 
levels of Bax protein in many mammalian cell lines (Johnson et al., 2003; Zhu et al., 
2005; Dewson et al., 2003; Nikrad et al., 2005; Akiyama et al., 2003).  
 
 
1.6 OBJECTIVES OF THIS STUDY 
      Evidence from gene deletion analyses of the Bax/Bak subfamily suggest that the 
multidomain molecules (Bax/Bak) are the central integrators of apoptosis signaling and 
appear to act downstream of the pro-survival and the BH3-only pro-apoptotic members of 
the BCL-2 family to regulate mitochondrial outer membrane permeabilization. While it 
has been reported that Bax and Bak are functionally redundant in mouse embryo fibroblast 
(MEF) cells, accumulating data indicate that Bax might play a dominant role, as an 
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executioner of the core apoptosis machine, over Bak in many cellular contexts. Despite the 
extensive knowledge acquired over the last decade in understanding the molecular 
functions of Bax in apoptosis signaling pathway, the molecular mechanism of Bax 
activation and function still remains incomplete and controversial. MOAP-1, initially 
termed MAP-1 (Modulator of Apoptosis-1), has been previously cloned as a binding 
partner of Bax from an yeast two-hybrid screen using Bax as bait (Tan etl al., 2001). 
MOAP-1 contains a BH3-like motif and mediates caspase-dependent apoptosis in 
mammalian cells when overexpressed. However, its functional relationship with Bax in 
contributing to apoptosis signaling in response to apoptotic stimulation has not been 
characterized. The functional regulation of MOAP-1 during apoptosis also remains totally 
unknown. Investigation of the regulatory mechanism of MOAP-1 might lead to important 
insights on understanding the functional relativity between MOAP-1 and Bax for 
promoting apoptosis signaling in mitochondria. The aims of this study were to explore the 
molecular function and regulation of the Bax-associating protein MOAP-1. 
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MATERIALS AND METHODS 
2.1 CHEMICAL AND REAGENTS 
2.1.1 Chemical 
        Staurosporine, thapsigargin, etoposide, cycloheximide, MG132 and LLnL were 
obtained from Sigma. Lactacystin and epoxomycin were purchased from Boston 
Biochemisty.  TRAIL was from Peprotech Inc. The pan caspase inhibitor z-VAD-FMK 
was obtained from Calbiochem.  
2.1.2 Commercial antibodies 
      Antibodies to Bcl-2 (100), myc (9E10 and A14), HA (F7 and Y11), Bax (N-20), Mcl-1 
(22 and S-19), GST (B-14), Bik/NBK (N-19) were purchased from Santa Cruz 
Biotechnology. Anti-Bak (Ab2) and anti-Bax (2D2) antibodies were from Oncogene 
Research Products. Anti-Cytochrome c antibodies for Western blot and concofol were 
from BD Biosciences Pharmingen, and antibodies against HSP60, actin and Cytochrome 
oxidase IV (COX-IV) were from Sigma.  
2.2 MOLECULAR BIOLOGY TECHNIQUES AND METHODS 
2.2.1 Plasmid construction 
      Expression plasmids for hMOAP-1 deletion mutants were generated by polymerase 
chain reaction (PCR) with corresponding primers incorporating appropriate restriction 
sites, and subcloned into the pXJ40HA, pXJ40Myc or pXJ40GST mammalian expression 
vectors driven by the CMV promoter. Substitution mutants of MOAP-1 were created using 
a QuikChange site-directed mutagenesis kit (Stratagene). Wide-type ubiquitin was 
amplified by PCR from SY5Y cDNA and subcloned into the Pxj40HA vector.  For stable 
transfection, full-length MOAP-1 cDNA was sub-cloned into the PIRESneo vector 
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containing an internal ribosome entry site (IRES), which permits MOAP-1 and the G418 
selection resistance marker to be translated from a single mRNA. The coding region of 
individual construct was sequenced to ensure that no error was introduced by PCR. PCS2-
Ub(K0) expression construct was a gift from Prof. M.Pagano (New York University) 
(Bloom et al., 2003). To generate MOAP-1 knockdown vectors, several annealed sets of 
oligonucleotides encoding short hairpin RNAs (shRNA) corresponding to different 
sequences in MOAP-1 coding region were cloned individually into pSilencer, pSilencer-
Hygromycin or pSilencer-G418 vector (Ambion). The target sequences in MOAP-1 
coding region for the two shRNAs R1 and R3 are: 1. R1: TTTGGACGCTGGATGTTTC 
(corresponding to nucleotides 541-559 of the coding sequence of human MOAP-1 cDNA) 
2. R3: TTACTGTCGATGAATGTCT (corresponding to nucleotides 683-701 of the 
coding sequence of human MOAP-1 cDNA). The corresponding control shRNAs with 
two nucleotides change were also generated and the changes are underlined: 1. R1-mut: 
TTTGGTCGCTCGATGTTTCTT and 2. R3-mut: TTACTCTCGAAGAATGTCTTT.   
2.2.2 Preparation of heat shock E.Coli competent cells  
      Saturated cultures of competent cells (e.g. DH5α, BL21, BL21 Gold) were obtained by 
inoculating 10 µl of cells into 10ml of 1 X LB with overnight shaking at 200 rpm in 37oC 
warm room. 8 ml of overnight culture was added into 800 ml of LB without ampicillin in 
2L-shaker-flask and grown for approximately 3-4 h at 37oC to reach OD600 0.7-0.8. The 
cells were harvested by centrifugation at 4,000 rpm for 5 min, resuspended in 240ml RF1 
solution (100 mM RbCl, 50 mM MnCl2, 10 mM CaCl2, 1M KoAc pH7.5 and 15% 
Glycerol),  and aliquoted into falcon tubes (50ml each). After incubation on ice for 10 
min, the cells were collected by centrifugation at 4,000 rpm for 10 min and resuspended in 
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8ml RF2 (10 mM MOPS, 10 mM RbCl, 75 mM CaCl2 and 15% Glycerol) each tube. The 
competent cells were aliquoted and stored at-80oC.  
2.2.3 Plasmid DNA transformation  
          The ligated DNA (20-30 µl), pure plasmid DNA (10-100 ng) or mutagenesis PCR 
product (5 µl) was added into 100-150 µl of competent cells, which were pre-thawed on 
ice. The mixture was incubated on ice for 20 min, heat-shocked for 2 min at 42oC water 
bath and immediately put back on ice for another 2 min. 1 ml pre-warmed LB was added 
into the mixture, followed by shaking at 37oC warm room for 1h. The cells were pelleted 
by centrifugation at low speed (around 5,000 rpm) for 2 min at room temperature. Most of 
the supernatant was discarded and the cells were resuspended in the remaining supernatant 
and spread on the LB agar plates containing the appropriate antibiotic.   
2.2.4 Agarose gel electrophoresis 
         To pour a gel, agarose powder is mixed with TAE buffer (40 mM Tris-acetate and 2 
mM EDTA) to the desired concentration. Most commonly, ethidium bromide (final 
concentration 0.5 µg/ml) is added to the gel at this point to facilitate visualization of DNA 
after electrophoresis. Samples containing DNA mixed with loading buffer [0.25% (w/v) of 
bromophenol blue and xylene cyanol in 25% (w/v) Ficoll (type 400)] are pipeted into the 
sample wells, followed by electrophoresis in TAE buffer. 100 bp or 1 kb DNA ladders 
(New England Biolabs) were used to determine the size of the DNA. The DNA bands 
were detected by UV illumination.  
2.2.5 Restriction enzyme digestion of DNA 
      The 20 μl reaction mixture contained 10 μl of Miniprep DNA or 1-2 μg of Maxiprep 
DNA, 1 μl of each restriction enzyme (BioLabs or Promega), 2 μl appropriate buffer, and 
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corresponding volume of distilled H2O. The digestion mixture was incubated at 37 oC for 
0.5-2 h.   
2.2.6 DNA ligation 
           50 ng vector and 3-fold molar excess of insert was combined, followed by addition 
of 1 µl of Quick T4 DNA Ligase and 2X Quick Ligation Buffer (New England BioLabs). 
The total volume was adjusted with dH2O to 30 µl and the mixture was incubated for 5-15 
min at room temperature. The resultant mixture was used for transformation. 
2.2.7 Purification of DNA fragment 
          DNA was extracted and purified from agarose gel by using QIAquick Gel 
Extraction Kit (QIAGEN). The DNA was excised from the agarose gel with a scalpel. 750 
µl of Buffer QG were added to solubilize the gel slice completely by incubating at 50 oC 
water bath for 10 min. For the purification of DNA from solution such as restriction 
enzyme digestion reaction, 750 µl of Buffer QG were added to the solution without further 
incubation at 50oC. The sample was applied to the spin column, followed by 
centrifugation. After washing with Washing Buffer, 40-100 µl of distilled water was 
added to the column, incubated for 1 min, followed by centrifugation for 1min at 
maximum speed. The eluted DNA was kept at 4oC for further analysis. 
2.2.8 DNA sequencing 
          The 20 μl sequencing reaction mixture contained 0.4-0.6 μg of DNA, 1 μl of 10 mM 
sequencing primer, 8 μl of Sequencing Mix and corresponding volume of distilled H2O. 
The sequencing PCR reaction was performed by 30-35 cycles of DNA denaturation at 
95oC for 30 sec, primer annealing at 52.5 for 10 sec, and extension at 60oC for 4min. The 
PCR product was applied to sequencing analysis. 
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2.2.9 Polymerase chain reaction (PCR) 
      PCR was performed by using the High Fidelity PCR system (Roche) or Pfu DNA 
polymerase (Promega). Usually about 10-50 ng of cDNA was used as template for each 
PCR reaction. The reaction buffer is supplemented with 1.75 mM MgCl2, 250 µM of the 
deoxy-adenine, deoxy-cytosine, deoxy-guanine and deoxy-thymidine nucleotides (New 
England Biolabs), 50 pM forward and reverse primers, and 2.5 Units of DNA polymerase.  
The PCR reaction was performed by 30-35 cycles of DNA denaturation at 95oC for 30 
sec, primer annealing at 50-60oC for 40 sec and DNA extension at 72oC for 1 min/1 kb 
after a pre-denaturation at 95oC for 5 min.  The PCR sample was kept at 4oC after a final 
step of DNA extension at 72oC for 3-5 min.  
2.2.10 Site-directed mutagenesis 
       Complementary primers were designed with the point mutations in the middle of the 
primers with 15–20 nucleotides of correct sequence on both sides. 50-100 ng of DNA, 125 
ng of each primer, 1 µl of dNTP mix (25 mM for each nucleotide) and 1 µl of Pfu DNA 
polymerase (2.5 U/µl) was used for each 50 µl reaction. The PCR reaction was performed 
by 16 cycles of DNA denaturation at 95oC for 30 sec, primer annealing at 50oC for 1 min 
and DNA extension at 68oC for 2 min/1 kb after a pre-denaturation at 95oC for 5 min.  The 
reaction was kept at 4oC after the last cycle. The newly synthesized and non-methylated 
DNA incorporated with the targeted mutant was obtained by addition of 1 µl of Dpn I to 
the reaction to digest the methylated wide type parental DNA templates. The DNA with 
the targeted mutation was transformed into DH5α E. Coli using the heat shock protocol as 
described above. The mutations for all plasmids were confirmed by sequencing. 
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2.2.11 Mini-preparation of plasmid DNA 
         The Wizard® Plus SV Minipreps DNA Purification System (Promega, Madison, WI, 
U.S.A.) was used for rapid isolation of small-scale plasmid DNA. The 2-4 ml overnight 
grown bacteria cultures were harvested by centrifugation for 5 min at 4,000 rpm and the 
supernatant was discarded. The pellet was completely re-suspended in Cell Re-suspension 
Solution [50mM Tris-HCl (pH7.5), 10mM EDTA and 100µg/ml RNase A] by vortexing, 
followed by the addition of Cell Lysis Solution (0.2M NaOH and 1% SDS). After 
incubation of the mixture for 5 min at room temperature, Alkaline Protease Solution was 
added, followed by incubation for another five minutes. The bacterial lysate was 
centrifuged at 13,200 rpm for 10 min at room temperature immediately after the addition 
of Neutralization Solution (4.09M guanidine hydrochloride, 0.759M potassium acetate 
and 2.12M glacial acetic acid, pH4.2).  The cleared lysate was transferred to the Spin 
column and centrifuged for 1 min at 13,200 rpm at room temperature. Column Washing 
Solution [162.8mM potassium acetate, 22.6mM Tris-HCl (pH7.5) and 0.109mM EDTA 
(pH8.0)] previously diluted with 95% ethanol was added to the Spin Column, followed by 
another centrifugation. The wash procedure was repeated once more before eluting DNA 
with 40-100 µl of distilled H2O.  
2.2.12 Maxi-preparation of plasmid DNA 
       Large-scale plasmid DNA isolation was performed by using the QIAGEN Plasmid 
Maxi Kit according to the manufacturer’s instruction. 400 ml of overnight grown bacteria 
cultures were harvested by centrifugation and subsequently incubated with P1 (Re-
suspension Buffer), P2 (Lysis Buffer) and P3 (Neutralization Buffer), which were similar 
to the procedure of miniprep as described above. After centrifugation, the clear supernant 
was carefully transferred to the pre-equilibrated QIAGEN-tip 500 column, followed by 
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washing with Buffer QC (1.0M NaCl, 50mM MOPS pH7.0 and 15% isopropanol). The 
DNA was eluted by Buffer QF (1.25M NaCl, 50mM Tris-HCl pH8.5 and 15% 
isopropanol) and precipitated by isopropanol. The DNA pellet was washed with 70% 
ethanol, air-dried and dissolved in 500-800 µl of distilled H2O. 
2.2.13 RNA extraction, cDNA preparation, and RT-PCR 
      Total cellular RNA was isolated using RNeasy Minikit (Qiagen) and treated with 
RNase-free DNase(Qiagen). RT was performed by using Superscript First Strand 
synthesis system (Invitrogen). The resulting cDNA was used for isolating certain genes. 
The abundance of mRNA of MOAP-1 was examined by reverse transcription (RT)-PCR. 
The sense and anti-sense primers for PCR were 5’-TTGGCACAGGCATTAGAGG-3’ and 
5’-GCCTTAGTACATAAGCCGAC-3’, respectively. Numbers of PCR cycles were 
estimated to be optimal to result in a linear relationship between the amount of input 
template and the amount of PCR product. Actin was used as an internal control. The 
amplification products were resolved on 1.5% agarose gels in the presence of 0.5 μg/ml 
ethidium bromide.  
2.3 MAMMALIAN CELL CULTURE, GENERATION OF STABLE CELL LINE, 
DRUG TREATMENT AND APOPTOSIS ANALYSIS  
2.3.1 Mammalian cell culture  
          COS-1 (African green monkey kidney fibroblast-like cell line), A431(Human 
epithelial carcinoma cell line) and HepG2 (Human hepatocellular liver carcinoma cell line) 
cells were grown in Dulbecco’s modified Eagle’s medium (DMEM, Sigma) containing 
1,000mg/ml glucose, supplemented with 10% (v/v) fetal bovine serum (FBS) purchased 
from Gibco-Invitrogen, 2mM L-glutamine (Sigma), 100 Units/ml penicillin and 100 ng/ml 
streptomycin (Sigma) and 10 mM N-2-hydroxyethyl peperazine-N’-2-ethanesulfonic acid 
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(HEPES, pH 7.3), and incubated at 37oC with 5% CO2. MCF-7 (Human breast carcinoma) 
cells were grown in RPMI 1640  supplemented with similar ingredients and 0.1 mM MEM 
non-essential amino acids (GIBCO BRL Life Technologies). HeLa (Human cervical 
adenocarcinoma cell line) cells were grown in MEM, supplemented with 10% FBS, 2mM 
L-glutamine, 0.2% (v/v) sodium hydrogen carbonate (7.5% NaHCO3), 100 Units/ml 
penicillin and 100 ng/ml streptomycin, 1mM sodium pyruvate and 0.1 mM MEM non-
essential amino acids. Cells were sub-cultured by sucking out the medium, rinsing with 
PBS, and digesting with trypsin to remove cells from the flask. Trypsinization was 
stopped by addition of culture medium.  
2.3.2 Transfection of mammalian cells 
        Cells were seeded in appropriate dishes approximately 16-36 h before transfection. 
Plasmid DNA diluted in 200 µl of OPTI-MEM®I (GIBCO), was mixed with 
LIPOFECTAMINE 2000 (GIBCO, 1-2 µl for 1 µg of plasmid DNA) diluted in 200 µl of 
OPTI-MEM®I. The mixture was incubated at room temperature for 20-45 min to allow the 
DNA-liposome complexes to form.  Appropriate amount of OPTI-MEM®I (5.5 ml for 10 
cm dish, 2ml for each well of a 6 well-plate) was added to the transfection mixture and 
transferred to cells pre-washed once with OPTI-MEM®I.  4-12 h after the transfection, 
transfection mixture was removed and the cells were incubated in complete growth 
medium for another 12-36 h before harvesting.  
2.3.3 Generation of stable cell lines 
      MCF-7 and HCT116 cells were transfected with pSilencer Hygromycin or pSilencer 
G418 MOAP-1 shRNA constructs and selected with 400 µg/ml hygromycin B 
(Invitrogen) or 1.25mg/ml G418(Gibco), respectively. Individual clonal lines were 
evaluated for the knockdown efficiency of MOAP-1 protein and used for further analysis. 
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To generate rescue lines in MOAP-1 RNAi knockdown background, the MCF-7 MOAP-1 
knockdown clonal line SM-R3-12 was transfected with pIRESneo vector or pIRESneo 
MOAP-1construct with 3 silent mutations within the region targeted by shRNA R3 
(TTACTGTTGACGAATGCCT) and selected in 300 µg/ml hygromycin B (Invitrogen) 
plus 1.25 mg/ml G418 (Gibco). The individual clonal lines were evaluated for the 
expression of myc-MOAP-1. For generation of stable cell lines expressing exogenous 
myc-tagged MOAP-1, HCT116 or MCF-7 cells were transfected with pIRESneo vector or 
pIRESneo myc-MOAP-1 construct and selected in 1.25 mg/ml G418 (Gibco). Individual 
clonal lines were evaluated for the expression of myc-MOAP-1. 
2.3.4 Drug treatment 
        Cells were sub-cultured into appropriate plates 24-36 h before drug treatment and 
cells were sub-confluent (50-70%) at the time of treatment. Drugs were added to cells at 
the doses and times specified in the text or figure legends.  
2.3.5 Apoptotic assay 
       WST-1 assay (Roche) was used to measure cell viability according to the 
manufacturer’s instruction. For detection of sub-G1 DNA, cells were washed once, 
resuspended in 200 µl of PBS, and fixed in a 50-fold excess of ice-cold 70% ethanol. Cells 
were recovered by centrifugation at 1000 g for 5 min at 4 °C, washed, stained with 50 
μg/ml propidium iodide for 30 min at room temperature, and analyzed with a FACScan 
flow cytometer (BD Biosciences). Mitochondrial potential change measured by 
MitoTracker Red staining was performed in accordance with the manufacturer's 
instructions (Molecular Probes). A minimum of 10,000 cells/sample was analyzed. 
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2.4 PROTEIN METHODOLOGY 
2.4.1 Cell lysate preparation, immunoprecipitation and Western blotting 
          Cells were washed with cold PBS, lysed in RIPA buffer [150 mM NaCl/50 mM 
Tris/HCl, pH 7.2/1% (w/v) deoxycholic acid/1% (v/v) Triton X-100/0.25 mM EDTA, pH 
8.0/ 0.2% (w/v) NaF/0.1% (w/v) sodium orthovanadate, 0.1% SDS] supplemented with 
‘complete’ protease inhibitors (Roche), followed by sonication for 30 min. For 
immunoprecipitation of activated Bax, cells were re-suspended in CHAPS lysis buffer (20 
mM Tris-HCl, pH7.5, 150 mM NaCl, 2 mM EDTA, 10% Glycerol, 1% CHAPS) 
supplemented with ‘complete’ protease inhibitors (Roche) as described (Murphy et al., 
2000; Yamaguchi and Wang, 2002).After centrifuged, the protein concentration in the 
supernatant was estimated by using the Bio-Rad protein assay reagent (Bio-Rad 
Laboratories) based on the absorbance at 595 nm wavelength in a spectrophotometer. 
Total cell lysates containing equal amount of proteins were rotated with appropriate 
antibodies (normally, 1-2 µg) for 2-12 h at 4oC, followed by incubation with protein A 
agarose beads (Roche) for 1-2 h.  The beads were washed with an appropriate buffer for at 
least 3 times. 20ul of 5X SDS Loading Buffer was added to the beads and boiled for 5-10 
min. The precipitates were separated by SDS/PAGE and transferred on to a Hybond C 
membrane. The membrane was blocked with PBS containing 0.1% Tween 20 and 5% 
milk overnight at 4oC with gentle shaking. Specific antibody was incubated with the 
membrane at an optimal dilution (usually 1: 500-1,000) in PBS containing 0.1% Tween 20 
and 1% milk for 1 h at room temperature with gentle shaking. The membrane was washed 
with PBS containing 0.2% Tween-20 for 3-4 times at 10 min intervals before incubation 
with corresponding horseradish peroxidase (HRP) conjugated secondary antibodies in 
PBS containing 0.1% Tween 20 and 1% milk for another 1 h. The membrane was washed 
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with PBS containing 0.2% Tween-20 for 3-4 times at 10 min intervals and visualized 
using ECL® solution from Amersham Biosciences or Pierce. For re-blotting, membranes 
were incubated in stripping buffer [62.5 mM Tris/HCl, pH 6.8/2% (w/v) SDS/100 mM 2-
mercaptoethanol] for 30 min at 50oC before blocking and incubating with antibodies.  
2.4.2 SDS-PAGE gel electrophoresis 
        The SDS-PAGE gel for all analysis contains both separating and stacking layers. The 
separating layer consisted of 7.5-15% acrylamide (29:1) (Genomic Solution Inc.), 0.375 M 
Tris-HCl pH8.8 and 0.1% (w/v) sodium dodecyl sulfate (SDS) and was polymerized by 
the addition of freshly prepared 0.1% (w/v) ammonium persulfate (APS) and 0.01% (v/v) 
TEMED. The stacking layer was composed of 4% acrylamide, 0.125 M Tris-HCl, pH6.8, 
and 0.1% SDS, and polymerized as described for the separating gels.  5X SDS loading 
buffer [5X: 125mM Tris-HCl (pH6.8), 4% SDS (v/v), 10% β-mercaptoethanol (v/v), 20% 
glycerol (v/v) and 0.4% bromophenol blue (w/v)] was mixed with protein samples. The 
mixture was boiled for 5-10 min, followed by centrifugation at maximum speed for 5-10 
min before loading into theSDS-PAGE gel. The running buffer consisted of 3% Tris-Base, 
14.4% glycine and 0.1% SDS. The proteins on the gel were directly stained with 
Coomassie Brillant Blue or transferred to Hybond C membrane in transfer buffer (3% 
Tris-Base, 14.4% glycine and 20% methanol) for Western blot analysis. 
2.4.3 Determination of protein half-life in vivo 
      For pulse-chase assay, cells were plated at a density of 5 × 106 cells per 10-cm dish. 
The cells were washed with phosphate-buffered saline (PBS), starved in 
methionine/cysteine-free DMEM (GIBCO-BRL) supplemented with 10% 
methionine/cysteine-free FBS (GIBCO-BRL) at 37°C for 30 min, then labeled with 500 
µCi of S35-cysteine/methionine (ICN) per plate at 37°C for 60 min. After labeling, the 
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cells were chased with complete DMEM containing 10% FBS and 2 M cold methionine 
and cysteine at 37°C for the indicated periods of time. Cells were collected and subjected 
to immunoprecipitation analysis as described below. CHX, a protein synthesis inhibitor, 
was also used to estimate protein half-life as previously described (Bloom et al., 2003).  
2.4.4 Subcellular fractionation   
       A total of 107-108 cells were resuspended in Buffer A (320 mM sucrose, 1 mM 
EDTA, 50 mM HEPES-KOH, pH 7.3, 1 µM dithiothreitol) supplemented with ‘complete’ 
protease inhibitors (Roche) and disrupted by 15-30 strokes through a 255/8gauge needle 
followed by centrifugation at 1,000g for 10 min at 4°C. Supernatants were centrifuged two 
times at 3,000g for 10 min each at 4°C to pellet mitochondria enriched fraction. 
Supernatants were further centrifuged at 100,000g for 30 min to obtain the ER and 
cytosolic fractions. Nuclei were isolated as described (Tan et al., 2001). Where indicated, 
mitochondria enriched fraction from 293T cells was further purified through sucrose 
gradients essentially as described (Antonsson et al., 2001). 
2.4.5 Analysis of sub-mitochondrial localization of protein 
         Digitonin treatment: To investigate the binding of protein to mitochondrial 
membrane, mitochondria were incubated with with 0-1.25 mg/ml of digitonin on ice for 
30 min. Mitochondria were then re-pelleted by centrifugation (10,000 rpm, 10 min) and 
immunobloted for the indicated proteins.   
        Protease K digestion:  To examine whether the particular proteins are resided in the 
outer membrane, mitochondria were incubated with 0-10 μg/ml of Protease K (Roche) on 
ice for 10 min. 10mM PMSF was added to stop Protease K digestion. Mitochondria were 
re-pelleted by centrifugation and immunobloted for the indicated proteins. 
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2.4.6 In vitro Cytochrome c release from isolated mitochondria 
     Mitochondria were isolated as described above. Isolated mitochondria were washed 
once with Buffer A and then resuspended at 0.5 mg/ml in Buffer B (250 mM sucrose, 10 
mM HEPES-KOH, pH 7.5, 2 mM KH2PO4, 5 mM Na+-Succinate, 0.25 mM EGTA, 
28mM β-mercaptoethanol) supplemented with ‘complete’ protease inhibitors. Equal 
amounts of mitochondria were incubated with recombinant tBid , Bax or Bak proteins at 
30°C for 30 min followed by centrifugation. Supernatants and pellets were subjected to 
fractionation by 13.5 % SDS-PAGE followed by Western blotting analysis. 
2.4.7 Association of in vitro tanslated proteins with isolated mitochondria 
      200,000 cpm in vitro translated, 35S-labeled MOAP-1, Bcl-xL, or hFem2 (cytosolic 
protein, as a negative control) were added to isolated mitochondria from MCF-7 cells (1 
mg/ml) resuspended in Import Buffer (250 mM sucrose, 80 mM KCl, 5 mM MgCl2, 2.5 
mM Na+-Succinate, 2 mM NADH, 20 mM HEPES-KOH, pH 7.5, 2 mM ATP) and 
incubated at 22°C for 30 min. Mitochondria pellet was obtained by centrifugation and the 
labelled proteins were resolved by SDS-PAGE.  
2.4.8 In vitro transcription and translation of protein 
    Plasmid DNA  with T7 promoter were translated sing TNT® T7 Coupled Reticulocyte 
Lysate System (Promega) according to the manufacturer’s instruction. The 50 μl in vitro 
translation mixture contained 40 μl of TNT® lysate, 2 μl of Mithionine (1mM), 0.5 μg of 
plasmid DNA, and corresponding volume of distilled H2O.  
2.4.9 Expression and purification of bacterial-expressed recombinant proteins   
     Plasmids encoding GST-fused, His-tagged or Intein-tagged proteins were transformed 
into E. coli BL21 Gold competent cells and single colonies were cultured in 10 ml LB 
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containing 50 µg/ml ampicillin at 37oC warm room to obtain saturated cultures. The 
saturated cultures were added to 400 ml of LB with 50 µg/ml ampicillin and grown for 
appropriate time to obtain 0.6-0.85 absorbance at 600 nm. The expression of recombinant 
proteins were induced by 0.7mM IPTG at 30°C for 3 h. Bacteria were harvested by 
centrifugation at 5,000 rpm for 5 min and freezed in -80oC for 30 min or overnight. 
Bacteria were thawed, lysed in 50mM Hepes buffer, pH7.3, 150mMNaCl with protease 
inhibitors by sonication or French Press and clarified by centrifugation at 12,000 rpm for 
30 min.  For GST fusion proteins, supernatant was collected and rotated with pre-washed 
glutathione–Sepharose 4B beads (Amersham) for 1 hr at 4oC. The beads were collected 
and washed several times with PBS. Recombinant Bak protein without GST tag will be 
released out by incubation the beads with appropriate amount of thrombin for 30-60 min 
at 4oC. Thrombin was inactivated by addition of PMSF. For Interin-tagged Bax protein, 
supernatant was collected and rotated with pre-washed Chitin beads (BioLabs) overnight 
at 4oC. The beads were collected and washed several times with PBS. DTT was used to 
induce the cleavage of Intein tag to produce recombinant Bax protein without any 
additional amino acid in comparison to the native Bax protein. For His-tagged tBid 
protein, supernatant was collected and rotated with pre-washed Ni beads (Amersham) in 
5mM imidazole, 100 mM NaCl, 20 Tris PH8.0 for 1 hr at 4oC. The beads were collected 
and washed several times with PBS. The recombinant tBid protein with His tag was eluted 
out by 250 mM imidazole. All eluted proteins were normally dialysised against PBS and 
stored at -80oC after resuspension with PBS/Glycerol in a 1:1 ratio containing the protease 
inhibitors. No detergent was used during the process for all recombinant proteins for in 
vitro Cytochrome c release assay. 
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2.4.10 Gel filtration analysis of Bax oligomerization 
    Cells were lysed in CHAPS  lysis buffer (20 mM Tris-HCl, pH7.5, 150 mM NaCl, 2 mM 
EDTA, 1% CHAPS) supplemented with ‘complete’ protease inhibitors (Roche).  In some 
instances, recombinant Bax protein or in vitro translated Bax protein were diluted in same 
CHAPS lysis buffer. All samples were passed through a 0.4 μm filter column before 
injecting into Suphedex 200HR 10/30 gel exclusion column (Amersham) pre-equilibrated 
with elution buffer (25 mM HEPES Ph7.4, 300 mM NaCl, 0.2 mM DTT and 1% CHAPS. 
The samples were eluted at a flow rate of 0.5 ml/min at 4 oC and the fraction of 0.5 ml 
(1min) were collected in the collection tube containing 20 ul of 10% NP-40 and 20 ul of 
50× ‘complete’ protease inhibitors (Roche) solution. Each fraction was 
immnunoprecipitated by a rabbit anti-Bax antibody (N20), followed by western blotting 
with a mouse anti-Bax antibody (AB3). 
2.4.11 Indirect Immunofluorescence (IF) 
      Cells grown on coverslips were fixed with methanol for 5 min or fixed with 2% 1% 
paraformaldehyde in PBS for 30 min at 4°C, followed by permeabilizing with 0.2% Triton 
X-100 for 10 min. For detection of Bax conformation change with anti-Bax antibody 
(N20), cells were fixed with 1% paraformaldehyde for 30 min and permeabilized with 
0.2% CHAPS. After sequentially washed with PBS, PBS containing 100 mM NH4Cl and 
then PBS, the cells were blocked with with FDB (PBS with 1 mM CaCl2, 1 mM MgCl2, 
5% normal goat serum, 10% fetal bovine serum, and 2% bovine serum albumin) for 30-60 
min at 4°C followed by incubation with primary antibodies in FDB for 1 h. After washing 
3 times with PBS containing 0.1% Triton X-100 or 0.1% CHAPS (for Bax activation), 
cells were incubated with the appropriate secondary antibodies conjugated with 
fluorescein isothiocyanate (FITC) (Molecular Probes) or Cy3 (Amersham Biosciences) for 
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1 hr at 4°C. Cells were then washed 3 times with PBS containing 0.1% Triton X-100 or 
0.1% CHAPS (for Bax activation), mounted with FluoroGuardTM antifade reagent (Bio-
Rad). Staining was visualized by MRC 1024 (Bio-Rad).  
2.4.12 Generation of in house antibodies 
      The rabbit (R5) and mouse (M6) MOAP-1 polyclonal antibodies were raised against 
bacterial GST-MOAP-1 (a.a. 116-351) proteins or GST-MOAP-1 (a.a 1-115). The GST 
protein preparation and purification as described in 2.4.9. The GST protein was further 
purified by SDS/PAGE gel. The protein eluted from SDS/PAGE was injected into mouse 






3.1 MOAP-1 IS REQUIRED FOR BAX-MEDIATED APOPTOSIS 
SIGNALING IN MITOCHONDRIA 
3.1.1  MOAP-1 is enriched in the mitochondrial outer membrane  
     MOAP-1 (Modulator of Apoptosis-1) was initially identified in a yeast two-hybrid 
protein-protein interaction screen using Bax as bait (Tan et al., 2001). MOAP-1 was found 
to associate with Bax, Bcl-2 and Bcl-xL and trigger apoptosis when over-expressed in 
mammalian cells (Tan et al., 2001). To determine the subcellular localization of 
endogenous MOAP-1, 293T cells were fractionated into cytosol, nuclei, light membrane 
(LM) and heavy membrane (HM) fractions and immunoblotted with MOAP-1 and other 
antibodies as indicated. The 39 KDa MOAP-1 protein was detected predominantly in the 
heavy membrane fraction enriched with the mitochondria marker (Figure 3.1.1A). 
      To investigate further the association of MOAP-1 with mitochondria, in vitro 
translated 35S-labelled proteins were incubated with isolated mitochondria.  MOAP-1 and 
Bcl-xL, but not the cytosolic protein hFEM-2, were found to readily associate with 
isolated mitochondria of healthy cells (Figure 3.1.1B). 
     Although anti-MOAP-1 antibodies R5 and M6 were able to detect overexpressed 
myc-MOAP-1 with similar efficiency as the myc antibody in mammalian cells, neither 
antibodies was able to detect a specific immunofluoresence signal corresponding to 
endogenous MOAP-1 in MCF-7, 293T or SH-SY5Y cells, suggesting that MOAP-1 
protein is at low abundance. To further confirm the mitochondrial localization of MOAP-
1, we employed confocal microscopy to visualize transiently expressed myc-MOAP-1 in 
MCF-7 cells. Myc-MOAP-1 is pro-apoptotic and exhibits a perinuclear staining pattern 
which co-localized with the mitochondria-specific dye, mitotracker red (Figure 3.1.1C, 
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Left panels). In contrast, the non-apoptotic form of MOAP-1, MOAP-1 (1-115) (Tan et 
al., 2001), showed a distinct punctuate staining pattern and displayed excellent co-
localization with mitotracker red (Figure 3.1.1C, Right panels). 
     To study the sub-mitochondrial localization of MOAP-1, mitochondria were subjected 
to digitonin and proteinase K (prot K) treatments. While mitochondrial matrix protein 
Hsp60 and inter membrane space protein Cytochrome c were readily released into 
supernatant, the level of  MOAP-1 remained unchanged upon digitonin treatment, 
suggesting that MOAP-1, similar to Bax and VDAC, is a membrane-associating  protein 
(Figure 3.1.1D). In contrast to Hsp60 and the inner membrane integrated protein COX-IV, 
MOAP-1, Bax and the outer membrane integrated protein VDAC were all sensitive to prot 
K digestion, suggesting that MOAP-1 associates mainly with mitochondrial outer 
membrane (Figure 3.1.1E). The sub-mitochondrial localization of different mitochondrial 
proteins is schematically depicted in Figure 3.1.1F.  
 
Figure 3.1.1      MOAP-1 protein is enriched in mitochondrial outer membrane. (A) Subcellular 
fractions from 293T cells were immunoblotted with the MOAP-1 antibody (R5) or antibodies against the 
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organelle-specific protein markers: COX-IV (mitochondria); calreticulin (ER); actin (cytosol) and p14/ARF 
(nuclear). Right panel: Sucrose gradient purified mitochondria from 293T cells were immunoblotted with R5 
or anti-Cytochrome c antibody. (B) MOAP-1 associates with isolated mitochondria. The indicated in vitro 
translated 35S-labelled proteins were incubated with mitochondria isolated from MCF-7 cells at 25 °C for 20 
min. Mitochondria were washed twice and repelleted by centrifugation. (C) Myc-MOAP-1 and the MOAP-1 
mutant (1-115) co-localize with mitotracker. MCF-7 cells were transiently transfected with Myc-MOAP-1 or 
Myc-MOAP-1 mutant (1-115). 16h after transfection, cells were stained with mitotracker(red) and anti-
myc(green). (D) MOAP-1 is a membrane bound mitochondrial protein. Mitochondria were incubated with 
indicated concentration of digitonin on ice for 30 min. Mitochondria were repelleted by centrifugation 
(10,000 rpm, 10 min) and immunobloted for the indicated protein.  (E) Mitochondrial MOAP-1 is highly 
sensitive to prot K digestion. Mitochondria were incubated with indicated concentration of prot K on ice for 
10 min. 10mM PMSF was added to stop prot K digestion. Mitochondria were repelleted by centrifugation 
and immunobloted for the indicated protein. (F) Schematic diagram to depict the sub-mitochondrial 
localization of various mitochondrial proteins. HSP is located in matrix without binding to membrane. Cox 
and VDAC are embedded in the inner and outer membrane, respectively. Cytochrome c is resided in the 
intermembrane space. Both Bax and MOAP-1 are located in the mitochondrial outer membrane.  
 
 
3.1.2 MOAP-1 is integrated into the mitochondrial membrane and 
associates with Bax during apoptosis  
     To examine whether MOAP-1 is tightly embedded in or just loosely bind to the 
mitochondrial outer membrane, in vitro translated MAOP-1, and Bak, which is known to 
be integrated into mitochondrial outer membrane, were incubated with isolated 
mitochondria to allow the association of in vitro translated proteins with mitochondria. 
These mitochondria were subjected to alkali extraction. MOAP-1 and the matrix protein 
HSP60 were completely removed from mitochondria, however, membrane binding protein 
Bak, VDAC and COX-IV were all resistant to alkali wash, suggesting that, unlike in vitro 
translated Bak which is integrated into the mitochondrial outer membrane, in vitro 
translated MOAP-1 just loosely associates with isolated mitochondria (Figure 3.1.2A). 
Interestingly, while mitochondrial MOAP-1 and Bax from healthy cells were completely 
removed by alkali extraction, mitochondrial MOAP-1 and Bax from TNF-treated cells 
became resistant to alkali (Figure 3.1.2B), suggesting that apoptotic stimuli promote the 
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integration of both Bax and MOAP-1 into the mitochondrial outer membrane. MOAP-1 is 
a protein enriched in the mitochondrial outer membrane in healthy and apoptotic cells. 
However, Bax is mainly localized in the cytosol in healthy cells, and apoptotic stimuli are 
known to promote the translocation of Bax to mitochondria. Although MOAP-1 was 
previously shown to be a Bax-associating protein when co-expressed (Tan et al., 2001), 
endogenous Bax/MOAP-1 association has not been demonstrated. The possibility that Bax 
and MOAP-1 may co-localize and associate only during apoptosis was investigated. 
Indeed, endogenous MOAP-1 was found to co-immunoprecipitate with endogenous Bax 
only in STS- or TNF-treated, but not in healthy cells (Figure 3.1.2C).  
 
 
Figure 3.1.2     MOAP-1, together with Bax, is integrated into mitochondrial membrane during 
apoptosis.  (A) In vitro-translated MOAP-1 loosely binds to mitochondria. Mitochondria pre-incubated with 
in vitro MOAP-1 or Bak protein were resuspended in 0.1M NaCO3 (pH10.5), where indicated, and 
incubated on ice for 20 min followed by sonication for 5 min. Mitochondria were repelleted by 
centrifugation (100,000 rpm, 20 min) and immunobloted for the indicated protein.  (B) Apoptotic stimuli 
induce integration of both MOAP-1 and Bax into mitochondrial outer membrane. Mitochondria isolated 
from control or TNF-treated (40 ng/mL, 7h) MCF-7 cells were washed and analysed as in (A). (C) 
Apoptotic stimuli promote endogenous Bax-MOAP-1 association. MCF-7 cells were treated with STS (1 
µM, 5 h) or TNF (40 ng/mL, 7 h). Cell lysates were immunoprecipitated with anti-Bax antibody.  
Immunoprecipitates were immunoblotted with MOAP-1 (M6) or Hsp60 antibody (upper panels). Total 




3.1.3 MOAP-1 is required for Bax-induced apoptosis signaling   
     The observation that Bax and Bak serve completely redundant function in apoptosis 
signaling in MEFs (Wei et al., 2001) raises the possibility that they may signal through a 
similar mechanism in mitochondria. Interestingly, while MOAP-1 is a binding partner for 
Bax during apoptosis, association of MOAP-1 with Bak was not observed in a variety of 
mammalian cell lines even under overexpression condition (data not shown). To permit 
evaluation of the possible role for MOAP-1 in Bax- and Bak- mediated apoptosis 
signaling, we utilized small interfering RNA (siRNA) to silence the expression of 
endogenous MOAP-1. Several RNAi constructs targeting the different region of MOAP-1 
mRNA were evaluated for the knockdown efficiency by transient transfection 
experiments.  R1(539), R2 (358) and R3 (604) constructs efficiently reduced the 
expression of myc-MOAP when co-expressed. However, the R4 (681) construct failed to 
diminish the expression of myc-MOAP-1 (Figure 3.1.3). R1 and R3 constructs were thus 
 
Figure 3.1.3   Knockdown efficiency of various RNAi constructs targeting different regions of MOAP-
1 mRNA.  Myc-MAOP-1 and MOAP-1 RNAi constructs were transfected into 293T cells together with the 
plasmid expressing GFP. 24h after transfection, cells were harvested. MOAP-1 and GFP levels were 
analysed by western blotting. The number refers to the position of the first nucleotide of each 21-nulceotide 
shRNA in the coding region of MOAP-1 mRNA. All mutant RNAi constructs contain 2 nucleotide mutation 
in the 21-nucleotide targeting sequence.      
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chosen for most of analyses in this study.  Transfections of the MOAP-1 siRNAs, R1 or 
R3, but not scrambled siRNA (Scr), into MCF-7 cells resulted in significant reduction 
(>80%) of endogenous MOAP-1 protein (Figure 3.1.4A). Silencing MOAP-1 by transient 
transfection of R1 or R3 siRNA in MCF-7 cells resulted in inhibition of Bax-mediated cell 
death determined by counting the percentage of cells with nuclear condensation in GFP 
positive cells (Figure 3.1.4A, Right panel). In contrast, diminishing MOAP-1 levels in 
these cells failed to inhibit Bak-induced cell death (Figure 3.1.4A, Right panel).  
      
Figure 3.1.4       MOAP-1 is required for Bax-induced apoptosis.   (A-B) Left panel: Transient expression 
of MOAP-1 siRNA constructs reduced endogenous MOAP-1 protein level in MCF-7 (A) or HCT116 (B) 
cells.  Expression constructs of scramble siRNA (Scr) or MOAP-1 siRNAs, R1 or R3, were transiently 
transfected into MCF-7 or HCT116 cells. 48h after transfection, endogenous MOAP-1 and Bax were 
immunoprecipitated from total lysates with anti-Bax and anti-MOAP-1(R5) antibodies followed by Western 
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analysis with anti-Bax and anti-MOAP-1(M6) antibodies. Aliquots of total lysates from HCT116 cells used 
for immunoprecipitation were analysed by Western blot with anti-actin antibody to document the 
equivalency of protein loading in each sample. (A-B) Right panel:  MCF-7 (A) or HCT116 (B) cells were 
first transfected with scramble siRNA (Scr) or MOAP-1 siRNAs, R1 or R3 for two days followed by a 
second transfection with either pXJ40 vector, HA-Bax or HA-Bak, together with the GFP reporter construct. 
Apoptosis was determined 8 h, 16 h and 24 h for MCF-7 cells or 24 h for HCT116 cells  later by counting 
the percentage of GFP-positive cells that exhibited condensed nuclei morphology. Results are presented as 
mean values +/- standard deviation (S.D.) from a representative experiment performed in triplicate. At least 
three independent experiments were performed and similar results were observed. 
 
      To determine further the functional relationship between MOAP-1 and Bax, we 
performed experiments in isogenic HCT116 cell lines with differing Bax genotypes. The  
R3 siRNA, was effective in lowering MOAP-1 levels in both Bax+/- and Bax-/- lines 
(Figure 3.1.4B, Left panel). Similar to MCF-7 cells, silencing MOAP-1 in these cells 
conferred selective resistance to Bax-induced apoptosis (Figure 3.1.4 B, Right panel). 
Further experiments performed in 293T and SH-SY5Y cells with the R1 or R3 siRNAs 
gave similar results (data not shown). 
 
3.1.4 Silencing MOAP-1 in mammalian cells confers resistance to diverse 
apoptotic stimuli 
     To expand our analyses of the role of MOAP-1 in apoptosis signaling, we generated 
stable MCF-7 lines harbouring either R1 or R3 siRNA. As parallel controls, we generated 
stable lines carrying siRNAs with two nucleotide mutation from the siRNA sequences (R1 




Figure 3.1.5    MOAP-1 knockdown MCF-7 cells are resistant to diverse apoptotic stimuli. (A) MOAP-
1 protein level is substantially reduced in SM-R3-12 cells stably expressing the MOAP-1 siRNA. Cell 
lysates were immunoprecipitated with Bax (N20) or MOAP-1 (R5) antibodies followed by immunoblotting 
with MOAP-1 (M6) or Bax (2D2) antibodies. (B) MOAP-1 knockdown cells are resistant to apoptotic death 
triggered by STS. Upper panel: Cells were harvested, stained with JC-1 for analysis of mitochondrial 
membrane potential change by flow cytometry. Middle panel: The extent of caspase activation following 
treatment with STS was assayed with AC-DEVD-AFC. Lower panel: Cell viability after STS treatment was 
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determined by WST-1 assay.  (C-E) MOAP-1 knockdown cells displayed resistance to apoptosis triggered 
by TNF (C), UV (D), and serum withdrawal (E). Cells were subjected to various apoptotic insults as 
indicated and the dose-dependent cell viability responses were determined by the following assays: JC-1 
(TNF) or trypan blue exclusion (UV and serum withdrawal).  Results are presented as percentage of control 
(mean ±SD, n=3)  
(>80%), while the levels of Bax appeared unchanged (Figure 3.1.5A). MCF-7 cells 
lacking MOAP-1 were healthy and displayed normal morphology (data not shown). Upon 
STS treatment, SM-R3-mut cells displayed typical apoptotic changes such as diffuse 
Cytochrome c staining (data not shown), nuclear condensation (data not shown), a rapid 
drop in mitochondrial membrane potential (Figure 3.1.5B, Upper panel), caspase 
activation (Figure 3.5B, Middle panel) and rapidly lost viability as demonstrated by WST-
1 assay (Figure 3.1.5 B, Lower panel). In contrast, SM-R3-12 cells were resistant to STS-
mediated changes associated with cell death (Figure 3.1.5B) and even exposed to STS for 
72h, a substantial portion of the cells remained viable (data not shown). Remarkably, the 
MOAP-1 knockdown cells were resistant to diverse apoptotic stimuli including TNF 
(Figure 3.1.5C), UV irradiation (Figure 3.1.5D), serum withdrawal (Figure 3.1.5E) and 
TRAIL (data not shown) in a variety of assays. The MOAP-1 knockdown MCF-7 cells 
that survived the STS or TNF treatment displayed long term survival and were 
subsequently able to form 60-70% more colonies in a clonogenecity assay than the control 
cells that were similarly treated (data not shown). The specificity of the effects was further 
studied by analysing two additional independent stable lines expressing the R3 MOAP-1 
siRNA and three other independent stable clonal lines expressing a completely different 
MOAP-1 siRNA, R1, for their sensitivity towards STS and TRAIL-induced killing and 
similar results were obtained (data not shown).    
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         To extend our analysis on the effect of MOAP-1 knockdown on apoptosis to other 
cell lines, HCT116 clonal lines stably expressing MOAP-1 R3 shRAN were generated. 
The MOAP-1 levels in the SH-R3-8 and SH-R3-9 clonal lines were dramatically reduced 
(>70%), while the levels of Bax appeared unchanged (Figure 3.1.6A). MOAP-1 deficient 
HCT116 cells are significantly more resistant than control cells to apoptotic effect 
triggered by STS or Trail (Figure 3.1.6A). Interestingly, the sensitivity of MOAP-1 
knockdown HCT116 cells appears to correlate with the knockdown efficiency as SH-R3-9 
clonal cells are more resistant to apoptotic than SH-R3-8 clonal cells. These data together 
suggest that the effects associated with knocking-down MOAP-1 observed in MCF-7 cells 
can be extended to other cell types.  
 
 
Figure 3.1.6   MOAP-1 deficient HCT116 cells exhibits resistant to apoptotic stimuli. (A) MOAP-1 
protein level is substantially reduced in the HCT116 clonal lines stably expressing the MOAP-1 siRNA R3. 
Total cell lysates were immunoprecipitated with Bax (N20) or MOAP-1 (R5) antibodies followed by 
immunoblotting with MOAP-1 (M6) or Bax (2D2) antibodies. (B) MOAP-1 knockdown HCT116 cells are 
resistant to apoptotic death triggered by Trail and STS. Cell viability after STS or Trail treatment (16h) was 





3.1.5 Conformation change and translocation of Bax triggered by apoptotic 
stimuli are inhibited in MOAP-1 deficient cells   
     Next, we examined whether MOAP-1 is required for mediating conformation changes 
and translocation of Bax during apoptosis. The conformation change and translocation 
associated with GFP-Bax activation were studied by using confocal microscopy. TNF- 
treated, GFP-Bax positive cells from the SM-R3-mut control line stained by the 
conformation-specific Bax antibody (N20) were clearly more readily seen (>80%) than 
those from the MOAP-1 RNAi knockdown SM-R3-12 line (<30%) (Figure 3.1.7A). Upon 
treatment with TNF, the initial diffuse staining of cytosolic GFP-Bax in control cells, but  
not MOAP-1 knockdown cells, readily assumed a punctuate staining pattern consistent 
with Cytochrome c release from mitochondria in those cells (Figure 3.1.7B). TNF-induced 
Bax translocation occurred in >80% of control cells but in <30% of MOAP-1 knockdown 
cells. 
      The effects of MOAP-1 knockdown on the activation, translocation and 
oligomerization of endogenous MOAP-1 were further investigated.  Upon TNF treatment, 
the conformation-specific Bax antibody, N20, revealed a clear difference in the kinetics of 
the effect on conformational change in Bax between the SM-R3-mut control and the SM-
R3-12 MOAP-1 RNAi knockdown cells (Figure 3.1.8A and 3.1.8B). The change of Bax 
conformation was detected 5 h after TNF treatment in SM-R3-mut cells whereas it was 
only detectable in SM-R3-12 cells after 12 h of treatment (Figure 3.1.8A). Upon treatment 
with TNF, Cytochrome c remained in the mitochondria in most SM-R3-12 MOAP-1 
RNAi knockdown cells, however, majority of SM-R3-mut control cells displayed 




Figure 3.1.7     GFP-Bax activation and translocation induced by TNF are compromised in MOAP-1 
knockdown cells.  (A) Silencing of MOAP-1 inhibits Bax activation induced by TNF.  SM-R3-mut and 
SM-R3-12 cells were transfected with GFP-Bax followed by a 12 h TNF treatment. Cells were 
immunostained with N20, a conformation-specific anti-Bax antibody and signals were detected with cy3-
conjugated secondary antibody. Six separate fields per plate were chosen and a total ≥200 GFP-positive cells 
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were counted. (B) Silencing of MOAP-1 inhibits Bax translocation and Cytochrome c release. SM-R3-mut 
and SM-R3-12 cells were transfected  and treated with TNF as in (A) The cells were fixed and processed for 
confocal microscopy to visualize GFP-Bax and Cytochrome c staining. Six separate fields per plate were 




Figure 3.1.8     Apoptotic stimuli-mediated conformation changes, translocation as well as 
oligomeization of endogenous Bax, and the release of Cytochrome c are all inhibited in MOAP-1 
depleted Cells. (A-B) TNF-mediated conformation change of Bax was inhibited in MOAP-1 knockdown 
cells. For immunoprecipitation analysis of Bax activation, equal amounts of total lysates from the TNF (40 
ng/mL, 12 h)-treated cells were immunoprecipitated with the conformation-specific anti-Bax antibody, N20. 
Cell lysates and immunoprecipitates were immunobloted with anti Bax. Confocal analysis was also 
preformed to compare Bax activation in control and MOAP-1 knockdown cells as described in Figure 3.1.6.   
(C) MOAP-1 knockdown attenuates Cytochromce c release in MCF-7 cells induced by TNF. (D) MOAP-1 
is required for apoptosis-mediated Bax translocation and Cytochrome c release. Cytosolic and mitochondrial 
fractions from cells treated with either STS (1 uM, 5 h) or TNF (40 ng/mL,10 h) were immunobloted with 
the indicated antibodies.  (E) TNF-induced Bax oligomerization is inhibited in MOAP-1 deficient cells. The 
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indicated control or MOAP-1 knockdown cells were treated with 40 ng/ml TNF for 16 h. The Bax 
oligomerization analysis was performed as described in Chapter 2.   
 
data, as shown in further fractionation analysis, TNF or STS effectively induced 
translocation of Bax from the cytosol to mitochondria as well as Cytochrome c from the 
mitochondria to the cytosol in SM-R3-mut cells (Figure 3.1.8D). In contrast, Bax 
remained largely cytosolic upon apoptotic treatments in SM-R3-12 cells (Figure 3.1.8D). 
Moreover, gel filtration analysis indicated that Bax oligomerization induced by TNF 
treatment was significantly compromised in MAOP-1 depleted cells (Figure 3.1.8E)  
 
3.1.6 MOAP-1 has a direct role in facilitating Bax function in releasing 
apoptogenic factors from mitochondria 
         Recombinant tBid, Bax and Bak are capable of releasing Cytochrome c directly 
from isolated mitochondria  (Desagher et al., 1999; Jurgensmeier et al., 1998; Wang et al., 
2001), suggesting that minimal components necessary for engaging these molecules for 
mediating mitochondrial signaling events resulting in Cytochrome c release may already 
be present in the mitochondria of healthy cells. It has been reported that full-length 
recombinant Bax proteins form oligomers if certain detergent are used during the 
preparation. However, similar to native Bax protein in healthy cells, full-length 
recombinant Bax proteins exist as monomer and they are unable to directly trigger 
Cytochrome c release from isolated mitochondria if they are produced and purified in 
detergent-free condition (Antosson et al., 2000). However, as shown in Figure 3.1.9, the 
recombinant Bax proteins can undergo spontaneous activation and significant amount of 




active conformation-specific Bax antibody, suggesting that recombinant Bax protein can 
be directly used to induce Cytochome c release from isolated mitochondria.  
 
Figure 3.1.9   Recombinant Bax proteins exist as onligomers and in an active conformation. (A) 
Oligomerization analysis of recombinant Bax proteins by FPLC. 25 ug of purified recombinant Bax proteins 
were injected into the column and different fractions were collected. Bax proteins in each fraction were 
analysed as described in Chapter 2. In vitro translated Bax proteins were used as control for monomeric Bax.  
(B) Recombinant Bax proteins are recognized by the conformation-specific Bax antibody. 0.2 ug of 
recombinant proteins were immunoprecipitated with the conformation-specific Bax antibody. In vitro 
translated Bax proteins were used as control for native and inactive Bax.  
 
      To investigate whether mitochondria-enriched MOAP-1 has a direct role in 
mediating Bax function in mitochondria, we evaluated and compared the effects of 
recombinant Bax, Bak and tBid proteins in directly releasing Cytochrome c from isolated 
mitochondria derived from the control and MOAP-1 knockdown cells. Purified 
recombinant Bax, Bak and tBid proteins were all able to release Cytochrome c from 
isolated mitochondria prepared from MCF-7 SM-R3-mut control (Figure 3.1.10) and 
HCT116 SH-R3-mut control cells (Figure 3.1.11). Interestingly, the activity of both Bax 
(Figure 3.1.10A and Figure 3.1.11A) and tBid (Figure 3.1.10B and Figure 3.1.11B) in  
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Figure 3.1.10     Mitochondria isolated from MOAP-1 deficient MCF-7 cells are resistant to Bax- and 
tBid-mediated direct release of Cytochrome c from isolated mitochondria. (A) Top panel, mitochondria 
isolated from the MOAP-1 deficient MCF-7 cells (SM-R3-12) or control cells (SM-R3-12) were incubated 
with various concentrations of purified recombinant Bax protein followed by centrifugation. The 
supernatants and pellets were analysed by western blotting with indicated antibodies.   Lower panel, the 
Cytochrome c release in top panel was subsequently quantified by densitometry. (B) Top panel, 
mitochondria preparations were incubated with the various concentrations of purified recombinant tBid 
protein followed by centrifugation. The supernatants and pellets were analysed by western blotting with 
indicated antibodies. Lower panel, the Cytochrome c release in top panel was subsequently quantified by 
densitometry. (C)  Mitochondria isolated from the indicated cells were incubated with various 
Results I 
 -87- 
concentrations of Bak followed by centrifugation. The supernatants and pellets were analysed by western 
blotting with indicated antibody. 
 
 
Figure 3.1.11    Mitochondria from MOAP-1 deficient HCT 116 cells are resistant to recombinant 
Bax- or tBid-mediated direct release of Cytochrome c. Mitochondria isolated from control HCT116 line 
(SH-R3-mut) and MOAP-1 deficient (SH-R3-9) lines were subjected to treatment with recombinant Bax (C) 
or t-Bid (D) for evaluating their effect in triggering direct release of Cytochrome c. 
 
releasing Cytochrome c from isolated mitochondria were all severely compromised in 
MOAP-1 knockdown cells. In contrast, no significant difference was noted in the 
Cytochrome c releasing activity of recombinant Bak on mitochondria isolated from 
MOAP-1 knockdown cells (Figure 3.1.10C). The ability of Bax and tBid, but not Bak, in 
releasing Smac/DIABLO from mitochondria was similarly affected in MOAP-1 
knockdown cells (data not shown). The significant reduction in efficacy of recombinant 
Bax and tBid in releasing Cytochrome c and Smac/DIABLO from MOAP-1 deficient 
mitochondria was not due to a compensatory increase of the pro-survival proteins in 
MOAP-1 knockdown cells as levels of Bcl-2, Bcl-xL and MCL-1 in mitochondria as well 





3.1.7 Stable expression of MOAP1 rescues the phenotypes associated with 
MOAP-1 knockdown 
      To ensure the phenotypes associated with MOAP-1 deficient cells are indeed a direct 
consequence of a reduction in MOAP-1 protein level, stable clonal rescue lines expressing 
myc-MOAP-1 (SM-R3-12-RES) in the background of SM-R3-12 cells were generated. 
Those rescue lines indeed regain sensitivity towards STS and TRAIL-mediated killing 
(Figure 3.1.12A). Furthermore, the translocation defect of Bax noted in MOAP-1 
knockdown cells (Figure 3.1.8D) was no longer detectable in the clonal rescue lines 
(Figure 3.1.12B). Similar to the defects in Bax translocation and Cytochrome c release in 
intact MOAP-1 knockdown cells, the dampened sensitivity of recombinant Bax and tBid 
proteins in mediating direct release of Cytochrome c from mitochondria isolated from 
MOAP-1 knockdown MCF-7 cells was largely restored in the stable myc-MOAP-1 rescue 
lines (Figure 3.1.12 C). Remarkably, iincubation of MOAP-1 deficient mitochondria with 
in vitro translated MOAP-1, but not reticulate lysate or in vitro translated VDAC, was able 
to restore the sensitivity of MOAP-1 deficient mitochondria to Bax-mediated Cyto c 






Figure 3.1.12  Stable expression of MOAP-1 restores sensitivity of MOAP-1 knockdown MCF-7 cells 
to apoptotic stimuli.  (A) MOAP-1 knockdown (SM-R3-12) or control (SM-R3-mut) cells with stable 
expression of myc-MOAP-1 were selected. A number of rescue clonal lines were subjected to overnight 
treatment with various concentrations of STS (left panel) or Trail (right panel) and cell viability was 
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determined with the WST-1 assay. (B) Stable expression of myc-MOAP-1 in the MOAP-1 knockdown cells 
is sufficient for restoring the sensitivity of MOAP-1 deficient cells to apoptotic stimuli-mediated Bax 
translocation and cyto c release. Cytosolic and mitochondria fractions from the indicated cells were 
immunoblotted with MOAP-1 (R5) or other indicated antibodies (C) Stable expression of myc-MOAP-1 in 
MOAP-1 knockdown cells restores the sensitivity of mitochondria to Bax- and tBid- induced release of 
Cytochrome c.    In vitro translated MOAP-1 restores the sensitivity of MOAP-1 deficient  mitochondria to 
Bax-mediated release of Cyto c. Mitochondria from MOAP-1 knockdown cells were pre-incubated with 
rabbit reticulate lysate (R. lysates), 35S-labelled in vitro translated MOAP-1 or VDAC (1×105 cpm) for 




       In this part of my thesis, MOAP-1 is found to be enriched in mitochondria and it 
associates with Bax during apoptosis. Knockdown of MOAP-1 protein in mammalian cell 
lines by small interfering RNAs (siRNA) blocks apoptosis induced by over-expression of 
Bax. MCF-7 and HCT116 cells with stable expression of MOAP-1 siRNAs exhibited a 
significant resistance to multiple apoptotic stimuli in triggering apoptotic death as well as 
in inducing conformation change and translocation of Bax. Remarkably, recombinant 
Bax- and tBid-induced Cytochrome c release from isolated mitochondria is significantly 
compromised in the MOAP-1 knockdown cells. Taken together, these data suggest that 







     Dr. Tan Kuan Onn initiated the study presented in this part of my thesis on the function 
of MOAP-1 as an effector in Bax-mediated apoptosis signaling. The results on the 
Cytochrome c release from isolated mitochondria were contributed by Dr. Sunil K. 
Sukumaran. The results on the characterization of MOAP-1 as an effector for Bax 
function in mitochondria have been published in PNAS (Tan KO, Fu NY, Sukumaran SK 
et al., MAP-1 is a mitochondrial effector of Bax.  Proc. Natl. Acad. Sci. USA 102: 14623-
14628, 2005). My contributions to the paper mainly included the investigation of MOAP-
1 knockdown efficiency of various RNAi sequences, the generation of MOAP-1 
knockdown HC116 clonal cells as well as MOAP-1 rescue clonal lines in the background 
of MOAP-1 knockdown MCF-7 cells, the production, purification and characterization of 
Bax recombinant protein, and the confocol study of Bax activation, Bax translocation as 
well as Cytochrome c release. I also participated in the experiments for characterizing sub-
mitochondrial localization of MOAP-1 protein by both digitonin extraction and alkali 
washing assay.  
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INHIBITION OF UBIQUITIN-MEDIATED DEGRADATION OF 
MOAP-1 PROMOTES BAX FUNCTION IN MITOCHONDRIA 
 
3.2.1 MOAP-1 protein in mammalian cells is rapidly up-regulated by 
multiple apoptotic stimuli  
     MOAP-1 is pro-apoptotic in mammalian cells when over-expressed (Tan et al., 2001). 
As shown in the previous result section, reduction of MOAP-1 protein levels by RNAi 
knockdown suppresses apoptosis triggered by multiple apoptotic stimuli. Since MOAP-1 
appears to be a low-abundance protein in mammalian cells and the level of MOAP-1 
could be an important determinant for influencing the sensitivity of mammalian cells to 
apoptotic signals, we decided to evaluate the potential effect of apoptotic stimuli on 
MOAP-1 protein levels in mammalian cells. Using a combined 
immunoprecipitation/Western blot analysis as previously described for detection of other 
low abundance proteins (Linares et al., 2003), MOAP-1 protein levels were first found to 
be rapidly up-regulated by TRAIL in HCT116 (Figure 3.2.1A). It was subsequently found 
that, upon TRAIL treatment, MOAP-1 levels were also increased in other mammalian 
cells, such as H1299, HeLa and SY5Y cells (Figure 3.2.1B). The induction of MOAP-1 by 
TRAIL displayed a similar kinetics as Bax activation in the HCT116, H1299 and HeLa 
cells (Fig. 3.2.1). Interestingly, while TRAIL failed to induce Bax activation (Figure 
3.2.1B) and apoptosis (data not shown) in SY5Y cells, it was effective in triggering up-
regulation of MOAP-1 protein levels in these cells (Figure 3.2.1B). 
       To assess the potential effects of other apoptotic stimuli on MOAP-1 levels, a number 
of cell lines were subjected to treatments with a series of known apoptotic stimuli, 
including the ER stress inducer thapsigargin (THA), DNA-damaging agents, serum 
Results II 
 -93- 
withdrawal, or the PKC inhibitor staurosporine (STS). With the exception of STS (Figure 
3.2.4), all apoptotic stimuli tested were able to rapidly enhance MOAP-1 levels in 
mammalian cell lines, including SY5Y, HCT116, HepG2, 293T, H1299 and HeLa cells  
 
 
Figure 3.2.1   Levels of endogenous MOAP-1 protein are rapidly up-regulated by TRAIL in 
mammalian cells. HCT116, H1299, HeLa or SY5Y cells were treated with TRAIL for the indicated periods 
of time. Equivalent RIPA lysates were subjected to immunoprecipitation (IP) with anti-MOAP-1 antibody 
(R5), followed by immuoblotting (IB) with anti-MOAP-1 antibody (M6). Actin was used as an internal 
control to demonstrate that equal amount of total proteins was used for IP.  The levels of Bcl-2, Bak and Bik 
in HCT116 cells were also measured using their respective antibodies. Bax activation (Act Bax) was 
monitored using a conformation-specific Bax antibody (N-20) as described in Materials and methods. 
(Figure 3.2.2 and Figure 3.2.3). While the up-regulation of MOAP-1 protein levels by 
DNA-damaging stimuli displayed a similar kinetic as that of p53 induction in the p53 
wild-type cells SY5Y and A2780 (Figure 3.2.5B and C), this effect was also observed in 
the p53 mutant cell 293T (Figure 3.2.3 and Figure 3.2.5A) and p53 null cell H1299 
(Figure 3.2.5D), suggesting that the up-regulation of MOAP-1 by DNA-damaging stimuli 
might not be mediated through a p53-dependent pathway. MOAP-1 has been shown to be 
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a mitochondria-enriched protein in the previous results section. The rise of MOAP-1 
protein levels upon etoposide (Figure 3.2.6) or TRAIL treatment (data not shown) was 
indeed mainly seen in the mitochondria-enriched fraction in Western analysis. MCF-7  
 
 
Figure 3.2.2     THA rapidly elevates MOAP-1 protein levels in mammalian cells.  (A) Induction of 
MOAP-1 by THA occurred during the early phase of apoptosis in HCT116 cells.  HCT116 cells were treated 
with 10 μM THA for the indicated periods of time. MOAP-1 levels and Bax activation were monitored. For 
detection of Cytochrome c release from mitochondria, the cells were fractionated into mitochondrial (Mito) 
and cytosolic (Cyto) fractions and analyzed by IB with anti-Cytochrome c antibody. (B) THA-induced 
mitochondrial depolarization were analysed by flow cytometry as described in Materials and methods. Data 
shown are representative of at least three independent experiments. (C) THA rapidly up-regulated MOAP-1 
protein levels in SY5Y or H1299 cells. SY5Y or H1299 cells were treated with 10 μM THA for the 
indicated periods of time. The cells were harvested and RIPA lysates were subjected to IP with the R5 anti-
MOAP-1 antibody.  Immunoprecipitates were analyzed by IB using the M6 anti-MOAP-1 antibody. HSP60 





Figure 3.2.3     Up-regulation of MOAP-1 by ETOP occurred during the early phase of apoptosis 
signaling through a caspase-independent manner.  (A) 293T cells were treated with 100 μM ETOP for 
the indicated periods of time. MOAP-1 levels and Bax activation were monitored. Caspase 3 activation (Act 
Casp3) was analysed in the RIPA lysates with a specific antibody recognizing only the cleaved Casp3. For 
detection of Cytochrome c release from mitochondria, the cells were fractionated into mitochondrial (Mito) 
and cytosolic (Cyto) fractions and analyzed by IB with anti-Cytochrome c antibody. (B) ETOP-induced 
DNA fragmentation were analysed by flow cytometry as described in Materials and methods. Data shown 
are representative of at least three independent experiments. (C) z-VAD-fmk failed to suppress the elevation 
of MOAP-1 protein levels induced by ETOP. 293 T cells were pretreated with 10 μM z-VAD for 1h before 
being subjected to 100 μM ETOP treatment for 16 h or 36 h.  MOAP-1 levels were analysed. (D) z-VAD-
fmk inhibited DNA fragmentation. 293 T cells were pretreated with 10 μM z-VAD or Vehicle (CT) for 1h 
before being subjected to 100 μM ETOP treatment for 16 h or 36 h.   DNA fragmentation was analyzed as in 






Figure 3.2.4   STS was able to trigger apoptosis, but failed to induce the up-regulation of MOAP-1 
protein. (A) HepG2 cells were treated with indicated concentration of CAM or STS for 16 h. Cells were 
harvested. The levels of MOAP-1 were detected by combined IP/western blotting as described in Figure 
3.2.3A. (B) HepG2 cells were treated with indicated concentration of CAM, STS, ETOP or Vehicle (CT) for 
24 h. Cells were harvested. The sub-G1 DNA was analyzed by flow cytometry.  
 
cells appear to have higher basal levels of MOAP-1 than other mammalian cell types (data 
not shown). Consistent with our previous observations in the previous result section, most 
apoptotic stimuli tested, with the exception of etoposide (ETOP) and camptothecin 
(CAM), were relatively ineffective for inducing up-regulation of MOAP-1 protein levels 
in these cells (data not shown). In comparison to rapid induction of apoptosis by TRAIL, 
apoptosis induced by THA, DNA-damaging agents and serum withdrawal is generally 
slower (Figure 3.2.2 and Figure 3.2.3). Nevertheless,  the up-regulation of MOAP-1 by 
multiple apoptotic stimuli was readily detected prior to those events that are known to 
associate with the commitment phase of apoptosis signaling such as Bax activation, 
Cytochrome c release from mitochondria, mitochondrial potential changes and the 
appearance of sub-G1 DNA content (Figure 3.2.2 and Figure 3.2.3). The broad spectrum 
caspase inhibitor z-VAD failed to inhibit MOAP-1 up-regulation by ETOP (Figure 
Results II 
 -97- 
3.2.3C) and TRAIL (data not shown) while it effectively blocked caspase-dependent 
apoptotic events such as DNA fragmentation (Figure 3.2.3D), indicating that the effect of 
apoptotic stimuli on MOAP-1 up-regulation is not dependent on a positive feedback 
mechanism driven by sustained capspase activation. Moreover, the up-regulation of 
MOAP-1 protein in the early stage of apoptosis is reversible as MOAP-1 levels were able 
to go down to basal by adding serum to cells grown in serum-free medium or replacing the 
medium containing ETOP with normal medium (Figure 3.2.7). 
 
Figure 3.2.5   DNA-damaging stimuli up-regulate MOAP-1 protein. (A) Multiple DNA-damaging 
stimuli were able to elevate MOAP-1 levels in 293T. 293T cells were treated with increasing concentrations 
of indicated DNA-damaging agents for 16 h. The cells were harvested and RIPA lysates were subjected to 
IP with the R5 anti-MOAP-1 antibody.  Immunoprecipitates were analyzed by IB using the M6 anti-MOAP-
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1 antibody. The concentrations used for each stimulus are: ETOP: 0, 10, 20, 50 and 100 μM; 5-Fu: 0, 10, 50, 
100 and 300 μM; Camptothecin: 0, 5, 10, 20 and 25 μM; Cisplatin: 0, 5, 10, 25 and 50 μM; Melphalan: 0, 
10, 25, 50 and 100 μM. The cells were treated with Vehicle as control. (B-C) Up-regulation of MOAP-1 
protein by DNA-damaging stimuli displayed a similar kinetics to that of p53 and p21 induction. p53 wild-
type cell lines SY5Y and A2780 were treated with 10  μM ETOP or 50 μM cisplatin respectively for the 
indicated periods of time. The cells were harvested and RIPA lysates were subjected to analysis as in (A) to 
detect the protein levels of MOAP-1. The same RIPA lysates were directly used to detect the levels of p53 
and p21 by IB. (D) MOAP-1 was up-regulated in p53-null H1299 cells. H1299 cells were treated with the 
indicated concentration of ETOP for 12 h. MOAP-1, p21 and p53 expression were analysed as in (B-C). 
 
Figure 3.2.6   Up-regulated MOAP-1 protein by ETOP was mainly detected in the mitochondria-
enriched fraction. 293T cells were treated with 100 μM etoposide. The cells were harvested at the indicated 
time points and fractionated into mitochondrial and cytosolic fractions. Mitochondrial and cytosolic 
fractions were analyzed by IB using anti-MOAP-1, anti-HSP60 (mitochondrial marker protein) or anti-Actin 




Figure 3.2.7   Up-regulation of MOAP-1 at the early stage of apoptosis is reversible. 293T cells were 
treated with ETOP for 3hr (A) or grown in serum-free medium for 16 h (B). Cells were then grown in the 
normal medium for the indicated periods of time before harvesting. MOAP-1 levels were measured by 
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combined immunoprecipitation/ western blot approach. HSP60 was used as internal control. The cells were 






3.2.2 Apoptotic stimuli stabilize MOAP-1 protein  
     To study the mechanism by which apoptotic stimuli promote an increase in MOAP-1 
protein levels, we first measured MOAP-1 mRNA levels by RT (reverse transcription)-
PCR. No significant difference was noted in MOAP-1 mRNA levels between control and 
TRAIL- or ETOP-treated cells (Figure 3.2.8A). Translational regulation has been found to 
play an important role in the regulation of levels of certain proteins by apoptotic stimuli 
(Holcik & Sonenberg, 2005). To examine the possibility of whether the induction of 
endogenous MOAP-1 by apoptotic stimuli could be a consequence of translational 
regulation through the 5’ or 3’ untranslated region (UTR) of MOAP-1 mRNA, cells were 
transiently transfected with a HA-tagged MOAP-1 expressing plasmid, in which only the 
coding region of MOAP-1 is transcribed under the control of the CMV promoter. Similar 
to the endogenous MOAP-1 protein, the levels of HA-tagged MOAP-1 protein were 
rapidly increased by treatment with TRAIL or ETOP (Figure 3.2.8B).  
       Since neither transcriptional nor translational mechanisms appear to have a 
significant role in mediating MOAP-1 up-regulation by apoptotic stimuli, a possible post-
translational mechanism underlying MOAP-1 up-regulation was explored. The half-life of 




Figure 3.2.8    Up-regulation of MOAP-1 is through a post-translational mechanism. (A) The levels of 
MOAP-1 mRNA were not affected by treatment with EOP or TRAIL. H1299 cells were treated with 50 
ng/ml TRAIL or 100 μM ETOP for the indicated periods of time. Total RNA was isolated from the cells and 
RT-PCR analysis was performed. Actin was used as an internal control. (B) Transiently expressed HA-
tagged MOAP-1 was up-regulated by TRAIL (Upper panels) and ETOP (Lower panels). HA-tagged MOAP-
1 construct was transfected into HCT116 or 293T cells. 16h after transfection, HCT116 and 293T cells were 
treated with 50 ng/ml TRAIL and 100 μM ETOP, respectively, for the indicated periods of time. The cells 
were harvested and RIPA lysates were analyzed by IB using anti-HA antibody. Equal loading of proteins 




Figure 3.2.9     MOAP-1 is a short-lived protein in mammalian cell lines. COS-1, SY5Y, HepG2 and 
HCT116 cells were treated with 50 µg/ml cycloheximide for the indicated periods of time before harvesting. 
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RIPA lysates were subjected to IP with anti-MOAP-1, Mcl-1 or Bax antibodies. Immunoprecipitates were 
analyzed by IB using the corresponding anti-MOAP-1, Mcl-1 or Bax antibodies.  
 
synthesis inhibitor CHX to block the translation of de novo protein. The remaining levels 
of MOAP-1 in the cells at different time points after CHX treatment were monitored by 
Western analysis after enrichment by immunprecipitation with anti-MOAP-1 antibody. 
MOAP-1 protein is rapidly turnovered in all cell lines tested, including COS-1, SY5Y, 
HepG2, 293T, H1299 and HCT116 (Figure 3.2.9). The half-life of MOAP-1 and Mcl-1, 
which is known to be a member of the Bcl-2 family with a relatively short half-life, was 
determined to be in the range of 20-30 and 60-100 min among the four cell lines studied, 
respectively (Figure 3.2.9). In contrast, Bax is a stable protein in mammalian cells as the 
levels of Bax remained unchanged upon CHX treatment at all the time points examined 
(even up to 16 h) (Figure 3.2.9 and data not shown). In addition, 293T cells were also 
subjected to both CHX treatment (Figure 3.2.10B) and pulse-chase analysis (Figure 
3.2.10B). Both approaches yielded similar results and the half-life of MOAP-1 is 
estimated to be only 25 min in the 293T cells (Figure 3.2.10C). Interestingly, TRAIL or 
ETOP treatment led to a pronounced increase in MOAP-1 half-life in comparison to the 
untreated control (Figure 3.2.10D). These data together suggest that protein stabilization, 
possibly through inhibition of its degradation, is likely to be a predominant mechanism 
underlying the observed effect on MOAP-1 up-regulation induced by multiple apoptotic 







Figure 3.2.10     MOAP-1 is a short-lived protein that can be stabilized by apoptotic stimuli. (A) 
Inhibition of de novo protein synthesis caused rapid elimination of endogenous MOAP-1 protein. 293T cells 
were incubated with 50 µg/ml CHX for the indicated periods of time. Equivalent RIPA lysates were 
subjected to IP with anti-MOAP-1 antibody (R5), followed by IB with anti-MOAP-1 antibody (M6). Actin 
was used as an internal control to demonstrate that equal amount of total proteins was used for IP. (B) Pulse-
chase assay for estimating the half-life of MOAP-1. 293T cells were labeled with S35-methionine/cysteine 
for 60 min. The cells were then chased for the indicated periods of time. Equivalent RIPA lysates were 
subjected to IP with anti-MOAP-1 antibody (R5). Immunoprecipitates were analyzed by autoradiography 
(for S35 MOAP-1) or by IB with anti-MOAP-1 antibody (for total MOAP-1).  HSP60 was used as an internal 
control to demonstrate that equal amount of total proteins was used for IP. (C) The half-life of MOAP-1 is 
estimated to be ~25 min. The relative amount of total MOAP-1 in (A) or S35-labeled MOAP-1 in (B) was 
quantified by densitometry and plotted with respect to time. MOAP-1 level at time 0 was defined as 100%. 
(D) TRAIL or ETOP treatment extended the half-life of MOAP-1. H1299 cells were pretreated with 50 
ng/ml TRAIL for 1 h or 100 μM ETOP for 3 h. Pulse-chase assay was then performed as in (B). The same 





3.2.3 MOAP-1 protein is selectively up-regulated by proteasome inhibitors 
        Many proteases are known to be involved in regulating protein stability in 
mammalian cells (Mayer, 2000). To determine which protease(s), if any, might be 
participating in MOAP-1 regulation, 293T cells were subjected to treatment with diverse 
protease inhibitors. Among all the protease inhibitors tested, only the proteasome  
 
 
Figure 3.2.11    Proteasome inhibitors enhanced MOAP-1 protein levels. (A-B) MOAP-1 protein level 
was selectively elevated by proteasome inhibitors. 293T cells were untreated (CT) or treated with the 
indicated protease inhibitors for 16 h. RIPA lysates were analyzed by IB with anti-MOAP-1 or anti-actin 
(loading control) antibodies. (C) MG132 up-regulated endogenous MOAP-1 levels in a variety of 
mammalian cell lines. An assortment of tumor cell lines and the primary human fetus foreskin fibroblast cell 
FS-4 was treated with MG132 or DMSO (CT) for 16 h. The cell lysates were analyzed as in (A). (D-E) 
Dosage and time course analysis of MOAP-1 up-regulation by proteasome inhibitors. For the time course-
dependent analysis, 293T cells were treated with 10 μM MG132 or 100 μM LLnL for the indicated periods 
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of time. For the dosage-dependent analysis, 293T cells were treated with indicated concentration of MG132 
or LLnL for 16 h before harvesting. 
 
inhibitors (i.e. MG132, LLnL, epoxomycin and lactacystin) were found to dramatically 
elevate endogenous MOAP-1 protein levels (Figure 3.2.11A and B), suggesting that the 
proteasome plays a role in degrading MOAP-1. In accordance with the previous 
observation that MOAP-1 is a short-lived protein in a variety of cell lines (Figure 3.2.9), 
MG132 and LLnL markedly enhanced MOAP-1 levels in an assortment of mammalian 
cell lines tested, including the human primary foreskin cells, FS-4 (Figure 3.2.11C). The 
up-regulation of MOAP-1 by proteasome inhibitors appeared to be duration (Figure 
3.2.11D) and dosage (Figure 3.2.11E) dependent. To confirm that the endogenous 37 KD 
protein which is dramatically up-regulated by proteasome inhibitors is indeed MOAP-1 
protein, the several antibodies raised against a peptide or GST fusion proteins 
corresponding to the different region of human or mouse MOAP-1 were raised and tested, 
the 37 KD protein can be detected by all of those anti-MOAP-1 antibodies (Figure 3.2.12).    
 
Figure 3.2.12     The 37 KD protein up-regulated by proteasome inhibitors can be detected by multiple 
anti-MOAP-1 antibodies.  (A) Different fragment of human (h) or mouse (m) MOAP-1 proteins were 
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prepared and used for raising anti-MOAP-1 antibodies. (B) 293T cells were left untreated or treated with 10 




Figure 3.2.13     MG132 up-regulated MOAP-1 through Extending Its Half-life. (A) The mRNA levels 
of MOAP-1 were not affected by proteasome inhibitors. 293T cells were treated with the indicated 
concentrations of MG132 , LLnL or Vehicle (CT) for 16 h. Total RNA was isolated and RT-PCR analysis 
was performed. Actin was amplified as an internal control. (B) Proteasome inhibition extended the half-life 
of MOAP-1. 293T cells were pretreated with vehicle or MG132 for 2 h, followed by addition of 50 μg/ml 
CHX to block the de novo synthesis of proteins.  The cells were harvested at the indicated time points and 
equivalent RIPA lysates were subjected to IP with anti-MOAP-1 antibody, followed by IB. Actin was used 
as an internal control to demonstrate that equal amount of total proteins was used for IP.  
 
 
Figure 3.2.14 ETOP-induced MOAP-1 up-regulation is not further increased by MG132.  (A) 
Proteasome inhibitors exhibited more dramatic effect on MOAP-1 up-regulation. 293T cells were treated 
with proteasome inhibitors, ETOP, CAM or vehicle (CT) for 16 h. MOAP-1 levels in total lysates were 
detected by anti-MOAP-1 antibody M6. Actin was used as loading control.  (B) ETOP failed to further 
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enhance the up-regulation of MOAP-1 levels by MG132. 293T cells were treated with MG132 alone or 
MG132 plus 100 μM ETOP for the indicated periods of time. Cells were harvested and analyzed as in (A).   
 
 
       It has been shown that some proteins, for example, the death receptor 5 (DR5) 
(Yoshida et al., 2005), can be indirectly up-regulated by proteasome inhibition through 
transcriptional induction. RT-PCR was performed to compare the mRNA levels of 
MOAP-1 in the control and proteasome inhibitor-treated cells and no notable difference 
was observed (Figure 3.2.13A). The half-life of MOAP-1 was dramatically extended in 
the presence of MG132 (Figure 3.2.13B), lending support to the idea that up-regulation of 
MOAP-1 by proteasome inhibition is primarily a consequence of an increase of MOAP-1 
protein stability.  
       While MOAP-1 protein levels are able to be significantly elevated by proteasome 
inhibition and apoptotic stimuli, the effect of proteasome inhibitors on the up-regulation of 
MOAP-1 are much more dramatic than that caused by apoptotic stimuli (Figure 3.2.14A). 
Hence, the combined immunoprecipitation/western blotting normally generates much 
clearer and reproducible results on the up-regulation of MOAP-1 by apoptotic stimuli. 
However, the elevation of MOAP-1 protein levels by proteasome inhibitors is readily 
detected in total cell lysates.  Levels of MOAP-1 protein up-regulated by MG132 were not 
further increased upon ETOP (Figure 3.2.14B), providing further evidence to support that 
apoptotic stimuli up-regulate MOAP-1, similar to MG132, primarily through affecting its 





3.2.4 MG132 induced MOAP-1 accumulation in mitochondria and its 
association with Bax  
         While depending on the cellular context and the balance of pro- and anti-apoptotic 
regulators, inhibition of proteasome may induce apoptosis or prevent apoptosis, various 
proteasome inhibitors are generally regarded as a potent inducer of apoptosis in many 
tumor cells and the therapeutic efficacy of certain proteasome inhibitors in tumor has been 
attributed to the induction of multiple apoptotic signaling pathways (Adams, 2004; 
Roccaro et al., 2006). Indeed, the proteasome inhibitor MG132 is a potent apoptosis-
inducer as loss of mitochondrial membrane potential was readily detected in 293T cells 
upon treatment with MG132 for 16 h or longer time (Figure 3.2.15A). Kinetic analysis 
represented here revealed that the rise of MOAP-1 protein levels in the presence of 
MG132 was mainly seen in the mitochondria-enriched fraction at all time points examined 
(Figure 3.2.15B). The release of Cytochrome c from mitochondria seemed to coincide 
with the accumulation of MOAP-1 in mitochondria (Figure 3.2.15B). It is noteworthy that, 
in contrast to an earlier study suggesting that Bax is a substrate of proteasome (Li & Dou, 
2000), under a variety of experimental conditions (Dewson et al., 2003; Nikrad et al., 
2005; Figure 3.2.15E), proteasome inhibitors appear to have no detectable effect on up-
regulating  Bax protein levels. However, MG132 was able to trigger Bax conformation 
changes (Figure 3.2.15C) and its integration into mitochondria (Figure 3.2.15D). MOAP-1 
protein was integrated into the mitochondria membrane (Figure 3.2.15D) and associated 
with Bax (Figure 3.2.15E) in MG132-induced apoptosis. This is consistent with the 
previous data in the previous result section (Figure 3.1.2) suggesting that apoptotic stimuli 
are able to promote MOAP-1 integration into the mitochondrial outer membrane and its 





Figure 3.2.15    MOAP-1 accumulation in mitochondria and its association with Bax accompany 
proteasome inhibitor-induced apoptosis.  (A) 293T cells treated with 10 μM MG132 or vehicle (CT) were 
harvested at the indicated time points. The mitochondrial potential change was analyzed by flow cytometry. 
(B) 293T cells were treated for the indicated period of time before harvesting. Cells were fractionated into 
mitochondrial and cytosolic fractions. Both fractions were analyzed by IB with anti-MOAP-1 antibody, anti-
COX-IV (a mitochondrial marker protein) or anti-actin (a cytosolic marker protein) antibodies.  (C) 293T 
cells grown in collagen-coated cover slip were treated with MG132 for 24 h. Bax activation was monitored 
by using the conformation-dependent Bax antibody. (D) Mitochondria isolated from the cells pre-treated 
with MG132 for the indicated period of time were re-suspended in 0.1M NaCO3 (alkali) and incubated on 
ice for 20 min followed by sonication for 5 min. Mitochondria were re-pelleted by centrifugation (100,000 
rpm, 20 min) and immunobloted for MOAP-1 or Bax. * Non-specific band recognized by the rabbit anti-
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MOAP antibody (R5) is easily removed by alkali wash. (E) 293T cells were treated with proteasome 
inhibitors or vehicle (CT) for 24 h. indicated periods of time. Cell lysates were immunoprecipitated with 
anti-Bax antibody.  Immunoprecipitates were immunoblotted with MOAP-1 (M6). Total lysates were 
immunoblotted with the anti-Bax or anti-MOAP-1 antibodies.  
 
 
3.2.5 Apoptotic stimuli inhibit poly-ubiquitination of MOAP-1 which is 
required for its degradation  
         Proteasome mediates protein degradation through both ubiquitin-dependent and -
independent mechanisms (Orlowski et al., 2003). The stabilizing effect of proteasome 
inhibitors on MOAP-1 protein led us to explore further whether MOAP-1 is a direct 
substrate for ubiquitination. Transiently expressed HA-tagged MOAP-1 was significantly 
up-regulated by MG132. Furthermore, in addition to the band corresponding to 
unmodified MOAP-1, a series of additional, slower migrating forms of the protein were 
observed in  cells treated with MG132 (Figure 3.2.16A, Left panels). It is possible that the 
higher molecular weight forms of proteins represent poly-ubiquitinated MOAP-1. To test 
this hypothesis, 293T cells were co-transfected with myc-tagged MOAP-1 and HA-tagged 
ubiquitin. Poly-ubiquitinated forms of myc-tagged MOAP-1 were readily observed in the 
transfected cells in the presence of MG132 (Figure 3.2.16A, Right panel). A similar 
experiment was performed to detect the poly-ubiquitinated forms of endogenous MOAP-
1, but in this instance MOAP-1 was immunoprecipitated with anti-MOAP-1 antibody (R5) 
and poly-ubiquitinated forms of MOAP-1 were detected by anti-ubiquitin antibody.  In the 
presence of MG132, poly-ubiquitinated forms of endogenous MOAP-1 protein were 
readily seen in SY5Y cells (Figure 3.2.16B), 293T, HCT116, COS-1 and H1299 cells 
(data not shown). To assess the requirement of poly-ubiquitination of MOAP-1 for 





Figure 3.2.16   Apoptotic stimuli suppress poly-ubiquitination of MOAP-1. (A) Proteasome inhibition 
caused accumulation of poly-ubiquitinated forms of transiently expressed MOAP-1 (Ub MOAP-1). Left 
panel: HA-MOAP-1 or control vector was co-transfected with pEGFP into 293T cells. 16 h after 
transfection, the cells were treated with 10 μM MG132 for another 16 h. RIPA lysates were analyzed by IB 
using anti-HA antibody. The levels of GFP were used to monitor transfection efficiency. Right panel: 293T 
cells were transfected with indicated HA-ubiquitin or myc-MOAP-1. 16 h after transfection, the cells were 
left untreated or treated with MG132 for another 16 h. RIPA lysates were subjected to IP with anti-HA-
conjugated beads, followed by IB with anti-myc antibody.  (B) Proteasome inhibition caused accumulation 
of ubiquitinated forms of endogenous MOAP-1 (Ub MOAP-1). Left panel: SY5Y cells were either left 
untreated or treated with 10 μM MG132 for 16 h. RIPA lysates were analyzed by IB with anti-MOAP-1 or 
anti-actin (loading control) antibodies. Right panel: SY5Y cells were left untreated or treated with MG132 
for 16 h. RIPA lysates were subjected to IP with MOAP-1 antibody or control IgG, followed by IB with 
anti-ubiquitin antibody. (C) MOAP-1 levels were elevated by inhibition of poly-ubiquitin chain formation. 
293T cells were transfected with MOAP-1-HA and pEGFP in combination with indicated amounts of 
plasmid expressing the lysine-less ubiquitin mutant [Ub(K0)]. 16h after transfection, the cells were 
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harvested and RIPA lysates were analyzed by IB with anti-HA antibody. The levels of GFP were used to 
monitor transfection efficiency. (D) TRAIL and ETOP inhibit poly-ubiquitination of MOAP-1. H1299 cells 
were treated with 50 ng/ml TRAIL for 1 h or 100 μM ETOP for 3 h before MG132 was added and the cells 
were incubated for another 12 h. The cells were harvested and analyzed as in (B).  
 
with the plasmid expressing the mutant ubiquitin [Ub(K0)], with all of its lysines mutated 
to arginines (Bloom et al., 2003). The lysine-less ubiquitin mutant competed with 
endogenous ubiquitin and hence prevented the formation of poly-ubiquitin chains. Levels 
of MOAP-1 were elevated in a dose-dependent manner directly proportional to the 
quantity of Ub(K0) plasmid transfected, suggesting that poly-ubiquitin chain formation is 
necessary for efficient degradation of MOAP-1 by the proteasome (Figure 3.2.16C). To 
investigate whether apoptotic stimuli have any effect on the ubiquitination process of 
MOAP-1, H1299 cells were pretreated with TRAIL or ETOP before incubating with 
MG132 to promote accumulation of ubiquitinated forms of endogenous MOAP-1. Both 
stimuli significantly reduced accumulation of ubiquitinated forms of MOAP-1 (Figure 
3.2.16D), suggesting that the effect of apoptotic stimuli on stabilizing MOAP-1 protein is 
likely mediated through inhibition of its poly-ubiquitination process. 
 
 
3.2.6 The center domain of MOAP-1 is required and sufficient for 
mediating its degradation by UPS 
        To identify the domain in MOAP-1 that might be essential for coupling MOAP-1 to 
UPS, a series of MOAP-1 deletion mutants were generated (Figure 3.2.17B). Interestingly, 
all the deletion mutants that contain the center portion of MOAP-1 (a.a. 141-190) were 
dramatically up-regulated by MG132 (Figure 3.2.17A). The smallest deletion mutant M6 
which can be effectively stabilized by MG132 contains only 50 aa, MOAP-1 141-190 
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(Figure. 4.17A). The expression level of this mutant is relatively low in comparison to the 
other longer deletion mutants such as the M5 mutant, and hence the M5 mutant was 
chosen for further analysis. Poly-ubiqitinated forms of the M5 mutant were readily 
detected in the presence of MG132 (Figure 3.2.17C). Levels of the M5 mutant was 
effectively elevated by either TRAIL or ETOP treatment (Figure 3.2.17D), suggesting that 
this region of MOAP-1 contains a functional domain sufficient for mediating the 
stabilization effect on MOAP-1 by apoptotic stimuli.  
      
 
 
Figure 3.2.17      The center domain of MOAP-1 is responsible for mediating its degradation by UPS. 
(A) The levels of deletion mutants containing the center element (a.a. 141-190) of MOAP-1 were up-
regulated upon proteasome inhibition. The indicated MOAP-1 wild-type (WT) and deletion mutants were 
co-transfected with pEGFP into 293T cells. 16 h after transfection, the cells were treated with vehicle or 
MG132 for another 16 h.  RIPA lysates were analyzed by IB with anti-myc antibody. The levels of GFP 
were used to monitor transfection efficiency.  (B) Schematic diagram to depict the deletion mutants of 
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MOAP-1 used in the analysis.  (C) Proteasome inhibition promoted accumulation of ubiquitinated forms of 
the M5 mutant. Myc vector control (Myc-CT) or the myc-M5 mutant of MOAP-1 (Myc-M5) was co-
transfected with HA-ubiquitin (HA-Ub) into 293T cells. 16 h after transfection, the cells were treated with 
MG132 for another 16 h. RIPA lysates were subjected to IP with anti-HA-conjugated beads, followed by IB 
with anti-myc antibody. (D) TRAIL or ETOP treatment elevated the levels of the M5 mutant. H1299 cells 
were transfected with the M5 mutant and pEGFP. 16 h after transfection, cells were treated with 50 ng/ml 
TRAIL or 100 μM ETOP or left untreated (Control) for another 12 h. RIPA lysate were analyzed as in (B).  
 
     To test whether the degradable property contained within the M5 mutant is 
transferable to a heterologous protein that is not normally regulated by UPS, the center 
domain of MOAP-1 represented by the M5 mutant was fused to the GST protein and the 
property of the chimera was evaluated. In comparison to the native GST protein, the GST-
M5 fusion protein became a short-lived protein (Figure 3.2.18A) and its levels were up-
regulated by treatments with MG132 (Figure 3.2.18B). Moreover, poly-ubiquitinated 
forms of GST-M5 fusion protein, but not the GST control protein, were also readily 




Figure 3.2.18     The degradation signal in the center domain of MOAP-1 is transferable. (A) 
Appending the center domain of MOAP-1 (the M5 mutant) destabilized the GST protein. 293T cells were 
transfected with either GST or GST-M5 expression plasmid. 16 h after transfection, the cells was treated 
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with 50 μg/ml CHX for the indicated periods of time.  RIPA lysates were analyzed by IB using anti-GST 
antibody. (B) The center domain of MOAP-1 (the M5 mutant) rendered the GST protein sensitive to 
proteasomal regulation. 293T cells were transfected with either GST or GST-M5 expression plasmid in 
combination with pEGFP. 16 h after transfection, the cells were treated with MG132 and analyzed as in (A). 
(C) Proteasome inhibition promoted accumulation of poly-ubiquitinated forms of the GST-M5 fusion 
protein. 293T cells were transfected with either GST or GST-M5 expression plasmid in combination with 
HA-ubiquitin (HA-Ub). 16 h after transfection, the cells were treated with MG132 and RIPA lysates were 
subjected to IP with anti-HA-conjugated beads, followed by IB with anti-GST antibody.  
 
 
3.2.7 Elevating MOAP-1 protein levels sensitizes mammalian cells to 
apoptotic stimuli  
       Reduction of MOAP-1 protein levels by RNAi knockdown has previously been 
shown to inhibit Bax-dependent apoptosis signalling in the previous result section. 
Although transiently over-expressed MOAP-1 is able to trigger apoptosis on its own (Tan 
et al., 2001), it is unclear whether higher basal levels of MOAP-1 in mammalian cells 
would have an effect on sensitizing cells to apoptotic signals. To evaluate this, HCT116 
clonal lines stably expressing exogenous myc-tagged MOAP-1 (HCT116 myc-MOAP-1 
cells) were generated. The expression levels of myc-MOAP-1 in all stable clonal lines are 
much lower in comparison to the expression upon transient over-expression conditions 
(data not shown), but their levels were significantly higher than the levels of endogenous 
MOAP-1 (Figure 3.2.19A). Moreover, both forms of MOAP-1 were tightly controlled by 
UPS and effectively up-regulated by apoptotic stimuli in the stable lines (data not shown). 
HCT116 myc-MOAP-1 cells were healthy and displayed normal growth and morphology 
(data not shown). These cells, however, were more sensitive to TRAIL- and THA-induced 
apoptosis as determined by WST-1 assay (Figure 3.2.19B) and mitochondrial potential 
changes (Figure 3.2.19C). Interestingly, while STS failed to up-regulate MOAP-1 protein 
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in HCT116 cells, higher levels of MOAP-1 had similar effect on heightening the 
sensitivity of HCT116 cells to the apoptotic effect of STS as to TRAIL and THA (data not  
 
 
Figure 3.2.19      Higher levels of MOAP-1 sensitize HCT116 cells to multiple apoptotic stimuli. (A) 
MOAP-1 expression in the HCT116 vector control and myc-MOAP-1 stable clonal lines. RIPA lysates were 
IP with anti-MOAP-1 or anti-Bax antibodies, followed by IB with anti-MOAP-1, anti-Bax or anti-myc 
antibodies. The arrows indicate the endogenous (Endo) or exogenous myc-MOAP-1(Exog). (B-C) Cell 
death analysis of HCT116 vector control or HCT116 myc-MOAP-1 cells subjected to treatment with TRAIL 
or THA. Cells grown in 96-well plate were treated with indicated concentrations of THA for 36 h or TRAIL 
for 16 h. Cell viability after treatment was determined by the WST-1 assay (B). Results are presented as 
percentage of control (mean ± SD, n = 3). Cells grown in 6-well plate were treated with 5 μM THA for 36 h 
or 10 ng/ml TRAIL for 16 h, harvested and stained with Mito-tracker Red for analysis of mitochondrial 
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membrane potential changes by flow cytometry (C). (D) Higher levels of MOAP-1 promoted TRAIL-
induced Bax activation. Vector 1# and MOAP-1 16# cells were treated with indicated concentrations of 
TRAIL for 5 h. Bax activation (Act Bax) was analyzed by using a conformation-specific Bax antibody (N-
20). (E) Higher levels of MOAP-1 increased the sensitivity of isolated mitochondria to recombinant Bax-
induced Cytochrome c release. Mitochondria isolated from Vector 1# or MOAP-1 16# cells were treated 
with recombinant Bax, followed by centrifugation. The supernatants (sup) and pellets were IB with anti-
Cytochrome c or HSP60 antibodies.  
 
 
Figure 3.2.20      Higher levels of MOAP-1 sensitize MCF-7 Cells to apoptotic stimuli. (A) Western 
blotting analysis of MOAP-1 expression in the MCF-7 vector control and myc-MOAP-1 stable clonal lines. 
RIPA lysates were immunoprecipitated with anti-MOAP-1 or anti-Bax antibodies followed by IB with anti-
MOAP-1 or anti-Bax antibodies. The arrows indicate the endogenous (Endo) and exogenous myc-MOAP-
1(Exog).(B) Caspase activity analysis of MCF-7 vector control or MCF-7 myc-MOAP-1 cells subjected to 
treatment with indicated concentrations of STS for 24 h. The extent of caspase activation following 
treatment with STS was assayed with AC-DEVD-AFC. Results are presented as percentage of control (mean 
± SD, n = 3). (C) Higher levels of MOAP-1 promoted TNFα-induced Bax activation. MCF-7 vector cells 
(Vector 3#) or MCF-7 cells expressing exogenous myc-tagged-MOAP-1 (MOAP-1 10#) were treated with 
Results II 
 -117- 
indicated concentrations of TNF for 4.5 h. Bax activation was analyzed using a conformation-specific Bax 
antibody.  
 
shown). These data suggest that the elevation of MOAP-1 protein levels does have a 
general effect on sensitizing cells to apoptotic stimuli. Elevation of MOAP-1 levels was 
able to facilitate Bax activation upon apoptotic stimulation(Figure 3.2.19D). More 
importantly, mitochondria isolated from HCT116 myc-MOAP-1 cells were clearly more 
sensitive than mitochondria from vector control cells to the Cytochrome c releasing effect 
of recombinant Bax protein (Figure 3.2.19E), lending further support to the idea that the 
levels of MOAP-1 correlate positively to the Cytochrome c releasing activity of Bax in 
mitochondria.  To extend our analysis on the effect of higher levels of MOAP-1 
expression on apoptosis to other cell lines, MCF-7 clonal lines stably expressing myc-
MOAP-1 were generated. Similar to HCT116 cells, higher levels of MOAP-1 also 
sensitized MCF-7 cells to apoptotic stimuli (Figure 3.2.20). 
 
3.2.8 MOAP-1 is a key short-lived protein required for Bax function in 
mitochondria 
      CHX treatment is known to have very diverse effects on apoptosis in ex vivo studies. 
It can significantly promote or block apoptosis when combined with different apoptotic 
stimuli in distinct cellular contexts (Hsu et al., 1997; Kreuz et al., 2001). The isolated 
mitochondria system has been routinely used for establishing the requirement of distinct 
mitochondrial proteins for promoting Cytochrome c releasing function of key 
mitochondrial apoptotic regulators such as Bax (Roucou et al., 2002; Annis et al., 2005; 
Baines et al., 2005; Nakgawa et al., 2005).  The contribution of mitochondrial short-lived 
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proteins as a whole in regulating the function of recombinant Bax in isolated mitochondria 
has not been explored. MOAP-1 knockdown by RNAi has previously been shown to 
attenuate recombinant Bax- and tBid-mediated Cytochrome c release in the previous result 
section. To test the possibility of whether depletion of mitochondrial short-lived proteins, 
including MOAP-1, by CHX would have resulted in a similar phenotype as the MOAP-1 
knockdown by RNAi on Bax- or tBid-mediated Cytochrome c release in isolated 
mitochondria, mitochondria were isolated from cells pre-treated with CHX for various 
durations. Even with just 1 h of CHX treatment, levels of mitochondrial MOAP-1 became 
undetectable, whereas the levels of Bax, Bak and Bcl-2 remained unchanged as the control 
protein HSP60 (Figure 3.2.21A). Similar to mitochondria isolated from MOAP-1 
knockdown cells as shown in the previous result section, mitochondria isolated from cells 
that were pretreated with CHX for a relatively short time (less than 2 h) were found to be 
resistant to the Cytochrome c releasing effect of recombinant Bax (Figure 3.2.21B) and 
tBid (Figure 3.2.21C), but not Bak (Figure 3.2.21D). The resistance of mitochondria 
isolated from CHX-pretreated cells to tBid-meidated Cytochrome c release is in agreement 
with the previous observations that Bax exhibits dominant function over Bak in certain 
mammalian cell types such as HCT116, and tBid-mediated Cytochrome c release is 
exclusively dependent on an intact Bax pathway in those cells (Arnoult et al., 2004).  
        As the molecular mechanism of Bax function in mitochondria has not been fully 
elucidated, it is unclear whether any other short-lived mitochondrial protein(s), in addition 
to MOAP-1, may also be required to facilitate the apoptotic function of Bax. To address 
this, mitochondria from CHX-pretreated cells were incubated with reticulate lysates or in 
vitro-translated MOAP-1, VDAC or the M2 mutant (a.a. 1-115) of MOAP-1 before being 
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exposed to recombinant Bax protein. Remarkably, exogenously-added MOAP-1, but not 
the mitochondrial protein VDAC or the M2 mutant of MOAP-1, was effective in restoring 
the Cytochrome c releasing effect of recombinant Bax (Figure 3.2.21E). 
 




Figure 3.2.21  MOAP-1 is a key short-lived protein required for recombinant Bax-mediated 
Cytochrome c release from isolated mitochondria. (A) Effects of CHX on the levels of Bcl-2 family 
proteins in mitochondria. HCT116 cells were treated with 50 μg/ml CHX for the indicated periods of time. 
The levels of MOAP-1, Bcl-2, Bak, Bax and HSP60 in mitochondrial fraction were analyzed by IB. (B-D) 
Mitochondria isolated from CHX-pretreated cells were resistant to Bax- and tBid-mediated Cytochrome c 
release. Mitochondria isolated from the control or CHX-pretreated HCT116 cells were incubated with 
recombinant Bax (B), tBid (C) or Bak (D) followed by centrifugation. The supernatants (sup) and pellets 
were IB with anti-Cytochrome c or HSP60 antibodies. (E) In vitro-translated MOAP-1 protein effectively 
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restored the sensitivity of mitochondria isolated from CHX-pretreated cells to Bax-mediated Cytochrome c 
release. Mitochondria from the cells pretreated with CHX for 2 h were pre-incubated with PBS, rabbit 
reticulate lysate (R. lysates), S35-labeled (1 x 104 cpm/methionine)  in vitro-translated MOAP-1, VDAC or 
the M2 mutant of  MOAP-1 (a.a. 1-115) for 20 min at 25°C. The mitochondria was washed twice, treated 
with recombinant Bax, and analyzed as in (B-D).  
 
3.2.9 Conclusions 
       My interest in understanding the role of MOAP-1 in mitochondria apoptosis signaling 
stimulated the analysis presented in this chapter on the regulation of MOAP-1 protein in 
mammalian cells. In this part of my thesis, MOAP-1 protein levels were first found to be 
rapidly up-regulated by multiple apoptotic stimuli. Further investigation revealed that 
MOAP-1 is a short-lived protein and is actively degraded via the ubiquitin-proteasome 
pathway. Apoptotic stimuli up-regulated MOAP-1 protein levels through inhibiting its 
poly-ubiquitination process and extending its half life. It has been further revealed that the 
center region (a.a. 141-190) of MOAP-1 is required for its degradation via UPS and is 
sufficient for coupling other unrelated proteins such as GST for UPS-mediated 
degradation. Higher basal level of MOAP-1 sensitizes cells to apoptotic stimuli and 
promotes recombinant Bax-mediated Cytochrome c release from isolated mitochondria. In 
contrast, mitochondria depleted of short-lived proteins by cycloheximide became resistant 
to Bax-mediated Cytochrome c release. Remarkably, incubation of these mitochondria 
with in vitro-translated MOAP-1 effectively restored the Cytochrome c releasing effect of 
recombinant Bax. In conclusion, it is postulated here that apoptotic stimuli facilitate the 







     The data on the Cytochrome c release from isolated mitochondria (Figure 3.2.19E and 
Figure 3.2.21) in this part of my thesis were contributed by Dr. Sunil K. Sukumaran. My 
sincere thanks also go to Dr. Tan Kuan Onn for sharing some of the MOAP-1 reagents, 






4.1 MOAP-1 IS A MITOCHONDRIAL EFFECTOR OF Bax  
       
        The recent structural data of Bax revealed that the putative transmembrane domain 
(helix α9) masks the hydrophobic cleft, which shares similar structural features to the 
BH3 ligand binding groove formed by the BH1-3 domains of Bcl-xL (Muchmore et al., 
1996; Sattler et al., 1997; Suzuki et al., 2000). This is the conformation adopted by Bax in 
its inactive cytosolic form (Suzuki et al., 2000). Apoptotic stimuli may render a 
conformation change leading to disengagement of helix α9 from its hydrophobic pocket 
by yet to defined mechanisms. Interestingly, the only discernable motif identifiable in 
MOAP-1 is a BH3-like domain at its N-terminal region (Tan et al., 2001). Unlike other 
BH3-only proteins, however, the BH3-like domain in MOAP-1 is required only for 
association with Bax, but not with the pro-survival Bcl-2 members (Tan et al., 2001). 
Furthermore, single point mutation of the conserved amino acid in any one of the three 
BH domains of Bax was shown to be sufficient for abolishing its binding to MOAP-1, 
suggesting the hydrophobic cleft of Bax could be the binding pocket for MOAP-1 (Tan et 
al., 2001).  It is interesting to note that MOAP-1 associates with Bax only during 
apoptosis which raises the possibility that both conformation change and mitochondrial 
targeting (translocation) of Bax are pre-requisite steps for permitting Bax-MOAP-1 
association.  
      Endogenous MOAP-1 only interacts with Bax during apoptosis and the MOAP-1 
knock-down has no significant effect on Bak-mediated apoptosis in transient tranfection 
experiments. However, despite the presence of Bak in the MCF-7 and HCT116 cells, 
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abolishing MOAP-1 in these cells was sufficient to confer significant resistance to 
multiple apoptotic stimuli. Furthermore, the severe impairment in apoptosis signaling in 
MOAP-1 deficient cells could also be substantiated by physiological outcomes such as 
anchorage independent growth and tumor growth (Tan et al., 2005). Our data thus lend 
further support to the idea concluded from other studies that Bax may not be serving 
completely redundant function to Bak and that it may have a dominant function over Bak 
in regulating the central apoptosis signalling mechanism in certain cellular contexts in 
human tumor cells (Zhang et al., 2000; LeBlanc et al., 2002; Putcha et al., 2002; 
Theodorakis et al., 2002; Cartron et al., 2003).    
      Similar to Bak, mitochondrial MOAP-1 does not appear to mobilize during apoptosis. 
It thus seems surprising that MOAP-1 could affect the translocation function of Bax. 
However, Bcl-xL and Bcl-2, which localize and act primarily in the mitochondria, are also 
known to be effective in inhibiting conformation change and translocation of Bax 
triggered by apoptotic stimuli (Murphy et al., 2000; Yamaguchi & Wang, 2002). 
Furthermore, while the activation of the effector caspase-3 and -7 is generally believed to 
be an event downstream of Bax activation, it is noteworthy that Bax activation is 
significantly attenuated in the absence of these two caspases (Lakhani et al., 2006). Thus, 
it is formally possible that a signal amplification cascade during apoptosis is at work in 
creating a positive feedback loop in driving a continuous activation of mitochondria-
dependent apoptotic events including Bax activation (Fletcher & Huang, 2006).   
The in vitro Cytochrome c release data from isolated mitochondria strongly suggest 
that MOAP-1 is a critical factor for Bax function in mitochondria. It is therefore surprising 
to note that MOAP-1, which appears to be necessary only for Bax-, but not Bak-mediated 
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apoptosis signaling, is also required for tBid to release Cytochrome c from isolated 
mitochondria as it is thought that tBid can engage mitochondrial apoptosis signaling by 
direct activation of either Bax or Bak and facilitating formation of their homo-oligomers 
(Eskes et al., 2000; Wei et al., 2000). Since Bax appears to exert a dominant function over 
Bak in many mammalian cell types, it could be that, in cells where Bax has a dominant 
role over Bak, an intact Bax-MOAP-1 pathway is necessary for efficient activation of Bak 
by tBid. Indeed, a recent study had demonstrated that the effective oligomerization of Bak 
is dependent on Bax, rather than tBid (Mikhailov et al., 2003). Furthermore, the ability of 
tBid, but not Bak, in releasing Cytochrome c from isolated mitochondria was also found to 
be severely inhibited in HCT116 Bax-/- cells (data not shown; Arnoult et al., 2004) which 
is one of the cell types known to display a dominant Bax function ( Zhang et al., 2000; 
LeBlanc et al., 2002; Theodorakis et al., 2002; Arnoult et al., 2004). In addition, recent 
data revealed that tBid appears to be a potent displacer of Bax from BclXL, but not at all a 
displacer of Bak from MCL-1 (Kuwana et al., 2005). This data would therefore be in line 
with the observations that releasing of Cytochrome c from isolated mitochondria by 
recombinant tBid protein could be severely inhibited in the absence of either MOAP-1 or 
Bax.  
      Humanin (Guo et al., 2003), Ku-70 (Sawada et al., 2003) and 14-3-3 (Nomura et al., 
2003) have recently been shown to be the cytosolic factors that may play a role in 
maintaining Bax in an inactive state and preventing its tarnslocation, whereas ASC was 
shown to be the specific adaptor protein that relays the p53-dependent stress response 
signal to Bax (Ohtsuka et al., 2004). A few other molecules which are proposed to be 
important for directing Bax activation in cytosol have also been reported. Information on 
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the essential components that regulate Bax function in mitochondria, however, remains 
absent and there are evidence arguing that certain unknown protein factor(s) in 
mitochondria is(are) required for Bax to control the mitochondria outer membrane 
permeabilization (Roucou et al., 2002; Annis et al., EMBO, 2005; Lucken-Ardjomande & 
Martinou, 2005; Zazami & Kroemer, 2003). MOAP-1 is the first molecule to be 
demonstrated to serve as an effector for Bax function in mitochondria.  Identification of 
MOAP-1 as a critical regulator of Bax-mediated apoptosis function would not only 
generate fresh and important information to further our understanding of the molecular 
regulation of mitochondrial apoptosis signaling in mammalian cells, but also provide fresh 
avenues for exploring novel therapeutic strategies in combating many major human 
diseases, including cancers. However, the underlying mechanism by which MOAP-1 
regulates Bax function in mitochondria still requires further investigation.  
 
 
4.2 MITOCHONDRIAL PRO-APOPTOTIC FUNCTION OF BAX IS 
REGULATED BY UPS THROUGH CONTROLING MOAP-1 
PROTEIN LEVELS 
 
        Our interests in gaining further understanding of the role of MOAP-1 in 
mitochondrial apoptosis signaling stimulated the analysis presented here on the regulation 
of MOAP-1 protein in mammalian cells. In this study, it was first found that MOAP-1 
protein levels were rapidly up-regulated by multiple apoptotic stimuli. Further 
investigation revealed that MOAP-1 is a short-lived protein and is actively degraded via 
the ubiquitin-proteasome pathway. Proteasome is the major non-lysosomal machinery for 
selective protein degradation in eukaryotes. It has been reported that proteasome activity is 
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compromised in cells exposed to apoptotic stimuli as some of the key subunits in the 19S 
regulatory complex of proteasome are cleaved by activated caspases (Sun et al., 2004). As 
a consequence, levels of proteins which are constitutively degraded by UPS are increased 
and large amount of ubiquitinated proteins are accumulated in the apoptotic cells (Sun et 
al., 2004). Interestingly, there have been some reports demonstrating that the proteasome 
is required for initiation of apoptosis triggered by certain stimuli (Sohn et al., 2006). Our 
data clearly showed that up-regulation of MOAP-1 is not a secondary consequence of 




Figure 4.1 Lysine residues in MOAP-1 protein. Red color box indicates the center region of MOAP-1 
coupling MOAP-1 to UPS degradation. 
 
     Ubiquitination is a pivotal step to mark proteins for degradation by the proteasome. 
Under the sequential action of E1 (ubiquitin-activating enzyme), E2 (ubiquitin-
conjugating enzyme, UBC) and E3 (ubiquitin ligase), ubiquitin is conjugated to substrate 
proteins. Distinct E3 ligases associate with their specific substrate proteins and transfer the 
activated ubiquitin to the target proteins through the isopetide bond formed between the 
carboxyl-terminal Gly (G76) of ubiquitin and the ε-NH2 group of lysine residue in   
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substrate proteins. During the initial phase of this study, the three lysines at the central 
domain of MOAP-1 (a.a. 115-190) appeared to be the obvious candidates for the assembly  
of the poly-ubiquitination chain(s) on the protein. However, mutation of all three of these 
lysines did not stabilize and/or inhibit poly-ubiquitination of MOAP-1. MOAP-1 has 17 
internal lysine residues (Figure 4.1). Subsequently, a series of MOAP-1 mutants lacking 
other internal lysines were generated and it was found that the MOAP-1 lysine-less mutant 
(all 17 lysines were mutated to Argines) or some other MOAP-1 mutants with more than 
12 lysines mutated to argines indeed can not be poly-ubiquitinated. However, since so 
many mutations have been introduced to the MOAP-1 proteins, it is difficult to conclude 
that failure of poly-ubiquitination of these mutants is because of the absence of the 
appropriate ubiquitination sites. It is highly likely that, due to structure changes, those 
mutants with excessive number of lysines mutated to argine fail to associate with the E3 
ligase, as a result, they can not be poly-ubiquitinated.  These data are consistent with the 
observations in other proteins showing that poly-ubiquitination sites of certain proteins 
might not be restricted to specific internal lysines. Therefore, it is technically very difficult 
to narrow down to a single or a few lysines (Herold et al., 2006; Demontis et al., 2006). 
Furthermore, while it was thought that E3 ligases conjugates ubiquitin to their target 
proteins through the isopetide bond formed between ubiquitin and the ε-NH2 group of 
lysine residue in substrate proteins, accumulating evidence demonstrates that the α-NH2 
group of N-terminal residue in some substrates, such as p21, MyoD, LMP1, ID2 and 
p14ARF (Ciechanover et al., 2005), can form a covalent isopetide bond with G76 of 
ubiquitn. Therefore, lysine residue is potentially dispensable for the ubiqiutination and 
degradation of certain substrate proteins. All together, it would be challenging to find out 
the actual residues that are ubiquitinated in MOAP-1 protein. 
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         While the specific E3(s) for MOAP-1 have yet to be identified, our data raise the 
possibility that inhibition of ubiquitination of MOAP-1 by its specific E3 ligase is the key 
mechanism underlying MOAP-1 up-regulation by multiple apoptotic stimuli. A variety of 
mechanisms, including post-translational modifications such as phosphorylation, 
sumolyation, regulation by specific deubiquitination enzymes, and association with a third 
negative regulatory partner, have all been shown to affect protein ubiquitination and its 
subsequent degradation via the proteasome (Pickart, 2004). Recently, MOAP-1 has been 
identified as a binding partner for the tumor suppressor RASSF1A in a yeast two hybrid 
screen (Baksh et al., 2005; Vos et al., 2006). Moreover, MOAP-1 has been shown to be 
pivotal for RASSF1A-mediated apoptosis through modulating Bax function (Baksh et al., 
2005; Vos et al, 2006). Interestingly, in addition to RASSF1A, MOAP-1 was also able to 
bind to other RASSF1 family protein, such as RASSF1C and RASSF6 (Baksh et al., 
2005; Vos et al., 2006). The preliminary data (Figure 4.2A) suggest that RASSF1A 
excellently co-localized with MOAP-1 in cytoskeleton-like structure when co-expressed. 
More interestingly, TRAIL triggered the MOAP-1 up-regulation and its association with 
RASSF1A in HCT116 cells (Figure 4.2B). Moreover, RASSF1 family proteins were able 
to elevate MOAP-1 protein levels (Figure 4.2C and D) and completely block its poly-
ubiquitination process when co-expressed (Figure 4.2E). In contrast, none of other 
interacting partners of MOAP-1, such as Bax, Bcl-2 and Bcl-xL (Tan et al., 2001), had 
similar effect on MOAP-1 degradation when co-expressed (Figure 4.2C). Since MOAP-1 
levels were still able to be up-regulated by TRAIL in RASSF1A deficient H1299 cells 
(Vos et al., 2006), RASSF1A might not be necessary for MOAP-1 stabilization by 




Figure 4.2 RASSF1family proteins stabilize MOAP-1. (A) RASSF1A and MOAP-1 co-localized in 
cytoskeleton like structure when co-expressed. MCF-7 cells were co-tansfected with myc-RASSF1A and 
MOAP-1-HA constructs. 16 h after transfection, cells were stained with anti-myc and anti-HA antibody, and 
visualized by confocal microscope. (B) TRAIL induced association of endogenous MOAP-1 with 
endogenous RASSF1A.  HCT116 cells were treated with TRAIL for indicated periods of time before 
harvesting. Cell lysates were immunoprecipitated with a rabbit anti-MOAP-1 antibody.  Immunoprecipitates 
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were immunoblotted with RASSF1A antibody. The blot was stripped and immunoblotted with a mouse anti-
MOAP-1 antibody again. (C) MOAP-1 was selectively stabilized by RASSF1 family member. Several 
plasmids expressing various MOAP-1 interacting proteins, including Bax, Bcl-2, Bcl-xL, MA2, RASSF1A 
and RASSF1C, were co-transfected with the MOAP-1-HA construct and pEGFP vector into 293T cells, 
respectively. 16 h after transfection, cells were harvested and analysis with anti-myc, anti-HA or anti-GFP 
antibodies. (D) Dosage-dependent stabilization of MOAP-1 by RASSF1A and RASSF1C. Different amounts 
of plasmids expressing RASSF1A or RASSF1C were transfected with the MOAP-1 construct and pEGFP 
vector into 293T cells.  16 h after transfection, cells were harvested and analyzed with anti-myc or GFP 
antibodies. (E) RASSF1 family proteins suppress MOAP-1 poly-ubiquitination. The indicated plasmids 
were tansfected into 293T cells. The cells were further treated with MG132 for another 16 h after 
transfection. Cell lysates were immunoprecipitated with anti-HA antibody-conjugated beads.  Poly-
ubiquitinated forms of MOAP-1 were immunoblotted with anti-Flag antibody.  
 
 
compensate the role of RASSF1A in RASSF1A deficient cell. More recently, it has been 
found that RASSF1C was translocated from the nucleus to the cytosol in the cells upon the 
treatment with DNA damaging agents (Kitagawa et al., 2006). It would be of great interest 
to explore whether the release of RASSF1C from the nucleus to the cytosol has any role in 
the up-regulation of MOAP-1 by DNA damaging agents. While multiple apoptotic stimuli 
were capable of stabilizing MOAP-1 protein possibly through inhibition of its 
ubiquitination-dependent degradation process, it is possible that the underlying molecular 
steps or regulators involved could be different for distinct stimuli. The precise mechanism 
by which individual apoptotic stimulus inhibits the ubiquitination and degradation of 
MOAP-1 remains to be investigated. 
      Several mitochondrial proteins, such as ARTS (Lotan et al., 2005) and Mcl-1 
(Nijhawan et al., 2003; Willis et al., 2005), which are involved in the regulation of 
mitochondria-dependent apoptosis signaling pathway, have been shown to be substrates of 
UPS. It is possible that a significant number of mitochondrial proteins that play important 
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roles in mediating apoptotic or survival signaling are short-lived proteins. Interestingly, 
mitochondria depleted of short-lived proteins by CHX are resistant to recombinant Bax- 
and tBid-mediated Cytochrome c release, demonstrating for the first time that the net 
effect of depleting short-lived mitochondrial proteins is similar to that observed in specific 
depletion of MOAP-1 by RNAi (Tan et al., 2005). Remarkably, incubation of 
mitochondria from CHX-pretreated cells with in vitro translated MOAP-1 protein alone 
was sufficient to restore the ability of recombinant Bax to release Cytochrome c. These 
data not only lend further support to the idea that MOAP-1 is an essential mitochondrial 
effector of Bax as suggested from our earlier data (Tan et al., 2005), but it also raises an 
intriguing possibility that MOAP-1 could be a key short-lived mitochondrial protein that is 
required for mediating Bax function in mitochondria. Notably, since Mcl-1 is an important 
molecule to sequester Bak in an inactive complex, and Mcl-1 is a relatively short-lived 
mitochondrial protein, it is expected that mitochondria with depletion of short-lived 
protein should be more sensitive to recombinant Bak-mediated Cyto c release. However, it 
is possible that majority of Mcl-1 protein already binds to endogenous Bak in 
mitochondria. Since Mcl-1 might only bind to the certain conformation state of Bak 
(Gelinas & White, 2005), it is not clear whether Mcl-1 can bind to the recombinant Bak 
with C-terminal truncation. Furthermore, it can not be ruled out that another 
cycloheximide sensitive factor might be required for Mcl-1 to ablate the function of Bak. 
      The first clinically-tested proteasome inhibitor, Bortezomib, has recently been 
successfully launched for cancer treatment (Adams, 2004; Nalepa et al., 2006). Several 
other proteasome inhibitors are also currently being tested in Phase I or Phase II trials 
against multiple cancers. The therapeutic efficacy of proteasome inhibitors in cancer 
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treatment has been attributed to the induction of apoptosis (Adams, 2004). Bax, a central 
regulator of mitochondria-dependent apoptosis pathway, is a very stable protein and its 
levels are not affected by proteasome inhibitors ((Johnson et al., 2003; Zhu et al., 2005; 
Dewson et al., 2003; Nikrad et a.l, 2005; Akiyama et al., 2003). The pro-apoptotic activity 
of Bax is mainly controlled by its conformation instead of its protein levels. It has been 
found that BH3-only molecule Bik/NBK-induced apoptosis is mediated by entirely Bax-
dependent mitochondrial pathway (Gillissen et al, 2003). Interestingly, Bik/NBK is 
accumulated in various cells treated with proteasome inhibitors and it could be one of the 
important mediators of proteasome inhibitor-induced apoptosis (Marshansky et al., 2001; 
Nikrad et a.l, 2005; Zhu et al., 2005). MOAP-1 has been demonstrated here to be 
constitutively and physiologically degraded by the proteasome. It would be of interest to 
clarify in future whether and how Bax activator Bik/NBK and Bax effector MAP-1 
cooperate to regulate Bax function in proteasome inhibitor-induced apoptosis. This might 
shed light on the understanding of the molecular mechanisms accounting for the 
therapeutic efficacy of clinically-used proteasome inhibitors.   
      It is noteworthy that proteasome inhibitors generally exhibit high toxicity to 
mammalian cells, likely because of their activities in inhibiting a broad spectrum of 
proteins regulated by UPS. Various E3 ubiquitin ligases, such as MDM2, IAPs, SCF and 
Mule (Sun, 2003; Yang et al., 2005; Chen et al., 2006), have emerged as attractive targets 
for cancer therapy. Different approaches have recently been developed to target specific 
E3 ligase activity (Nalepa et al., 2006). One approach, based on the inhibition of the E3 
ubiquitin ligase activity of MDM2, has been explored for screening small molecule 
chemical inhibitors of MDM2 (Yang et al., 2005). Interestingly, another approach, based 
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on the crystal structure of MDM2 bound to a peptide from its substrate p53, has also been 
successfully employed to identify the small molecular weight compound Nutlin-3 that 
blocks the interaction of MDM2 with p53. Indeed, degradation of p53 by MDM2 was 
abolished and the p53 pathway became active in mammalian cells upon treatment with 
Nutlin-3 (Vassilev et al., 2004). As the center domain of MOAP-1 (a.a.116-190) was 
found to be as sensitive as the wild-type protein to the regulatory effect of UPS, this 
region of MOAP-1 in principle should contain the docking site for its specific E3 ligase. It 
is anticipated that chemical compounds with activity in interfering interaction between 
MOAP-1 and its E3 ligase should have a specific effect in stabilizing MOAP-1 protein. As 
higher levels of MOAP-1 sensitize cells to Bax-mediated apoptosis signaling, these 
compounds could have the potential to be explored clinically as anti-tumor agents. As 
mitochondria are increasingly being recognized as promising targets for cancer therapy 
(Green & Kroemer, 2004; Galluzzi et al., 2006), identification of UPS as a mechanism for 
regulating protein stability of MOAP-1 would thus afford the opportunity for 
conceptualizing a novel therapeutic strategy aimed at altering the functional activity of 













5.3 FUTURE PERSPECTIVE 
 
         MOAP-1 was first identified as a Bax-associating protein several years ago. The 
findings in this thesis would definitely offer the important insights for further 
understanding of the mitochondrial control of apoptosis signaling. There are several 
interesting directions for future work which would be highly relevant to extend the 
research work described in this thesis.    
(1) Understanding the molecular mechanism by which MOAP-1 act as an effector for 
Bax function in mitochondria; 
(2) Identification of the specific E3 ligase for MOAP-1; 
(3) Addressing the detailed mechanism by which distinct apoptotic stimuli conferred 
MOAP-1 stabilization; 
(4)  Generation of knockout animals to gain further insights on the physiological 
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Apoptotic stimuli induce conformational changes in Bax and trig-
ger its translocation from cytosol to mitochondria. Upon assem-
bling into the mitochondrial membrane, Bax initiates a death
program through a series of events, culminating in the release of
apoptogenic factors such as cytochrome c. Although it is known
that Bax is one of the key factors for integrating multiple death
signals, the mechanism by which Bax functions in mitochondria
remains controversial. We have previously identified modulator of
apoptosis-1 (MAP-1) as a Bax-associating protein, but its functional
relationship with Bax in contributing to apoptosis regulation
remains to be established. In this study, we show that MAP-1 is a
critical mitochondrial effector of Bax. MAP-1 is a mitochondria-
enriched protein that associates with Bax only upon apoptotic
induction, which coincides with the release of cytochrome c from
mitochondria. Small interfering RNAs that diminish MAP-1 levels in
mammalian cell lines confer selective inhibition of Bax-mediated
apoptosis. Mammalian cells with stable expression of MAP-1 small
interfering RNAs are resistant to multiple apoptotic stimuli in
triggering apoptotic death as well as in inducing conformation
change and translocation of Bax. Similar to Bax-deficient cells,
MAP-1-deficient cells exhibit aggressive anchorage-independent
growth. Remarkably, recombinant Bax- or tBid-mediated release of
cytochrome c from isolated mitochondria is significantly compro-
mised in the MAP-1 knockdown cells. We propose that MAP-1 is a
direct mitochondrial target of Bax.
apoptosis  mitochondria  Bcl-2 family  tumor suppressor
Proteins of the Bcl-2 family are central regulators of survival andapoptotic signals through mitochondria by affecting permeabi-
lization of mitochondria outer membrane, and thereby regulating
the release of death-promoting factors (1–4). The Bcl-2 family
consists of three subfamilies of prosurvival or proapoptotic mole-
cules. Most members of the BH3-only subfamily of proapoptotic
molecules act by relaying distinct death signals to the mitochondria
through binding to members of the multidomain prosurvival sub-
family (e.g., Bcl-2 and Bcl-XL), whereas the BH3-only molecule,
Bid, appears to have an additional role in promoting activation of
members of the multidomain proapoptotic subfamily such as Bax
and Bak (3–5).
Murine embryonic fibroblasts (MEFs) with Bax or Bak deleted
displayed no defect in apoptosis (4, 6). However,MEFswith double
Bax and Bak knockouts showed dramatic resistance to diverse
apoptotic stimuli, suggesting that Bax and Bak are central, but
redundant, regulators of apoptosis signaling (6, 7). However, anal-
yses of apoptosis signaling events in neurons obtained from knock-
out animals and human cell lines and tumors suggest that Baxmight
exert a dominant function over Bak in certain cell contexts (8–12).
Bak is a resident protein in mitochondria, and its proapoptotic
activity is restrained by associating with VDAC2 (13) or Mcl-1 (14,
15). In contrast to Bak, Bax is predominantly localized in cytosol or
loosely attached tomitochondrial membranes in an inactive form in
healthy cells (16). Apoptotic stimuli cause the unfolding of N and
C termini of Bax (17–19). These structural changes may facilitate
translocation of Bax from cytosol to mitochondria where Bax
oligomerizes into a high molecular weight complex, leading to
permeabilization of the mitochondrial outer membranes (20–22).
Interestingly, other studies suggest that conformation changes and
translocation of Bax to mitochondria alone are insufficient for
engaging its molecular function in mitochondria (23, 24).
It has recently been shown that tBid, Bax, and a defined lipid
environment were sufficient to reconstitute some properties of
mitochondrial membrane permeabilization (MMP) (22). However,
this artificial system does not recapitulate all of the properties of
MMP (22, 25). Indeed, additional unidentified factor in mitochon-
dria is needed for Bax function in mitochondria (24).
Because Bax was shown to interact withVDAC (26) and adenine
nucleotide translocator (27), which constitute, in part, the mito-
chondrial permeability transition pore (MPTP), it was proposed
that Bax may function in mitochondria by facilitating the opening
of MPTP, and the opening of MPTP may eventually lead to
mitochondrial swelling, rupture of the outer membrane, and sub-
sequent release of cytochrome c (Cyto c). However, recent work in
characterizing the phenotypes of cyclophilin D knockout animals
casts doubt on the idea (28–30). Cyclophilin D/ cells are severely
defective in MPTP opening stimulated by necrotic, but not apo-
ptotic stimuli (28, 29). Moreover, mitochondria isolated from
cyclophilin D/ cells exhibited no defect in the effect of recom-
binant Bax- or tBid-induced Cyto c release (28, 29). Here, we
present evidence to demonstrate that modulator of apoptosis-1
(MAP-1) is a critical effector for Bax function in mitochondria.
Materials and Methods
Immunoblotting, Immunoprecipitation, and Indirect Immunofluores-
cence. Western blotting and immunoprecipitation were performed
as described (31). For coimmunoprecipitation of endogenous
MAP-1 and Bax, MCF-7 cells were resuspended in lysis buffer (20
mM TrisHCl, pH 7.5150 mM NaCl2 mM EDTA10% glycer-
ol2%CHAPS) and homogenized. Immunoprecipitation and con-
focal analysis of active Bax was performed by using anti-Bax
conformation-dependent antibody (N20, Santa Cruz Biotechnol-
ogy) as described (23, 32, 33). The rabbit (R5) and mouse (M6)
anti-MAP-1 polyclonal antibodies were raised against bacterial
GST-MAP-1 (amino acids 116–351) protein. Indirect immuofluo-
rescence was performed according to the procedure described by
Chua et al. (34).
Subcellular Fractionation. Mitochondria, endoplasmic reticulum,
and cytosolic fraction were isolated as described earlier (34). Nuclei
were isolated as described (31). Where indicated, mitochondria-
enriched fraction was further purified through sucrose gradients
essentially as described (21, 35).
Generation of Stable MAP-1 RNA Interference (RNAi) Knockdown and
Rescue Lines. MCF-7 and HCT116 cells were transfected with
pSilencerHygromycin or pSilencerG418MAP-1 short hairpinRNA
(shRNA) constructs and selected with 400 gml hygromycin B
(Invitrogen) or 1.25 mgml G418 (GIBCO), respectively. Individ-
ual clonal lines were evaluated for the knockdown efficiency of
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MAP-1 protein and used for further analysis. See Supporting Text,
which is published as supporting information on the PNASweb site,
for details of the construction of small interfering RNA (siRNA)
expression plasmids and their target sequences in human MAP-1
mRNA. To generate rescue lines in MAP-1 RNAi knockdown
background, the MCF-7 MAP-1 knockdown clonal line SM-R3-12
was transfected with pIRESneo vector or pIRESneo MAP-1
construct with three silent mutations within the region targeted by
shRNA R3 (TTACTGTTGACGAATGCCT) and selected in 300
gml hygromycin B (Invitrogen) plus 1.25mgmlG418 (GIBCO).
The individual clonal lines were evaluated for the expression of
myc-MAP-1.
Apoptosis Assays. To detect apoptosis in transfected cells, Bax, Bak,
or MAP-1 construct was cotransfected with GFP reporter, and
GFP-positive apoptotic nuclei were scored as described (34). To
measure apoptosis in stable lines, viability was determined by JC-1
(Molecular Probes), WST-1 (Roche Diagnostics), or caspase activ-
ity (Calbiochem) according to the respective manufacturer’s in-
structions. The clonogenicity assay was performed essentially as
described (34).
In Vitro Cyto c Release. Equal amounts of mitochondria were
incubated with recombinant m-tBid (amino acids 60–195), hBax
(full length), or hBak delta TM (amino acids 1–190) proteins at
30°C for 30 min followed by centrifugation. Supernatants and
pellets were subjected toWestern blotting analysis. All recombinant
proteins were generated under detergent-free conditions as de-
scribed (17). See Supporting Text for details of the preparation of
recombinant proteins.
Results
MAP-1 Is a Mitochondria-Enriched Protein. MAP-1 was initially
identified in a yeast two-hybrid screen using Bax as bait (31). To
determine the subcellular localization of endogenousMAP-1, 293T
cells were fractionated into cytosol, nuclei, light membrane, and
heavy membrane (HM) fractions and immunoblotted with MAP-1
and other antibodies as indicated. The 39-kDa MAP-1 protein was
detected predominantly in the HM fraction enriched with the
mitochondria marker (Fig. 1A Left). Moreover, MAP-1 and Cyto
c were also readily detected in the sucrose gradient-purified mito-
chondria (Fig. 1A Right).
A series of deletion mutants of MAP-1 were made to determine
the sequence requirement for mitochondrial targeting. The wild-
type MAP-1 and the MAP-1(1–115) mutant were found to be
highly enriched in the HM fraction, whereas all of the N-terminal
deletion mutants were cytosolic, suggesting that the N-terminal
region ofMAP-1 is necessary for targetingMAP-1 tomitochondria
(Fig. 1B). Further fine mapping of the mitochondrial targeting
sequence was hindered because some deletionmutants were poorly
expressed.
Although both R5 and M6 antibodies were able to detect
overexpressed myc-MAP-1 with similar efficiency as myc antibody
in mammalian cells, neither antibody was able to detect a specific
immunofluorescence signal corresponding to endogenous MAP-1
inMCF-7, 293T, or SH-SY5Y cells, suggesting thatMAP-1 protein
is at low abundance. To further confirm the mitochondrial local-
ization of MAP-1, we used confocal microscopy to visualize tran-
siently expressed myc-MAP-1 in MCF-7 cells. Myc-MAP-1 is
proapoptotic and exhibited a perinuclear staining pattern that
colocalized with the mitochondria-specific dye, mitotracker (Fig.
1C Upper). In contrast, the nonapoptotic form of MAP-1, MAP-
1(1–115) (31), displayed excellent colocalization with mitotracker
(Fig. 1C Lower). To investigate further the association of MAP-1
with mitochondria, in vitro translated 35S-labeled proteins were
incubated with isolated mitochondria. MAP-1 and Bcl-XL, but not
the cytosolic protein hFEM-2, were found to readily associate with
isolated mitochondria (Fig. 1D).
To study the submitochondrial localization ofMAP-1,mitochon-
dria were subjected to digitonin and proteinase K (prot K) treat-
ments. Although mitochondrial matrix protein Hsp60 and inter-
membrane space protein Cyto c were readily released into
supernatant, the level of MAP-1 remained unchanged upon digi-
tonin treatment, suggesting thatMAP-1, similar to Bax andVDAC,
is a membrane-associating protein (Fig. 1E). In contrast to Hsp60
Fig. 1. MAP-1 is a mitochondrial protein residing at outer membrane. (A)
(Left) Subcellular fractions from 293T cells were immunoblotted with the
MAP-1 antibody (R5) or antibodies against the organelle-specific protein
markers: COX (mitochondria), calreticulin (ER), actin (cytosol), and p14ARF
(nuclear). (Right) Sucrose gradient purifiedmitochondria from293T cellswere
immunoblotted with R5 or anti-Cyto c antibody. (B) The N-terminal region of
MAP-1 is required for mitochondrial targeting. The Myc-MAP-1 deletion
mutants were transiently transfected into MCF-7 cells. Lysates from trans-
fected cells were subjected to fractionation analysis as in A. HM and cytosolic
fractions were immunoblotted with anti-myc antibody. (C) Myc-MAP-1 and
the MAP-1 mutant (1–115) colocalize with mitotracker. MCF-7 cells were
transiently transfected with Myc-MAP-1 or Myc-MAP-1 mutant (1–115). Six-
teen hours after transfection, cells were stained with mitotracker (red) and
anti-myc (green). (D) MAP-1 associates with isolated mitochondria. The indi-
cated in vitro translated 35S-labeled proteins were incubated with mitochon-
dria isolated fromMCF-7 cells at 25°C for 20 min. Mitochondria were washed
twice and repelleted by centrifugation. (E) MAP-1 is a membrane bound
mitochondrial protein. Mitochondria were incubated with indicated concen-
tration of digitonin on ice for 30 min. Mitochondria were repelleted by
centrifugation (10,000  g; 10 min) and immunoblotted for the indicated
protein. (F) Mitochondrial MAP-1 is highly sensitive to prot K digestion.
Mitochondria were incubated with indicated concentration of prot K on ice
for 10 min. PMSF (10 mM) was added to stop prot K digestion. Mitochondria
were repelleted by centrifugation and immunoblotted for the indicated
protein.
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and the inner membrane integrated protein COX 4, MAP-1, Bax,
and the outer membrane integrated protein VDAC were all
sensitive to prot K digestion, suggesting that MAP-1 associates
mainly with mitochondrial outer membrane (Fig. 1F).
MAP-1 Interacts with Bax During Apoptosis. Apoptotic stimuli are
known to promote translocation of Bax to mitochondria. We
examined the possibility that Bax and MAP-1 may colocalize and
associate only during apoptosis. Upon apoptosis induction, excel-
lent colocalization patterns forMAP-1 and Bax were detected (Fig.
7A, which is published as supporting information on the PNAS web
site). Although MAP-1 was previously shown to be a Bax-
associating protein, endogenous BaxMAP-1 association has not
been demonstrated (31). Endogenous MAP-1 was found to coim-
munoprecipitatewith endogenousBax only in staurosporine (STS)-
or TNF-treated cells, but not in healthy cells (Fig. 2A). The time
course ofBaxMAP-1 association coincidedwith the appearance of
Cyto c in cytosol during apoptosis (Fig. 7B). Interestingly, although
mitochondrial MAP-1 and Bax from healthy cells were completely
removed by alkali extraction, mitochondrial MAP-1 and Bax from
TNF-treated (Fig. 2B) or STS-treated (data not shown) cells
became resistant to alkali, suggesting that apoptotic stimuli pro-
mote the integration of both Bax and MAP-1 into the mitochon-
drial outer membrane.
MAP-1 Is Required for Bax-Induced Apoptosis Signaling. The obser-
vation that Bax and Bak serve a completely redundant function in
apoptosis signaling in murine embryonic fibroblasts (7) raises the
possibility that they may signal through a similar mechanism in
mitochondria. Interestingly, although MAP-1 is a binding partner
for Bax during apoptosis, association of MAP-1 with Bak was not
observed even under overexpression condition (data not shown).
To permit evaluation of the possible role for MAP-1 in Bax- and
Bak-mediated apoptosis signaling, we used siRNA to silence the
expression ofMAP-1.MAP-1 siRNAsR1 orR3, but not scrambled
siRNA (Scr), significantly reduced endogenous MAP-1 protein
(80%) (Fig. 8A, which is published as supporting information on
the PNAS web site). Silencing MAP-1 by transient transfection of
R1 or R3 siRNA inMCF-7 cells inhibited Bax-mediated cell death,
as determined by counting the percentage of cells with nuclear
condensation in GFP-positive cells (Fig. 3A) or by a more objective
assay measuring the luciferase reporter activity to monitor the
survival of transfected cells (Fig. 8B). In contrast, diminishing
MAP-1 levels in these cells failed to inhibit Bak-induced cell death
(Fig. 3A). Further experiments performed in 293T and SH-SY5Y
cells with the R1 or R3 siRNAs gave similar results (data not
shown).
To further determine the functional relationship between
MAP-1 and Bax, we performed experiments in isogenic HCT116
cell lines with differing Bax genotypes. TheR3 siRNAwas effective
in loweringMAP-1 levels in bothBax/ andBax/ lines (Fig. 8A).
Similar to MCF-7 cells, silencing MAP-1 in these cells conferred
selective resistance to Bax-induced apoptosis (Fig. 3B Left). Inter-
estingly, MAP-1 overexpression triggered apoptosis to similar
degree in both Bax/ and Bax/ lines (Figs. 3B Right and 8C),
suggesting thatMAP-1may act as a downstreameffector ofBax and
can be spontaneously activated when it reaches relatively high level
in the cells.
Silencing MAP-1 in MCF-7 Cells Confers Resistance to Diverse Apo-
ptotic Stimuli. To expand our analyses of the role of MAP-1 in
apoptosis signaling, we generated stable MCF-7 lines harboring
either R1 or R3 siRNA. As parallel controls, we generated stable
lines carrying siRNAs with two nucleotide mutations from the
siRNA sequences (R1 mut and R3 mut). The MAP-1 levels in the
SM-R3-12 clonal line was dramatically reduced (80%), whereas
the levels of Bax appeared unchanged (Fig. 4A). MCF-7 cells
Fig. 2. Apoptotic stimuli induce association of BaxwithMAP-1 and promote
their integration to mitochondrial membrane. (A) Apoptotic stimuli promote
endogenous Bax-MAP-1 association.MCF-7 cells were treatedwith STS (1M,
5h)or TNF (40ngml, 7h). Cell lysateswere immunoprecipitatedwithanti-Bax
antibody. Immunoprecipitates were immunoblotted with MAP-1 (M6) or
Hsp60antibody (Upper). Total lysateswere immunoblottedwith the indicated
antibodies (Lower). (B) Apoptotic stimuli promote integration of bothMAP-1
and Bax into mitochondrial outer membrane. Mitochondria isolated from
control or TNF-treated (40 ngml, 7 h) MCF-7 cells were resuspended in 0.1M
Na2CU3 (pH 11.5), where indicated, and incubated on ice for 20 min followed
by sonication for 5 min. Mitochondria were repelleted by centrifugation
(350,000  g, 20 min) and immunoblotted for the indicated protein.
Fig. 3. MAP-1 is required for Bax-induced, but not Bak-induced, apoptosis.
(A) MCF-7 cells were first transfected with scramble siRNA (Scr) or MAP-1
siRNAsR1orR3 for 2days followedbya second transfectionwithpXJ40 vector,
HA-Bax, orHA-Bak togetherwith theGFP reporter.Apoptosiswasdetermined
by counting the percentage of GFP-positive cells that exhibited condensed
nuclei morphology. (B) (Left) HCT116 Bax/ or Bax/ cells were subjected to
identical transfection protocols as inA, and the cells were processed 18 h after
the second transfection. (Right)MAP-1 induces apoptosis in Bax/ andBax/
cells with similar efficacy. HCT116 Bax/ or Bax/ cells were transiently
transfected with either pXJ40 vector, HA-Bax, or Myc-MAP-1. The percentage
apoptosis was determined as in A. Results are presented as percentage of
control (mean  SD, n  3).








lacking MAP-1 were healthy and displayed normal morphology
(data not shown). Upon STS treatment, SM-R3-mut cells displayed
typical apoptotic changes, such as diffuse Cyto c staining (data not
shown), nuclear condensation (data not shown), a rapid drop in
mitochondrial membrane potential (Fig. 4B Top), and caspase
activation (Fig. 4B Middle), and rapidly lost viability as demon-
strated by WST-1 assay (Fig. 4B Bottom). In contrast, SM-R3-12
cells were resistant to STS-mediated changes associated with cell
death (Fig. 4B) and, even when exposed to STS for 72 h, a
substantial portion of the cells remained viable (data not shown).
Remarkably, the MAP-1 knockdown cells were resistant to diverse
apoptotic stimuli including TNF (Fig. 4C), UV irradiation (Fig.
4D), serum withdrawal (Fig. 4E), and TNF-related apoptosis-
related ligand (TRAIL) (data not shown) in a variety of assays (Fig.
4 and data not shown). The MAP-1 knockdown MCF-7 cells that
survived the STS or TNF treatment displayed long-term survival
and were subsequently able to form 60–70% more colonies in a
clonogenecity assay than the control cells that were similarly treated
(data not shown). The specificity of the effects was further studied
by analyzing two additional independent stable lines expressing the
R3 MAP-1 siRNA and three other independent stable clonal lines
expressing a completely different MAP-1 siRNA, R1, for their
sensitivity toward STS and TRAIL-induced killing; similar results
were obtained (Fig. 9C, which is published as supporting informa-
tion on the PNAS web site, and data not shown). MAP-1-deficient
HCT116 cells are significantly more resistant than control cells to
apoptotic effects triggered by STS or TRAIL (Fig. 10B, which is
published as supporting information on the PNAS web site),
suggesting that the effects associated with knocking down MAP-1
observed in MCF-7 cells can be extended to other cell types.
Conformation Change and Translocation of Bax Triggered by Apopto-
tic Stimuli Are Inhibited in MAP-1-Deficient Cells.Next, we examined
whether MAP-1 is required for mediating conformation change
and translocation of Bax during apoptosis. Upon TNF treatment,
the conformation-specific Bax antibody revealed a clear difference
in the kinetics of the effect on conformational change in Bax
between the SM-R3-mut and the SM-R3-12 cells. The change was
detected 5 h after TNF treatment in SM-R3-mut cells, whereas it
was only detectable in SM-R3-12 cells after 12 h of treatment (Fig.
5A). As shown in fractionation analysis, TNF or STS effectively
induced translocation of Bax from the cytosol to mitochondria as
Fig. 5. Apoptotic stimuli-mediated conformation change and translocation
of Bax are inhibited inMAP-1-depleted cells. (A) TNF-mediated conformation
changeof Baxwas affected inMAP-1 knockdown cells. Equal amounts of total
lysates from the TNF-treated (40 ngml) cells were immunoprecipitated with
the conformation-specific anti-Bax antibody, N20. Cell lysates and immuno-
precipitates were immunoblotted with anti Bax. (B) MAP-1 is required for
apoptosis-mediated Bax translocation and Cyto c release. Cytosolic and mito-
chondrial fractions from cells treated with either STS (1 M, 5 h) or TNF (40
ngml,10 h) were immunoblotted with the indicated antibodies. (C) Stable
expression of myc-MAP-1 in the MAP-1 knockdown cells is sufficient for
restoring the sensitivity of MAP-1-deficient cells to apoptotic stimuli-
mediated Bax translocation and Cyto c release. Cells were treated and ana-
lyzed as in B.
Fig. 4. MAP-1 knockdown MCF-7 cells are resistant to diverse apoptotic
stimuli. (A) MAP-1 protein level is substantially reduced in SM-R3-12 cells
stably expressing the MAP-1 siRNA. Cell lysates were immunoprecipitated
with Bax (N20) or MAP-1 (R5) antibodies followed by immunoblotting with
MAP-1 (M6) or Bax (2D2) antibodies. (B) MAP-1 knockdown cells are resistant
to apoptotic death triggered by STS. (Top) Cells were harvested and stained
with JC-1 for analysis of mitochondrial membrane potential change by flow
cytometry. (Middle) The extent of caspase activation following treatment
with STS was assayed with AC-DEVD-AFC. (Bottom) Cell viability after STS
treatment was determined by WST-1 assay. (C–E) MAP-1 knockdown cells
displayed resistance to apoptosis triggered by TNF (C), UV (D), and serum
withdrawal (E). Cells were subjected to various apoptotic insults as indicated
and the dose-dependent cell viability responses were determined by the
following assays: JC-1 (TNF) or trypan blue exclusion (UV and serum with-
drawal). Results are presented as percentage of control (mean  SD, n  3).
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well as Cyto c from the mitochondria to the cytosol in SM-R3-mut
cells (Fig. 5B). In contrast, Bax remained largely cytosolic upon
apoptotic treatments in SM-R3-12 cells (Fig. 5B). The conforma-
tion change and translocation associated with Bax activation were
further studied by using confocal microscopy. TNF-treated, GFP-
Bax-positive cells from the SM-R3-mut line stained by the N20
antibody were more readily seen (80%) than those from the
SM-R3-12 line (30%) (Fig. 11A, which is published as supporting
information on the PNASweb site). Upon treatment with TNF, the
initial diffuse staining of cytosolic GFP-Bax in control cells, but not
MAP-1 knockdown cells, readily assumed a punctuate staining
pattern consistent with the release of Cyto c from mitochondria
(Fig. 11B, which is published as supporting information on the
PNASweb site). TNF-inducedBax translocation occurred in80%
of control cells but in30% ofMAP-1 knockdown cells (Fig. 11B).
The phenotype associated with MAP-1-deficient cells is indeed
a direct consequence of a reduction in MAP-1 protein level,
because stable clonal rescue lines expressing myc-MAP-1 (SM-R3-
12-RES) in the background of SM-R3-12 cells were found to regain
sensitivity toward STS- and TNF-related apoptosis-related ligand-
mediated killing (Fig. 12, which is published as supporting infor-
mation on the PNAS web site). Furthermore, the translocation
defect of Bax noted in MAP-1 knockdown cells (Fig. 5B) was no
longer detectable in the clonal rescue lines (Fig. 5C and data not
shown).
MAP-1 Has a Direct Role in Facilitating Bax Function in Releasing
Apoptogenic Factors from Mitochondria. Recombinant tBid, Bax,
and Bak are capable of releasing Cyto c directly from isolated
mitochondria (36–38). To investigate whether MAP-1 has a direct
role in mediating Bax function in mitochondria, we evaluated and
compared the effects of recombinant Bax, Bak, and tBid proteins
in directly releasingCyto c from isolatedmitochondria derived from
the control and MAP-1 knockdown cells. Purified recombinant
Bax, Bak, and tBid proteins were all able to release Cyto c from
isolated mitochondria prepared from SM-R3-mut and SH-R3-mut
cells (Figs. 6A and 10 C and D). Interestingly, the activity of both
Bax (Figs. 6A and 10C) and tBid (Fig. 6A and 10D) in releasing
Cyto c from isolated mitochondria were all severely compromised
in MAP-1 knockdown cells. In contrast, no significant difference
was noted in the Cyto c releasing activity of recombinant Bak on
mitochondria isolated from MAP-1 knockdown cells (Fig. 6A and
data not shown). The ability of Bax and tBid, but not Bak, in
releasing SmacDIABLO (1–3) from mitochondria was similarly
affected in MAP-1 knockdown cells (data not shown). Further
analyses of two additional stable clonal lines derived from R3 and
three from R1 siRNA with respect to the Cyto c-releasing function
of recombinant Bax protein yielded similar results (Fig. 9B and data
not shown).
The dampened sensitivity of MAP-1-deficient mitochondria to
Bax- or tBid-mediated release of Cyto c was largely restored in the
stable myc-MAP-1 rescue lines (Fig. 6B and data not shown).
Furthermore, incubation of MAP-1-deficient mitochondria with
in vitro translated MAP-1, but not reticulate lysate or in vitro
translated VDAC, was able to restore the sensitivity of MAP-1-
deficient mitochondria to Bax-mediated Cyto c release (Fig. 6C).
Discussion
The structural data of Bax revealed that the putative transmem-
brane domain (helix 9) masks the hydrophobic cleft, which has
structural features similar to the BH3 ligand-binding groove
formed by the BH1–3 domains of Bcl-XL (17, 39, 40). Apoptotic
stimuli trigger disengagement of helix  9 from the hydrophobic
pocket. Interestingly, the only motif identifiable in MAP-1 is a
BH3-like domain (31). A single point mutation of the conserved
amino acid in any one of the three BH domains of Bax was shown
to be sufficient for abolishing its binding to MAP-1, suggesting
that the hydrophobic cleft of Bax could be the binding pocket for
MAP-1 (31).
Endogenous MAP-1 only interacts with Bax during apoptosis,
and the MAP-1 knockdown has no significant effect on Bak-
mediated apoptosis in transient transfection experiments. Interest-
ingly, despite the presence of Bak in the MCF-7 and HCT116 cells,
abolishing MAP-1 in these cells was sufficient to confer significant
resistance to multiple apoptotic stimuli. Thus, our data support the
idea concluded from other studies that Bax may not be serving
completely redundant function to Bak and that it may have a
dominant function over Bak in regulating the central apoptosis
signaling in certain cellular contexts (8–12).
Similar to Bak, mitochondrial MAP-1 does not appear to mo-
bilize to cytosol during apoptosis. Thus, it seems surprising that
MAP-1 could affect the conformation change and translocation of
Bax. However, Bcl-XL and Bcl-2, which localize and act primarily
in the mitochondria, are also known to be effective in inhibiting
conformation change and translocation of Bax triggered by apo-
ptotic stimuli (32, 33). Therefore, it is possible that a signal
amplification cascade is at work in creating a positive feedback loop
in driving a continuous and sustained activation of the mitochon-
drial signaling pathway during apoptosis.
The in vitro Cyto c release data from MAP-1-deficient mito-
chondria strongly suggest thatMAP-1 is a critical factor for theCyto
c releasing function of Bax in mitochondria. It is surprising to note
that MAP-1, which appears to be necessary only for Bax-mediated,
but not Bak-mediated, apoptosis signaling, is also required for tBid
Fig. 6. MAP-1 is required to facilitate Bax- and tBid-mediated release of Cyto c from isolated mitochondria. (A) Mitochondria isolated from control or MAP-1
knockdown cells were incubated with recombinant Bax, tBid, or Bak followed by centrifugation. The supernatants and pellets were immunoblotted with
indicated antibodies. (B) Stable expression of myc-MAP-1 in MAP-1 knockdown cells restores the sensitivity of mitochondria to Bax- and tBid-induced release of
Cyto c. Mitochondria isolated fromMAP-1 knockdown or rescue cells were treated and analyzed as in A. (C) In vitro translated MAP-1 restores the sensitivity of
MAP-1-deficient mitochondria to Bax-mediated release of Cyto c. Mitochondria from MAP-1 knockdown cells were preincubated with rabbit reticulate lysate
(R. lysates), 35S-labeled in vitro translatedMAP-1, or VDAC (1 105 cpm) for 20min at 25°C. Themitochondria was washed twice, treatedwith recombinant Bax,
and analyzed as in A.








to release Cyto c from isolated mitochondria, because it is thought
that tBid can engage mitochondrial apoptosis signaling by direct
activation of either Bax or Bak and facilitating formation of
homo-oligomers (20, 41). In cells where Bax has a dominant role
over Bak, an intact Bax-MAP-1 pathway may actually be necessary
for efficient activation of Bak by tBid. Indeed, a recent study
demonstrated that effective oligomerization of Bak depends on
Bax, rather than tBid (42). The ability of tBid, but not Bak, in
releasing Cyto c from isolated mitochondria was also found to be
severely inhibited inHCT116 Bax/ cells (data not shown; ref. 43),
which is one of the cell types known to display a dominant Bax
function (9–11, 43). Moreover, recent data revealed that tBid
appears to be a potent displacer of Bax from Bcl-XL, but not a
displacer of Bak from Mcl-1 (44). These data are therefore in line
with the observations that releasing of Cyto c from isolated
mitochondria by tBid could be severely inhibited in the absence of
either MAP-1 or Bax.
Bax is frequently inactivated in tumors of the microsatellite
mutator phenotype, which comprise 15% of human colon, gastric,
and endometrial cancers (45, 46). Inactivation of the Bax gene
confers an obvious selective advantage for tumor growth during
clonal evolution (9, 45). If MAP-1 is indeed a crucial target for
Bax-mediated signaling, MAP-1 knockdown cells should acquire
similar growth advantages exhibited by Bax/ cells (46). Indeed,
MAP-1 knockdown cells formed foci aggressively on soft agar (Fig.
10E and Fig. 13A, which is published as supporting information on
the PNAS web site), suggesting that MAP-1 may have a role in
suppressing anchorage-independent growth in tumor cells. Further-
more, MAP-1-deficient MCF-7 cells xenografted to athymic nude
mice resulted in significantly larger tumors than those derived from
the control cells (Fig. 13B).
While our manuscript was being reviewed, Baksh et al. (47)
published their interesting finding that the tumor suppressor,
RASSF1A, can specifically link death receptor signaling to Bax
activation through binding to MAP-1. Their finding provides a
putative mechanism to account for the role ofMAP-1 in mediating
Bax conformation change in certain cell types in response to the
death receptor signals. Interestingly, a recent report suggests that
endogenous protein products of RASSF1 (1A, 1B, and 1C) are
predominantly localized in mitochondria (48). Baksh et al. (47)
demonstrated that loss of RASSF1A in mammalian cells resulted
in dampening of apoptotic effect triggered by the death receptor
signaling. Our study showed that knocking down MAP-1 in mam-
malian cells confers inhibition of apoptosis signaling triggered by
multiple stimuli and promotes anchorage independent and tumor
growth. Moreover, molecular analysis of MAP-1 function suggests
that MAP-1 has a significant role as an effector of Bax in mito-
chondria. The current study, together with the finding of Baksh et
al. (47), underscore the important role of MAP-1 in apoptosis
signaling and lend further support to the idea that MAP-1 could be
a key regulator in a tumor suppressor axis.
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The multidomain proapoptotic protein Bax of the Bcl-2 family is a
central regulator for controlling the release of apoptogenic factors
from mitochondria. Recent evidence suggests that the Bax-
associating protein MOAP-1 may act as an effector for promoting
Bax function inmitochondria. Here,we report thatMOAP-1 protein
is rapidly up-regulated bymultiple apoptotic stimuli in mammalian
cells. MOAP-1 is a short-lived protein (t12  25 min) that is
constitutively degraded by the ubiquitin-proteasome system. In-
duction of MOAP-1 by apoptotic stimuli ensues through inhibition
of its polyubiquitination process. Elevation of MOAP-1 levels
sensitizes cells to apoptotic stimuli and promotes recombinant
Bax-mediated cytochrome c release from isolated mitochondria.
Mitochondria depleted of short-lived proteins by cycloheximide
(CHX) become resistant to Bax-mediated cytochrome c release.
Remarkably, incubation of these mitochondria with in vitro-
translated MOAP-1 effectively restores the cytochrome c releasing
effect of recombinant Bax. We propose that apoptotic stimuli can
facilitate the proapoptotic function of Bax inmitochondria through
stabilization of MOAP-1.
apoptosis  Bcl-2 family  proteasome  DNA damage
Mitochondria are the major organelles involved in the signaltransduction and biochemical execution of apoptosis (1).
Proteins of the Bcl-2 family are central transducers of survival and
apoptotic signals (2). They act at mitochondria by regulating the
permeability and integrity of the mitochondrial outer membranes,
thereby controlling the release of apoptogenic factors. The Bcl-2
family consists of three major subfamilies of prosurvival or proapo-
ptoticmolecules. TheBH3-only proteins (Bim, Bad, Bid, Bik, Noxa,
Puma, and Hrk) serve as sentinels for the initiation of apoptosis by
modulating the function of the multidomain prosurvival (Bcl-2,
Bcl-w,Mcl-1, Bcl-XL, andA1/Bfl-1) or proapoptotic Bcl-2members
(Bax and Bak) (3–5). The prosurvival family members prevent cell
death mainly by interrupting oligomerization of Bax/Bak, largely
through binding and sequestering activator BH3 domains and
thereby preventing their interaction with Bax/Bak (6, 7). Although
the molecular details about how the Bcl-2 family of proteins
regulates mitochondrial apoptotic signaling remain to be resolved,
the multidomain proapoptotic molecules Bax and Bak have been
shown to be the essential effectors responsible for the execution of
apoptosis mediated through multiple signals (6, 8, 9).
Modulator of apoptosis (MOAP-1), initially namedMAP-1, was
identified as a binding partner of Bax in a yeast two hybrid screen
(10). MOAP-1 contains a BH3-like motif and is capable of trig-
gering apoptosis in mammalian cells when overexpressed (10, 11).
Knocking down MOAP-1 by RNAi confers inhibition of apoptotic
signaling triggered by multiple apoptotic stimuli and promotes
anchorage-independent growth of tumor cells (11). Remarkably,
isolated mitochondria fromMOAP-1 knockdown cells were highly
resistant to the cytochrome c (Cyto c)-releasing effect of recom-
binant Bax, suggesting that MOAP-1 may act as an effector for
facilitating Bax function in mitochondria (11). Interestingly, it has
recently been demonstrated that the tumor suppressor RASSF1A
specifically links cell death receptor- (12) and activated -Ras-
mediated (13) apoptotic signaling to Bax activation through binding
to MOAP-1.
The ubiquitin-proteasome system (UPS) plays important roles
in regulatingmany cellular and physiological processes, including
apoptosis. Many key regulators in the apoptosis and survival
pathway, such as p53, NF-B, the IAP family, are known to be
regulated by UPS (14, 15). Accumulating evidence also suggests
that UPS has a role in directly regulating the levels of certain pro-
and antiapoptotic members of the Bcl-2 family, including Bik,
Bim, A1/Bfl-1, and Mcl-1 (16–19). Here, we present evidence to
show that rapid inhibition of UPS-dependent degradation of
MOAP-1 by multiple apoptotic stimuli may play an important
role in facilitating Bax function in mitochondria.
Results
MOAP-1 Protein Is Rapidly Up-Regulated by Multiple Apoptotic Stim-
uli. MOAP-1 is proapoptotic in mammalian cells when overex-
pressed (10, 11). Reduction of MOAP-1 levels by RNAi knock-
down suppresses apoptosis triggered by multiple apoptotic
stimuli (11). Because MOAP-1 appears to be a low-abundance
protein in mammalian cells (ref. 11 and data not shown) and the
level of MOAP-1 could be an important determinant for influ-
encing the sensitivity of mammalian cells to apoptotic signals, we
decided to evaluate the potential effect of apoptotic stimuli on
MOAP-1 protein levels in mammalian cells. Using a combined
immunoprecipitation (IP)/Western blot analysis as described in
ref. 20 for detection of other low-abundance proteins, MOAP-1
protein levels were first found to be rapidly up-regulated in
HCT116, H1299, SY5Y, and HeLa cells upon tumor necrosis
factor-related apoptosis-inducing ligand (TRAIL) treatment
(Fig. 1A). The induction of MOAP-1 by TRAIL displayed a fast
kinetics similar to Bax activation in the HCT116, H1299 and
HeLa cells (Fig. 1A). Interestingly, although TRAIL failed to
induce Bax activation (Fig. 1A) and apoptosis (data not shown)
in SY5Y cells, it was effective in triggering up-regulation of
MOAP-1 protein in these cells (Fig. 1A).
To assess the effect of other apoptotic stimuli onMOAP-1 levels,
a number of cell lines were subjected to treatment with a series of
apoptotic stimuli, including the endoplasmic reticulum stress in-
ducer thapsigargin (THA), DNA-damaging agents, serum with-
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drawal, or the PKC inhibitor staurosporine. Except staurosporine,
all apoptotic stimuli tested were able to rapidly enhance MOAP-1
levels in mammalian cell lines, including SY5Y, HCT116, HepG2,
293T, H1299, and HeLa cells [Fig. 1 B–D Left and supporting
information (SI) Fig. 6 and data not shown]. Although the up-
regulation of MOAP-1 levels by DNA-damaging stimuli displayed
a similar kinetic as that of p53 induction in SY5Y and A2780 cells,
which are known to harbor wild-type p53 (21) (SI Fig. 6 B and C),
similar effect was also observed in the p53mutant cell 293T (SI Fig.
6A) and p53 null cell H1299 (SI Fig. 6D), suggesting that the
up-regulation of MOAP-1 by DNA-damaging stimuli involves a
p53-independent mechanism. MOAP-1 has been shown to be a
mitochondria-enriched protein (11). The accumulation of
MOAP-1 protein upon etoposide (ETOP) (SI Fig. 6E) or TRAIL
treatment (data not shown)wasmainly seen in the heavymembrane
fraction containing mitochondria. MCF-7 cells appear to have
higher basal levels of MOAP-1 than other mammalian cell types
(data not shown). Consistent with our previous observations (11),
most apoptotic stimuli tested, with the exception of ETOP and
camptothecin, were relatively ineffective for inducing up-regulation
of MOAP-1 protein in these cells (data not shown). In contrast to
rapid induction of apoptosis by TRAIL, apoptosis induced by
THA,DNA-damaging agents and serumwithdrawal appears much
slower (Fig. 1 B and C and data not shown). Nevertheless, the
up-regulation ofMOAP-1 by multiple apoptotic stimuli was readily
detected before those commitment events of apoptotic signaling,
such as Bax activation, Cyto c release from mitochondria, mito-
chondrial potential changes and the appearance of subG1 DNA
content (Fig. 1 B and C; data not shown). The broad spectrum
caspase inhibitor z-VAD failed to inhibitMOAP-1 up-regulation by
ETOP (Fig. 1D Left) and TRAIL (data not shown), whereas it
effectively blocked DNA fragmentation (Fig. 1D Right), indicating
that the effect of apoptotic stimuli onMOAP-1 up-regulation is not
dependent on a positive feedback mechanism driven by sustained
caspase activation.
Apoptotic Stimuli Stabilize MOAP-1 Protein. To study the mecha-
nism by which apoptotic stimuli promote an increase inMOAP-1
protein levels, we first measured MOAP-1 mRNA levels by
real-time PCR. No significant difference was noted in MOAP-1
mRNA levels between control and TRAIL- or ETOP-treated
cells (SI Fig. 7A). Translational regulation by the 5 or 3 UTR
of mRNAs has been found to play an important role in the
regulation of levels of certain proteins by apoptotic stimuli (22).
To exclude this possibility, cells were transiently transfected with
a HA-tagged MOAP-1-expressing plasmid, in which only the
coding region of MOAP-1 is transcribed under the control of the
CMV promoter. Similar to the endogenous MOAP-1 protein,
the levels of HA-taggedMOAP-1 protein were rapidly increased
by treatment with TRAIL or ETOP (SI Fig. 7B).
Fig. 1. Apoptotic stimuli up-regulate MOAP-1 protein during the early phase of apoptotic signaling. (A) Levels of endogenous MOAP-1 protein were rapidly
up-regulated by TRAIL. The indicated cells were treated with TRAIL for various periods of time. RIPA lysates were subjected to IP with the rabbit anti-MOAP-1
antibody (R5), followed by IB with the mouse anti-MOAP-1 antibody (M6). Actin was used as an internal control to demonstrate that equal amount of total
proteins was used for IP. The levels of Bcl-2, Bak, and Bik in the total lysates of HCT116 cells were also measured with their respective antibodies. Bax activation
(Act Bax) wasmonitored by using a conformation-specific Bax antibody (N-20). (B and C) Induction ofMOAP-1 by THA and ETOP occurred during the early phase
of apoptotic signaling. HCT116 cells (B) or 293T cells (C) were treated with 20 M THA or 100 M ETOP, respectively, for the indicated periods of time. MOAP-1
levels, Bax activation (Act Bax), Capase 3 activation (Act Casp3), and Cyto c release were monitored (B and C Left). For detection of Cyto c release from
mitochondria, the cells were fractionated into heavy membrane fractions enriched with mitochondria (Mito) and cytosolic (Cyto) fractions. THA-induced
mitochondrial depolarization (B Right) or ETOP-induced DNA fragmentation (C Right) were analyzed by flow cytometry as described inMaterials andMethods.
Data shown are representative of at least three independent experiments. (D) Caspase inhibition fails to suppress the elevation of MOAP-1 protein induced by
ETOP. 293T cellswerepretreatedwith 10Mz-VAD for 1hbeforebeing subjected to100METOP treatment for 16hor 36h. (Left)MOAP-1 levelswere analyzed
as in A. (Right) DNA fragmentation was analyzed as in C. Results are presented as percentage of apoptotic cells (mean  SD, n  3).
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Because neither transcriptional nor translational mechanism
appears to have a significant role in mediating MOAP-1 up-
regulation by apoptotic stimuli, we next explored possible post-
translational mechanism underlying MOAP-1 regulation. We first
determined the half-life of MOAP-1 in mammalian cells. The
protein synthesis inhibitor CHX was added to the 293T cells to
block the de novo protein synthesis. The remaining levels of
MOAP-1 in the cells at different time points after CHX treatment
were monitored (Fig. 2A). In addition, 293T cells were also sub-
jected to pulse–chase analysis (Fig. 2B). Both approaches yielded
similar results and the half-life of MOAP-1 is estimated to be 25
min in 293T cells (Fig. 2C). To ensure that the fast turnover of
MOAP-1 is not limited to 293T cells, the time-dependent decay of
MOAP-1 by CHX was measured in COS-1, SY5Y, HepG2 and
HCT116 cells. The half-life of MOAP-1 was estimated to be
between 20–30 min among these four cell lines (SI Fig. 8). In
contrast, Bax is a stable protein, because its level remained un-
changed upon CHX treatment even up to 16 h (SI Fig. 8 and data
not shown). Interestingly, TRAIL or ETOP treatment led to a
pronounced extension of MOAP-1 half-life compared with the
untreated control (Fig. 2D). These data together suggest that
protein stabilization, possibly by inhibition of its degradation, is
likely to be a predominantmechanism underlying the up-regulation
of MOAP-1 induced by apoptotic stimuli.
Apoptotic Stimuli Inhibit Polyubiquitination of MOAP-1, Which Is
Required for Its Degradation by Proteasome. Many proteases are
known to be involved in regulating protein stability in mammalian
cells (23). To determine which protease(s) might be participating in
MOAP-1 regulation, 293T cells were subjected to treatment with
diverse protease inhibitors.Among all of them, only the proteasome
inhibitors (i.e., MG132, LLnL, epoxomycin and lactacystin) were
found to dramatically elevate endogenous MOAP-1 protein levels
through extension of its half-life in all of the cell lines tested,
including the human primary foreskin cell FS-4 (SI Fig. 9 and data
not shown), suggesting that the proteasome system plays a major
role in the fast turnover of MOAP-1. Interestingly, levels of
MOAP-1 protein being up-regulated byMG132 were not increased
further upon ETOP (SI Fig. 9F) or TRAIL treatment (data not
shown), providing additional evidence that apoptotic stimuli up-
regulate MOAP-1 primarily through affecting its stability, instead
of increasing MOAP-1 mRNA levels.
The stabilizing effect of proteasome inhibitors on MOAP-1 led
us to explore further whether MOAP-1 is a direct substrate for
ubiquitination. Transiently expressed HA-tagged MOAP-1 was
significantly up-regulated by MG132. Furthermore, in addition to
the band corresponding to unmodified MOAP-1, a series of addi-
tional, slower migrating forms of the protein were observed in the
cells treated with MG132 (Fig. 3A Upper). It is possible that the
higher molecular weight bands represent the polyubiquitinated
forms ofMOAP-1. To test this hypothesis, 293T cells were cotrans-
fected with myc-tagged MOAP-1 and HA-tagged ubiquitin (Ub).
Polyubiquitinated forms of myc-tagged MOAP-1 were readily
observed in the transfected cells in the presence ofMG132 (Fig. 3A
Lower). A similar experiment was performed to detect the polyu-
biquitinated forms of endogenous MOAP-1, but in this instance
MOAP-1 was immunoprecipitated with anti-MOAP-1 antibody
and polyubiquitinated forms of MOAP-1 were detected by anti-Ub
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Fig. 2. MOAP-1 is a short-lived protein that can be stabilized by apoptotic
stimuli. (A) Inhibition of de novo protein synthesis caused rapid elimination of
endogenous MOAP-1 protein. 293T cells were incubated with 50 g/ml CHX
for the indicated periods of time.MOAP-1 protein levels weremonitored as in
Fig. 1. Actin was used as an internal control. (B) Pulse–chase analysis for
estimating the half-life of MOAP-1. 293T cells labeled with S35-methionine/
cysteine were chased for the indicated periods of time. RIPA lysates were
subjected to IP with anti-MOAP-1 antibody (R5). Immunoprecipitates were
analyzed by autoradiography (for S35 MOAP-1) or by IB with anti-MOAP-1
antibody (for total MOAP-1). HSP60 was used as an internal control. (C) The
half-life of MOAP-1 is estimated to be 25 min. The relative amount of total
MOAP-1 in A or S35-labeledMOAP-1 in Bwas quantified by densitometry and
plottedwith respect to time.MOAP-1 level at time 0was defined as 100%. (D)
TRAIL or ETOP treatment extended the half-life of MOAP-1. H1299 cells were
pretreated with 50 ng/ml TRAIL for 1 h or 100 M ETOP for 3 h. Pulse–chase
assay was then performed as in B. The same concentration of TRAIL or ETOP
was maintained during the entire period of pulse–chase analysis.
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Fig. 3. Apoptotic stimuli suppress polyubiquitination of MOAP-1. (A) Pro-
teasome inhibition caused accumulation of polyubiquitinated forms of tran-
siently expressed MOAP-1 (Ub MOAP-1). (Upper) HA-MOAP-1 or control vec-
tor was cotransfected with pEGFP into 293T cells. Sixteen hours after
transfection, the cells were treated with 10 M MG132 for another sixteen
hours. RIPA lysates were analyzed by IB, using anti-HA antibody. The levels of
GFP were used to monitor transfection efficiency. (Lower) 293T cells were
transfectedwith indicated plasmids. Sixteen hours after transfection, the cells
were left untreatedor treatedwithMG132 for another 16h. RIPA lysateswere
subjected to IP with anti-HA-conjugated beads, followed by IB with anti-myc
antibody. (B) Proteasome inhibition caused accumulation of ubiquitinated
forms of endogenous MOAP-1 (Ub MOAP-1). SY5Y cells were either left
untreated or treated with 10 M MG132 for 16 h. (Upper) RIPA lysates were
analyzed by IB with anti-MOAP-1 or anti-actin (loading control) antibodies.
(Lower) RIPA lysates were subjected to IP with MOAP-1 antibody or control
IgG, followed by IB with anti-Ub antibody. (C) MOAP-1 protein levels were
elevated by inhibition of polyubiquitin chain formation. 293T cells were
cotransfected with MOAP-1-HA and pEGFP in combination with indicated
amounts of plasmid expressing the lysine-less Ub mutant [Ub(K0)]. Sixteen
hours after transfection, the cells were harvested, and RIPA lysates were
analyzed by IB with anti-HA antibody. The levels of GFP were used tomonitor
transfection efficiency. (D) TRAIL and ETOP inhibit polyubiquitination of
MOAP-1. H1299 cellswere treatedwith 50 ng/ml TRAIL for 1 h or 100METOP
for 3 h before MG132 was added, and the cells were incubated for another
12 h. The cells were harvested and analyzed as in B.








antibody. In the presence of MG132, polyubiquitinated forms of
endogenousMOAP-1 protein were readily seen in SY5Y cells (Fig.
3B), 293T, HCT116, COS-1 and H1299 cells (data not shown). To
assess the requirement of polyubiquitination of MOAP-1 for its
degradation by the proteasome, HA-taggedMOAP-1 was cotrans-
fected with the plasmid expressing the mutant Ub [Ub(K0)], with
all of its lysines mutated to arginines (24). Levels of MOAP-1 were
elevated in a dose-dependent manner directly proportional to the
amount of Ub(K0) plasmid transfected, suggesting that polyubiq-
uitin chain formation is necessary for efficient degradation of
MOAP-1 by the proteasome (Fig. 3C).
To identify the domain in MOAP-1 that might be essential for
couplingMOAP-1 toUPS, a series ofMOAP-1 deletionmutants
were generated (SI Fig. 10A). All of the deletion mutants that
contain the center portion of MOAP-1 (amino acids 141–190)
have a short half-life (data not shown) and they were all
dramatically up-regulated by MG132 (SI Fig. 10B). Moreover,
the polyubiquitination of the M5 mutant (MOAP-1 amino acids
115–190) was readily detected in the presence of MG132 (SI Fig.
10D). Levels of this mutant was effectively elevated by either
TRAIL or ETOP treatment (SI Fig. 10C), suggesting that the
center region of MOAP-1 contains a functional domain sufficient
for mediating the stabilization effect on MOAP-1 by apoptotic
stimuli. Interestingly, the degradable property contained within the
M5mutant is transferable to a heterologous proteinGST that is not
normally regulated by UPS (SI Fig. 10 E–G).
To investigate whether apoptotic stimuli have any effect on the
ubiquitination process of MOAP-1, H1299 cells were pretreated
with TRAIL or ETOP before incubating with MG132 to pro-
mote accumulation of ubiquitinated forms of endogenous
MOAP-1. Both stimuli significantly reduced accumulation of
ubiquitinated forms of MOAP-1 (Fig. 3D), suggesting that the
effect of apoptotic stimuli on stabilizing MOAP-1 protein is
likely to be mediated through inhibition of its polyubiquitination
process. The inhibition of polyubiquitination of MOAP-1 by
apoptotic stimuli is unlikely to be a general phenomenon during
the early phase of apoptotic signaling, because the global accu-
mulation of total polyubiquitinated proteins in H1299 cells
induced by MG132 is not inhibited by ETOP or TRAIL treat-
ment (SI Fig. 11A). Furthermore, although the levels of BH3-
only protein Bik can be dramatically elevated in the presence of
proteasome inhibitors (ref. 16 and SI Fig. 11B), neither ETOP
nor TRAIL could up-regulate levels of Bik protein (SI Fig. 11B)
and inhibit accumulation of polyubiquinated forms of Bik stim-
ulated by MG132 (SI Fig. 11C).
Elevating MOAP-1 Protein Levels Sensitizes Mammalian Cells to Apo-
ptotic Stimuli.Reduction of MOAP-1 levels by RNAi knockdown
approach was shown to inhibit Bax-dependent apoptotic signal-
ing (11). Although transiently overexpressed MOAP-1 is able to
trigger apoptosis on its own (10, 11), it is unclear whether higher
basal levels of MOAP-1 in mammalian cells would sensitize cells
to apoptotic signals. To evaluate this, HCT116 clonal lines stably
expressing exogenous myc-tagged MOAP-1 (HCT116 myc-
MOAP-1 cells) were generated. The expression levels of myc-
MOAP-1 in stable clonal lines are much lower compared with
the expression upon transient overexpression conditions (data
not shown), but their levels were significantly higher than the
levels of endogenous MOAP-1 (Fig. 4A). Moreover, both forms
of MOAP-1 were tightly controlled by UPS and effectively
up-regulated by apoptotic stimuli in the stable lines (data not
shown). HCT116 myc-MOAP-1 cells were healthy and displayed
normal growth and morphology (data not shown). These cells,
however, were more sensitive than vector cells to TRAIL- and
THA-induced apoptosis as determined byWST-1 assay (Fig. 4B)
and mitochondrial potential changes (Fig. 4C). Interestingly,
although staurosporine failed to up-regulate MOAP-1 in
HCT116 cells (data not shown), higher levels of MOAP-1 had
similar effect on heightening the sensitivity of HCT116 cells to
the apoptotic effect of staurosporine as to TRAIL and THA
(data not shown). These data suggest that elevation of MOAP-1
protein levels has a general effect on sensitizing cells to apoptotic
stimuli. In comparison with vector cells, higher levels of activated
Bax were detected upon treatment with TRAIL in the cells
stably expressing exogenous myc-MOAP-1 (Fig. 4D). Mitochon-
dria in heavy membrane fractions isolated from HCT116 myc-
MOAP-1 cells were clearly more sensitive than those from vector
cells to the Cyto c releasing effect of recombinant Bax (Fig. 4E),
further supporting the idea that the levels of MOAP-1 correlate
positively to sensitivity of mitochondria to the Cyto c releasing
effect of Bax. To extend our analysis on the effect of higher levels
of MOAP-1 expression on apoptosis to other cell lines, MCF-7
clonal lines stably expressing myc-MOAP-1 were generated. As
in HCT116 cells, higher basal levels of MOAP-1 also sensitized
MCF-7 cells to apoptotic stimuli (SI Fig. 12 and data not shown).
MOAP-1 Is a Key Short-Lived Protein to Promote Bax Function in
Mitochondria. CHX treatment is known to have very diverse






Fig. 4. Higher levels of MOAP-1 sensitize the HCT116 cells to multiple
apoptotic stimuli. (A) MOAP-1 expression in the HCT116 vector control and
myc-MOAP-1 stable clonal lines. RIPA lysates were immunoprecipitated with
anti-MOAP-1 or anti-Bax antibodies, followed by IB with anti-MOAP-1, anti-
Bax or anti-myc antibodies. The arrows indicate the endogenous (Endo) or
exogenous myc-MOAP-1(Exog). (B and C) Cell death analysis of HCT116 vec-
tor control or HCT116myc-MOAP-1 cells subjected to treatmentwith TRAIL or
THA. Cells grown in 96-well plate were treated with indicated concentrations
of THA for 36hor TRAIL for 16 h. Cell viability after treatmentwas determined
by theWST-1 assay (B). Results arepresentedaspercentageof control (mean
SD, n 3). Cells grown in 6-well plate were treated with 5 MTHA for 36 h or
10 ng/ml TRAIL for 16 h, harvested and stained with Mito-tracker Red for
analysis ofmitochondrialmembrane potential changes by flow cytometry (C).
(D) Higher levels ofMOAP-1 promote TRAIL-induced Bax activation. Vector 1#
andMOAP-1 16# cellswere treatedwith indicated concentrations of TRAIL for
5h. Baxactivation (ActBax)wasanalyzedbyusinga conformation-specificBax
antibody (N-20). (E)Higher levels ofMOAP-1 increase the sensitivityof isolated
mitochondria to recombinant Bax-induced Cyto c release. Heavy membrane
fractions containingmitochondria isolated from Vector-1 or MOAP-1–16 cells
were treated with recombinant Bax, followed by centrifugation. The super-
natants (sup) and pellets were immunoblotted with anti-Cyto c or HSP60
antibodies.
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promote or block apoptosis when combined with different
apoptotic stimuli in distinct cellular contexts (25, 26). The
contribution of mitochondrial short-lived proteins as a whole in
regulating the function of recombinant Bax in isolated mito-
chondria has not been explored. MOAP-1 knockdown by RNAi
has been shown to attenuate recombinant Bax- and tBid-
mediated Cyto c release (11). To test the possibility that deple-
tion of short-lived proteins in mitochondria, including MOAP-1,
by CHX would result in a similar phenotype as the MOAP-1
knockdown by RNAi on Bax- or tBid-mediated Cyto c release in
isolated mitochondria, heavy membrane fractions containing
mitochondria were isolated from the cells pretreated with CHX
for various durations. Even 1 h of CHX treatment was sufficient
to deplete MOAP-1 in the heavy membrane fractions to unde-
tectable levels, whereas the levels of Bax, Bak Bcl-2 and HSP60
remained unchanged (Fig. 5A). Similar to mitochondria isolated
from MOAP-1 knockdown cells (11), mitochondria in heavy
membrane fractions isolated from cells that were pretreated with
CHX for relatively short time (2 h) were found to be resistant
to the Cyto c releasing effect of recombinant Bax (Fig. 5B) and
tBid (data not shown). Because the molecular mechanism of Bax
function in mitochondria has not been fully elucidated, it is
unclear whether any other short-lived mitochondrial protein(s),
in addition to MOAP-1, may also be required to facilitate the
apoptotic function of Bax. To address this, heavy membrane
fractions containing mitochondria isolated from CHX-
pretreated cells were preincubated with reticulate lysates or in
vitro-translated MOAP-1, VDAC or an inactive mutant of
MOAP-1 (M2mutant, amino acids 1–115), before being exposed
to recombinant Bax protein. Remarkably, exogenously added
MOAP-1, but not the mitochondrial protein VDAC or the M2
mutant, was effective in restoring the Cyto c releasing effect of
recombinant Bax (Fig. 5C).
Discussion
It has been reported that proteasome activity is compromised in
cells exposed to apoptotic stimuli, because some of the key
subunits in the 19S regulatory complex are cleaved by activated
caspases (27). As a consequence, levels of proteins that are
constitutively degraded byUPS would increase and large amount
of ubiquitinated proteins would be accumulated in the apoptotic
cells (27). Interestingly, it has also been demonstrated that
proteasome is required for initiation of apoptosis triggered by
certain stimuli (16, 19, 28). Our data clearly showed that
up-regulation of MOAP-1 is not a consequence of apoptosis, but
it is rather an early event in the apoptotic signaling process
engaged by multiple stimuli.
Ubiquitination is a pivotal step to mark proteins for degradation
by the proteasome. Distinct E3 ligases associate with their specific
substrate proteins and transfer the activated Ub to the target
proteins through the isopeptide bond formed between the carboxyl-
terminal Gly (G76) of Ub and the -NH2 group of lysine residue
in substrate proteins. Although MOAP-1 has 17 internal lysine
residues, the three lysine residues at the center domain ofMOAP-1
(K161, K163, and K164) are the obvious candidate lysines that
might be critical for the assembly of polyubiquitin chains, because
polyubiquitination of the MOAP-1 M5 mutant (amino acids 115–
190) can be readily detected. However, mutation of a single or all
three of these lysines to arginine did not significantly suppress the
ubiquitination of MOAP-1 (data not shown). Further systematic
mutation analyses of lysine residues in full length MOAP-1 protein
yielded similar results (data not shown) and it appears that, similar
to certain Ub substrates (29, 30), no specific essential lysine residue
for the polyubiquitination can be identified, suggesting that a
unconventional mechanism may be involved in MOAP-1 polyu-
biquitination (29, 30).
A variety of mechanisms, including posttranslational modifi-
cations, such as phosphorylation, sumolyation, regulation by
specific deubiquitination enzymes, and association with a third
negative regulatory partner, have all been shown to be involved
in affecting protein ubiquitination and its subsequent degradation
by the proteasome (31). Multiple apoptotic stimuli stabilize
MOAP-1 protein probably through inhibition of its ubiquitination-
dependent degradation process. The underlying molecular steps
and regulators involved, however, could be distinct for individual
stimulus. The precise mechanism by which individual apoptotic
stimulus inhibits the ubiquitination and degradation of MOAP-1
remains to be investigated.
Several mitochondrial proteins, such as ARTS (32) and Mcl-1
(16, 19), which are involved in the regulation of mitochondria-
dependent apoptotic signaling, have been shown to be substrates of
UPS. It is possible that a significant number of mitochondrial
proteins that play important roles inmediating apoptotic or survival
signaling are short-lived proteins. Interestingly, heavy membrane
fractions containing mitochondria depleted of short-lived proteins
by CHX are resistant to recombinant Bax- and tBid-mediated Cyto
c release, demonstrating that the net effect of depleting short-lived
proteins in mitochondria is to reduce rather than heighten the
sensitivity of mitochondria to recombinant Bax-mediated Cyto c
release. Surprisingly, incubation of the heavy membrane fractions
containing mitochondria from CHX-pretreated cells with in vitro
translated MOAP-1 protein alone was found to be sufficient to
restore the ability of recombinant Bax to release Cyto c. These data
lend further support to the idea thatMOAP-1 plays an effector role
for Bax function inmitochondria as suggested from our earlier data
(11) and raises an intriguing possibility thatMOAP-1 could be a key
short-livedmitochondrial protein required for facilitating Bax func-
tion in mitochondria.
The first clinically tested proteasome inhibitor, Bortezomib,
has recently been successfully launched for cancer the treatment
of multiple myeloma (33, 34). It is noteworthy that proteasome
Fig. 5. MOAP-1 is a key short-lived protein to facilitate Bax-induced Cyto c
release from isolated mitochondria. (A) Effects of CHX on the levels of Bcl-2
family proteins in heavy membrane fractions containing mitochondria.
HCT116 cellswere treatedwith50g/mlCHX for the indicatedperiodsof time.
The levels of MOAP-1, Bcl-2, Bak, Bax, and HSP60 were analyzed by IB. (B)
Mitochondria isolated from CHX-pretreated cells were resistant to Bax-
mediated Cyto c release. Heavymembrane fractions containingmitochondria
isolated fromthe control orCHX-pretreatedHCT116 cellswere incubatedwith
recombinant Bax followed by centrifugation. The supernatants (sup) and
pellets were immunoblotted with anti-Cyto c or HSP60 antibodies. (C) In
vitro-translated MOAP-1 protein effectively restored the sensitivity of mito-
chondria fromCHX-pretreated cells to theCyto c releasingeffectofBax.Heavy
membrane fractions containing mitochondria from the cells pretreated with
CHX for 2 h were preincubated with PBS, rabbit reticulate lysate (R. lysate),
S35-labeled (1  104 cpm/methionine) in vitro-translated MOAP-1, VDAC, or
the M2 mutant of MOAP-1 (amino acids 1–115) for 20 min. The mitochondria
was washed twice, treated with recombinant Bax, and analyzed as in B.








inhibitors generally exhibit high toxicity to cells, presumably
because of their activities in inhibiting a broad spectrum of
proteins regulated by UPS. Interestingly, an experimental ap-
proach based on the crystal structure of MDM2 bound to a
peptide from its substrate p53, has been successfully used to
identify the small molecular weight compound Nutlin-3 that
specifically blocks the interaction between MDM2 and p53.
Indeed, degradation of p53 byMDM2was abolished, and the p53
pathway became active in cells upon treatment with Nutlin-3
(35). Because the center domain of MOAP-1 (amino acids
116–190) is as sensitive as the wild-type protein to the regulatory
effect of UPS, this region of MOAP-1 might contain the docking
site for its specific E3 ligase. It is anticipated that chemical
compounds with activity in interfering interaction between
MOAP-1 and its E3 ligase should have a specific effect in
stabilizing MOAP-1 protein. Because higher levels of MOAP-1
sensitize cells to Bax-mediated apoptotic signaling, these com-
pounds might be potential antitumor agents. Mitochondria are
increasingly being recognized as promising targets for cancer
therapy (36, 37), identification of UPS as a mechanism for
regulating stability of MOAP-1 would thus afford the opportu-
nity for conceptualizing therapeutic strategies aimed at altering
the functional activity of Bax in mitochondria.
Materials and Methods
Cell Culture, Transfection, and Generation of Stable Lines. Cells were
cultured in 5% CO2 in RPMI 1640, DMEM, or Mycoy’s 5A
medium supplemented with 10% FBS. Lipofectamine 2000
reagent (Invitrogen, Carlsbad, CA) was used for transfection.
For generation of stable cell lines expressing exogenous myc-
tagged MOAP-1, HCT116 or MCF-7 cells were transfected with
pIRESneo vector or pIRESneo myc-MOAP-1 construct and
selected in 1.25 mg/ml G418 (Gibco, Carlsbad, CA). Individual
clonal lines were evaluated for the expression of myc-MOAP-1.
Determination of Protein Half-Life in Vivo.A pulse–chase assay was
performed as described in ref. 16. Cells were harvested, and cell
lysates were subjected to IP analysis as described below. CHX,
a protein synthesis inhibitor, was also used to estimate protein
half-life as described in ref. 24.
Immunoblotting (IP) and Immunoprecipitation (IP). Cells (1 107)
were harvested and resuspended in 500 l of RIPA buffer (50
mM Hepes, pH 7.4/150 mM NaCl/1% Nonidet P-40/0.1% SDS/
0.25% Na-deoxycholate/1 mM EDTA/1 mM Na3VO4) supple-
mented with ‘‘complete’’ protease inhibitors (Roche, Indianap-
olis, IN), followed by sonication for 30 min at 4°C. After
centrifugation to remove insolubles (350,000  g for 20 min),
protein content in cell lysates was determined (Bio-Rad, Her-
cules, CA). Equal amount of proteins for each cell lysate was
subjected to IB or IP as described in ref. 10. Bax activation was
analyzed as described in ref. 11.
Cell-Death Assay and Flow Cytometry Analysis. WST-1 assay
(Roche) was used to measure cell viability. For detection of
subG1 DNA, cells were fixed in cold 70% ethanol, stained with
50 g/ml propidium iodide, and analyzed with a FACScan flow
cytometer (BD Biosciences, San Jose, CA). Mitochondrial po-
tential change, measured by MitoTracker Red staining, was
performed in accordance with the manufacturer’s instructions
(Molecular Probes, Eugene OR).
In Vitro Cyto c Release. Equal amounts of heavy membrane
fractions containing mitochondria were incubated with recom-
binant Bax or tBid at 30°C for 30 min, followed by centrifugation
at 7,500  g for 10 min at 4°C. Supernatants and pellets were
subjected to Western blot analysis as described in ref. 11.
Supporting Information. Real-time PCR, subcellular fraction-
ation, expression and purification of recombinant Bax and t-Bid
proteins, and further details on antibodies, chemicals, and
plasmid construction are provided in SI Materials and Methods.
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